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ABSTRACT 
MARTIN JAN TELKO 
INVESTIGATION OF ELECTROSTATIC CHARGING PHENOMENA IN DRY 
POWDER INHALERS AND THE EFFECT ON DEPOSITION 
(Under the direction of Professor Anthony J. Hickey.) 
 
Dry powder inhalers (DPI) are an important drug delivery option, for the treatment of respiratory 
diseases, and, increasingly, for the delivery of systemically acting drugs and vaccines. Most DPI 
formulations consist of micronized drug blended with larger carrier particles. The interactions 
between drug and carrier are a major determinant of DPI performance. Electrostatic interactions 
between particles are recognized as one mode of particle interaction. Simulations, in vitro and in vivo 
studies indicate that electrostatic charge affects the delivery and deposition of aerosol particles in the 
lung. Yet, the occurrence and origins of electrostatic charge on medicinal aerosol particles are poorly 
investigated and understood.  
The major physicochemical properties of two drugs (albuterol sulfate and budesonide) and a 
number of excipients (lactose, glucose and calcium phosphate) were assessed. Deposition studies with 
model formulations using the electrical low pressure impactor showed that micronized drug particles 
are subject to significant triboelectrification. Particle charge levels were shown to be several orders of 
magnitude larger than had previously been estimated. A multivariate experimental design framework 
was employed to investigate the effects of various formulation factors on the charging of the two 
drugs; it was shown that several formulation variables, in particular the excipient, have profound 
effects on charge acquired by micronized drug particles available to the lungs. The charging behavior 
observed in deposition studies agreed largely with bulk electrostatic measurements conducted on the 
raw materials. It was thus concluded that the origin of the charge was contact charging between 
 iii
particles of the formulation. The charging behavior was further elucidated through inverse gas 
chromatography measurements, in which the surface acid/base properties of the excipients were 
determined. Surface acid/base parameters, which characterize the tendency of a material to act as 
electron donor or acceptor in intermolecular interactions, correlated with the charges obtained in 
Faraday well experiments and particle charges acquired during DPI actuation, which suggests the 
three phenomena are closely related. The rank-order observed (from least to most electron 
withdrawing) was albuterol, lactose, glucose, calcium phosphate, budesonide. The study provides a 
mean of characterization that can be used to predict charging propensity which can assist the DPI 
product development process.  
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1. INTRODUCTION  
 
1.1. General Introduction 
Dry powder inhalers (DPI) are an increasingly important drug delivery option, for the treatment 
of respiratory diseases, as well as for the fast and noninvasive delivery of systemically acting drugs 
and vaccines. Most DPI formulations consist of micronized drug blended with larger carrier particles, 
which enhance flow, reduce aggregation and aid in dispersion. During DPI actuation, the formulation 
is fluidized, dispersed into aerosol particles, and enters the patient’s airways. Under the influence of 
inspiratory airflow, the drug particles separate from the carrier and are transported into the lungs 
while the larger carrier particles are deposited on the oropharyngeal surfaces and are cleared by 
dissolution and swallowing. If the forces acting between the particles of the formulation are too 
strong, the shear of the airflow may not be sufficient to separate drug from the carrier particles 
resulting in low deposition efficiency.  
Significant effort is being expended in understanding the underlying physicochemical parameters 
influencing DPI performance. Numerous particle design and characterization techniques have been 
applied toward this end. The work has largely been aimed at controlling particle interactions to 
enhance dispersion, thereby decreasing variability and increasing delivery of drug to the lung 
periphery. Aerosol electrostatic properties have not been studied in this context. Particle charging is 
being used in a number of industries to control particle behavior. Charge may also be a design 
advantage for medicinal aerosols. It is postulated that triboelectric charging is a major factor in drug 
delivery from DPIs and that its characterization and control can be utilized to enhance DPI 
performance.  
 
 1.2. Formulation Development 
Formulation development encompasses an array of processes in which an active pharmaceutical 
ingredient (API) is incorporated into a drug product. While biological activity of the API is a 
prerequisite for a successful dosage form, it is not the sole determinant of efficacy. Factors such as 
stability, processability, delivery and availability to target organ, contribute significantly to an 
efficacious pharmaceutical system. Optimization of these factors is a key development task, and the 
final product is often a compromise between pharmaceutical and practical (i.e. economic/engineering) 
considerations. Formulation development is challenging because molecules with pharmacological 
activity often display poor physicochemical properties. In fact, the same molecular characteristics that 
confer pharmacological activity, e.g. high receptor affinity, frequently limit a compound’s 
pharmaceutical utility making it difficult or even unsuitable for delivery.1, 2 This is particularly true 
for many of the compounds that are identified by high-throughput screening methods.2, 3 
Development of pharmaceuticals for inhalation is a particular challenge, as it involves the 
preparation of a formulation and the selection of a device for aerosol dispersion. The lungs have 
lower buffering capacity than other delivery sites (e.g. the GI tract or the blood) which limits the 
range of excipients that could potentially enhance delivery outcomes. The patient is an additional 
variable, presenting unique barriers for pulmonary delivery, both in terms of respiratory tract anatomy 
and physiology, and mode of inhalation:4 There are greater complexities in administering an inhaled 
aerosol than there are for oral administration of tablets or capsules, the dominant route and means of 
delivery. Variability in delivered dose to individual or populations of patients may be substantial.5, 6 
Consequently, reproducible therapeutic effect is difficult to assure. 
Treatment of respiratory diseases using inhalers requires delivery of sufficient drug to the lungs to 
bring about a therapeutic response. For optimal efficacy, drug administration must be reliable, 
reproducible and convenient. This goal can be achieved by a combination of formulation, metering 
and inhaler design strategies.7 The technical and clinical aspects of device design and selection have 
been extensively reviewed elsewhere.8-10 The following discussion highlights the design of dry 
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 powder inhaler formulations to achieve the delivery goals. To that end, an understanding of dry 
powder physics and surface chemistry is essential.  
 
1.3. Dry Powder Inhalers 
1.3.1. Development of the DPI 
Inhaled drug delivery systems can be divided into three principal categories: pressurized metered 
dose inhalers (pMDIs), dry powder inhalers (DPI), and nebulizers, each class with its unique strengths 
and weaknesses. This classification is based on the physical states of dispersed phase and continuous 
medium and within each class further differentiation is based on metering, means of dispersion, or 
design. Nebulizers are distinctly different from both pMDIs and DPIs in that the drug is dissolved or 
suspended in a polar liquid, usually water. Nebulizers are used mostly in hospital or ambulatory care 
settings and are not typically used for chronic disease management because when considered with 
their auxiliary pump and tubing they are larger in size and less convenient. In addition, the aerosol is 
delivered continuously over an extended period of time. pMDIs and DPIs, bolus drug delivery 
devices, contain solid drug, suspended or dissolved in a nonpolar volatile propellant or in a dry 
powder mix (DPI) that is fluidized when the patient inhales. The clinical performance of different 
types of inhalation devices has been thoroughly examined in many clinical trials which have been 
reviewed by Barry and O’Callaghan and more recently by Dolovich et al.8, 10 The authors of both 
papers conclude that no device is clinically superior to the next and that decisions regarding device 
selection should be directed by other factors, such as convenience, cost, and patient preference.  
The pMDI, first approved in 1956, was also the first modern inhaler device.11 With a global 
market share of ca. 80% in 2004 the pMDI remains the most widely used device.12 The development 
of DPIs has been motivated by the desire for alternatives to pMDIs, to reduce emissions of ozone-
depleting and greenhouse gases (CFCs and HFAs, respectively) used as propellants, and to facilitate 
the delivery of formulations of macromolecules and products of biotechnology. Concurrently, DPIs 
proved successful in addressing other, device and formulation-related shortcomings of the pMDI. 
  3
 DPIs are, by their predominantly passive nature, easier to use, more stable, and highly efficient 
systems. pMDIs deliver their dose at high velocities, because they are pressurized at more than 5 
atmospheres, which makes premature deposition in the oropharynx more likely.13, 14 Thus pMDIs 
require careful coordination of actuation and inhalation. Despite enhancements to their design (e.g. 
use of spacers)15, incorrect use of pMDIs is still a prevalent problem; Giraud and Roche described 
poor coordination of actuation and inhalation that accounted for decreased asthma control in a 
significant portion of patients treated with corticosteroid pMDIs.16 DPIs require little or no 
coordination of actuation and inhalation since they are activated by the patient’s inspiratory airflow, 
This has frequently resulted in better delivery to the lungs than was achieved with comparable 
pMDIs.17 Since DPIs are typically formulated as one-phase solid particle blends, they are also 
preferred from a stability and processing standpoint.18 Dry powders are at a lower energetic state, 
which reduces the rate of chemical degradation and likelihood of reaction with contact surfaces. By 
contrast, pMDI formulations, which include propellant and cosolvents, may extract organic 
components from the device components.19 The main advantages and disadvantages of the DPI (over 
the pMDI) are summarized in Table 1.1. For great detail on the evolution of delivery devices, 
excellent reviews are available.11, 20 
The development of several new DPI devices, which have been reviewed elsewhere18, 21-23 and the 
commercial success of the bronchodialator-corticosteroid combination product Advair® have further 
stimulated interest in and development of DPIs.7  
 
Table 1.1. Dry powder inhalers vs. metered dose inhalers (Modified from Ashurst et al., 2000) 
 
 
Advantages of the DPI 
 - Environmental sustainability, propellant-free design 
 - Little or no patient coordination required 
 - Formulation stability 
 
Disadvantages of the DPI 
 - Deposition efficiency dependent on patient’s inspiratory air flow 
 - Potential for dose uniformity problems 
- Development and manufacture more complex/expensive 
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 1.3.2. Principles of Operation 
The principles of dry powder inhaler design are shown in Figure 1.1. Most DPIs contain 
micronized drug blended with larger carrier particles, which prevents aggregation, assists in metering 
and helps flow. The important role these carrier particles play will be discussed in depth in Section 
1.6: Powder and Aerosol Physics. The dispersion of dry powder aerosols is conducted from a static 
powder bed. In order to generate the aerosol the particles have to be moved. Movement can be 
brought about by several mechanisms. Passive inhalers employ the inspiratory flow of the patient for 
fluidization and aerosol generation. When the patient activates the DPI by inhaling through it, airflow 
within the device creates shear and turbulence; and the generation of velocity gradients introduces air 
into the powder bed. Thus, the static powder blend is fluidized and enters the patient’s airways. At the 
mouthpiece, the drug particles separate from the carrier particles and are carried deep into the lungs 
while the larger carrier particles impact in the oropharynx and are cleared. Thus, deposition in the 
lungs is determined by the patient’s variable inspiratory airflow.24-26 One of the main explanations for 
the low deposition efficiency encountered with DPIs is inadequate drug/carrier separation.27 Dose 
uniformity is a challenge in the performance of DPIs. This is a greater concern with powders than 
with liquids because of the discrete nature of particulates.  
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Figure 1.1. Principle of dry powder inhaler design. The formulation, typically consisting of micronized drug 
blended with larger carrier particles is dispensed in a metering system. An active or passive dispersion system 
entrains the particles in the patient’s airways where drug particles separate from the carrier and are carried into 
the lung. 
 
Various dispersion mechanisms have been adopted for DPI designs.22 While most DPIs are 
breath-activated, relying on the inhalation for aerosol generation, several power-assisted devices 
(pneumatic, impact force, vibratory) have been developed or are currently under development. These 
devices are being considered for the delivery of systemically acting drugs with narrow therapeutic 
windows.28 It is important to note that these “active” inhalers are not subject to the same limitations as 
passive inhalers and have a different advantage/disadvantage profile. Moreover, it has been suggested 
that if shear and turbulence could be standardized by using a dispersion mechanism independent of 
the patient’s breath, high levels of delivery efficiency and reproducibility may be achieved. Thus, an 
active inhaler may provide formulation independent delivery.29 Despite brief market entry of a 
compressed gas assisted device (Exubera®), the subsequent product withdrawal means there are no 
commercially available active dispersion DPIs. Therefore, in the interest of brevity, these devices are 
not discussed here; the reader is instead referred to other literature.28-30 
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 1.4. Drug Properties and Manufacture 
1.4.1. The Active Pharmaceutical Ingredient 
The respiratory tract is both a therapeutic target and route for delivery. It is an attractive delivery 
route because it does not subject drugs to the same harsh conditions they may experience in the 
gastrointestinal tract (i.e. pH and enzyme levels)31, yet it remains noninvasive and convenient. 
Bioavailibility for proteins and other macromolecules is greater than in any other noninvasive 
delivery route.32, 33 For these reasons, oral inhalation is increasingly being explored for the delivery of 
systemically acting drugs, including therapeutic proteins such as recombinant human granulocyte 
colony-stimulating factor (rhG-CSF),34 insulin;35-37 drugs to treat bone disorders,38 and vaccinations.39 
Systemically active drugs need to be absorbed into the circulation; therefore, they should be delivered 
to the alveoli, the terminal regions of the lung from which absorption is most efficient. Absorption 
through the alveolar-vascular membranes can take place via transcellular diffusion, paracellular 
diffusion (through tight junctions), and transcellular vesicular transport. The absorption mechanism 
depends on the drug.  
Pulmonary drug delivery is also the most effective way of treating diseases of the airways. The 
majority of pulmonary drugs on the market are pharmaceuticals to treat obstructive airway ailments, 
such as asthma and chronic obstructive pulmonary disease (COPD). Most of these drugs fall into one 
of three therapeutic categories: 
1. 2-adrenergic agonists 
2. Corticosteroids and cromones. 
3. Anticholinergics 
 
Tronde et al. found that of 34 inhaled drugs commercially available in 2001 (including anesthetics, 
but excluding lung surfactant preparations and macromolecules), 12 compounds were 2-adrenergic 
agonists and six compounds were corticosteroids.40 The chemistry and pharmacology of these 
molecules has been reviewed elsewhere.41 For effective delivery, it is important to understand the 
pharmacology of the drug, so that the correct physiology can be targeted. Unlike systemically active 
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 drugs, the three drug classes above need not be absorbed into the circulation to exert their 
pharmacological activity. Most -adrenergic receptors are located in the alveoli.42Anticholinergics 
target muscarinic cholinergic receptors, which are moderately distributed throughout the airways and 
periphery. The trachea is more densely populated with M3 muscarinic cholinergic receptors than -
adrenergic receptors.43 Corticosteroids target inflammatory cells, which are located throughout the 
airways and alveoli.42 Having mentioned receptor distribution it is not clear which receptors must be 
targeted for maximal therapeutic effect. 
In contrast to the oral route, for which various structure-bioavailability relationships have been 
developed3, 44-47 and applied to the screening of drug candidates, the structure-bioavailibility 
relationship for inhaled drugs remains largely unexplored. One notable exception is the publication by 
Tronde et al., in which the authors examined marketed inhaled pharmaceuticals for physicochemical 
similarities and have studied their absorption.40 The range of physicochemical properties of these 34 
small-molecule therapeutic agents incorporated in oral inhalation products in 2001 are listed in Table 
1.2. 
 
Table 1.2. Mean Physicochemical Properties of marketed small-molecule drugs for oral inhalation (Modified 
from Tronde et al., 2003) 
Physicochemical Property 10
th to 90th 
Percentile 
cLogD (pH 7.4) - Logarithm of octanol/water 
distribution coefficient -6.3 – 3.8 
Molecular weight (Da) 225 – 482 
Polar surface area (Å2) 65 – 178 
cLogP - Logarithm of octanol/water partition 
coefficient -1.0 – 4.1 
Hydrogen bond donors 2 – 6 
Hydrogen bond acceptors 4 – 11 
 
Since the number of drugs is small, it is hard to establish guidelines analogous to Lipinski’s Rule of 
Five, one of the prominent structure-absorption relationships for orally-active compounds.3 As shown 
in Table 1.2, most properties examined varied widely, or were closely linked to the respective drug 
category. No extremes were noted for any of the properties, but inhaled drugs were generally more 
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 polar than oral drugs. Several drugs that showed poor oral permeability were well absorbed in the 
lungs. Absorption appeared to be mostly related to the polar surface area of the molecule. However, 
overall, Tronde et al. concluded that the range of physicochemical properties acceptable for 
respiratory delivery was wider than for orally administered drugs. Tronde et al. did not, however, 
consider active transport which plays a role for several inhaled drugs.  
Given the wide range of physicochemical properties that make a drug suitable for pulmonary 
absorption (compared to orally administered drugs), there is, nonetheless, one critical requirement a 
drug must meet to qualify for respiratory delivery; this requirement is potency. Current inhalation 
devices limit the quantity of drug that can be delivered to the lungs, in a single dose, to a few 
milligrams. Thus, in order to be considered for inhalation therapy, drugs need to be therapeutically 
effective in the microgram or milligram range. With the development of new inhalers, this quantity is 
likely to increase in the future. However, potency will continue to be a limiting factor. Moreover, it is 
questionable if the lungs are able to manage large single doses administered chronically. 
Anatomically, the lungs have evolved to prevent entry of airborne particulates. This sets a limit to the 
use of particularly large molecules and explains the success of receptor agonists and endogenous or 
endogenous-like molecules such as cromones.  
The evolution of combination therapy using single inhaler , e.g. corticosteroid and long-acting 2-
adrenergic agonist48 has brought about new formulation challenges. In designing combination 
inhalers, one must also consider drug-drug interaction, whether chemical, pharmacokinetic, or 
pharmacodynamic in nature, in addition to the other developmental aspects.49 
 
1.4.2. API Preparation 
The final steps of bulk drug manufacture are crystallization from solution, followed by filtration, 
and drying. Typically the drug particle size is not well controlled during these steps. In order to be in 
the respirable size range (<5m in diameter), the drug particle size must be reduced in a separate unit 
operation. The formulator has several options at his/her disposal, and may evaluate several methods 
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 to find the one that works best for the specific drug. The size reduction technique most frequently 
employed is milling. There are many different mills, but only a few are able to mill dry powder to the 
required particle size range of 1 – 5m. The three main types of mills used in DPI manufacture are 
fluid-energy mills such as the jet mill, high peripheral speed mills such as the pin-mill, and the ball 
mill. The basic designs are described here, more in-depth discussion of operation with detailed 
illustrations, capacity and performance are reviewed elsewhere.50 Mechanical processing, such as 
milling, has been shown to affect the crystallinity of the material;51 this effect must be considered. 
The jet-mill52 or air attrition mill, is the most useful technique; it reduces particle size via high 
velocity particle-particle collisions. Unmilled particles are introduced into the milling chamber. High-
pressure nitrogen is fed through nozzles and accelerates the solid particles to sonic velocities. 
Inadvertently, particles collide and fracture. While moving around the mill, larger particles are 
subjected to higher centrifugal forces and are pushed to the outer perimeter of the chamber. Small 
particles because of their aerodynamic size exit the mill through the central discharge stream. 
Depending on nitrogen pressure and powder feed rate, particles down to the 1m in diameter can be 
produced. 
A pin mill uses mechanical impact to grind material by both particle-particle and particle-solid 
collisions. A pin mill is equipped with a series of concentrically mounted pins located on a spinning 
rotor and stationary stator plate. Powder is fed to the milling chamber and transported through the 
milling chamber by centrifugal force. Milled product is collected from the bottom. The pin mill can 
produce single-micron particles;53 however, not as small as the jet mill. Conversely, its power 
consumption is lower than that of the jet mill. 
The ball mill54 is essentially a rotating cylinder loaded with drug and milling media, balls that 
grind the drug between each other as they tumble inside the mill. The size and material of the milling 
media can be varied. Ball milling is very slow and the process is poorly scalable, which is why 
tumbling ball mills are only used in the laboratory.  
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 Other techniques for making micron-size particles involve direct particle formation from solution. 
Spray-drying and supercritical fluid crystallization are noteworthy approaches for controlling particle 
size. These techniques are distinctly different from milling, in that the particles are constructed (i.e. 
size is increased) whereas size is decreased during milling. In spray-drying,55, 56 the drug is dissolved 
in water or solvent and sprayed as fine mist into a heated expansion chamber. The droplets dry 
leaving behind tiny particles of drug that are collected at the bottom of the chamber. Spray-drying can 
produce more spherical particles than milling; however, spray-dried particles are mostly amorphous 
in structure.57 
A supercritical fluid (SCF) is a single phase with liquid-like density and gas-like transport 
properties. SCFs exhibit pressure-tunable solubility, which makes them well-suited for 
recrystallization operations. Several techniques have emerged that use supercritical fluids, most 
notably CO2 or propane, as solvents (e.g. Rapid Expansion of Supercritical Solutions, RESS58) or as 
antisolvents (e.g. Solution-Enhanced Dispersion by Supercritical Fluids, SEDS59) for the formation of 
small particles. These methods have been used to prepare particles suitable for delivery to the lungs. 
Schiavone et al. noted that SEDS yielded smoother budesonide particles with reduced surface area 
compared to milled drug. This in turn resulted in higher emitted dose in the Turbospin.60 “Particle 
engineering” using SCFs is the subject of intense research in the pharmaceutical industry; excellent 
reviews on this topic have been published.61  
For each technique it is important to consider the effect it has on the drug. Spray-drying and SCF 
methods offer more flexibility and the possibility of morphology control in addition to size control, 
but they may often only yield amorphous material or an undesired polymorph. Milling remains the 
process of choice for micronization of drug, because it is simple, more predictable, easy to scale up, 
and inexpensive. However, spray-drying, SCF, and a few other techniques remain alternatives for the 
formulator to consider when milling does not produce the desired results. 
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 1.5. Excipients 
The particle size distribution affects the deposition of drug in the respiratory tract. However, 
before drug can be delivered to the lungs, drug particles must leave the DPI and separate from each 
other and from other components in the formulation. Thus, a DPI formulation must undergo flow, 
fluidization, deaggregation and aerosolization. However, micron-size particles, particularly those 
resulting from high-energy operations such as jet-milling have high surface areas and surface 
energies, which result in poor flow and a high tendency to aggregate. Formulation strategies aim at 
alleviating these problems. 
One way to improve the non-pharmacological properties of a drug is through the addition of 
excipients. In general, excipients are used to enhance the physical or chemical stability of the API, its 
mechanical properties, and/or pharmaceutical properties such as dissolution and permeation. In DPI 
formulations, excipients function first and foremost as carrier particles. Usually no more than a few 
milligrams of drug need to be delivered, and excipients provide bulk, which improves handling, 
dispensing, and metering of the drug. Excipients also reduce drug cohesiveness by occupying the high 
energy sites of the drug particles. 
The primary function of the lungs is respiration. To fulfill this purpose, the lungs have a large 
surface area and thin peripheral epithelia. Unlike the gastrointestinal tract, the lungs have limited 
buffering capacity. Many compounds that could enhance drug delivery outcomes, also have the 
potential to irritate or injure the lungs. Consequently, the array of potential excipients is limited to 
compounds that are endogenous to the lungs and can easily be metabolized or cleared.  
Currently, lactose is the only excipient used in DPIs marketed in the USA. The reasons for this 
are both historical and physicochemical/ pharmaceutical in nature. Lactose had long been used as an 
excipient in oral dosage forms before being employed in DPIs. It has established safety and stability 
profile, manufacturing process with tight controls over purity and physical properties, and was 
available and inexpensive from the dairy industry. Lactose is highly crystalline, has smooth surfaces 
and satisfactory flow properties, which are desirable properties for a DPI carrier particle.7 It is less 
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 hygroscopic than other sugars and is quite versatile; several manufacturers offer excipient grade 
lactose of varying size and different morphologies. One drawback of lactose is that it is a reducing 
sugar, which makes it incompatible with drugs that have primary amine moieties.62   
Other sugars, such as mannitol,63, 64 have been shown to be feasible alternatives to lactose and it is 
expected that these sugars will eventually find their way into approved products. Glucose is already 
used in DPIs in Europe. Phospholipids, such as phosphatidyl choline and cholesterol have also been 
used in experimental liposomal formulations.65, 66 Several other materials have been included in 
experimental DPI formulations with varying objectives and varying success rates.67-69 
Excipients can make up over 99% of the product by weight, making them crucial determinants of 
overall DPI performance. Despite the limited excipient options they must be carefully selected; 
physicochemical properties, such as size and morphology have a profound effect of the performance 
of the formulation.70-74 The adhesive forces must be carefully considered; inadequate separation of 
drug and carrier is the main reason for deposition problems. The formulator may also choose to 
modify the excipient before combining it with the drug. It should also be noted that excipients are not 
always required; the Pulmicort (budesonide) Turbuhaler® (Astra-Zeneca, Lund, Sweden) is an 
example of an excipient-free formulation. 
 
1.6. Powder and Aerosol Physics  
The character of particulate systems is central to the performance of DPIs. Powders present 
unique design challenges. Powders are two-phase gas-solid systems. When they are static, they 
behave as solids, when they flow powders resemble liquids easily assuming the shape of the 
containing vessel.50 When a powder is dispersed in air, as is the case after actuation of a DPI, in many 
ways it conforms to its carrier gas (though unlike gases or vapors, pharmaceutical powders are non-
equilibrium systems). Whereas gas and liquid behavior is understood and accurately predicted by 
equations derived from first principles, physical equations governing powders are often empirical or 
rely on assumptions that are only approximations to real systems, such as homogeneity in size and 
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 shape of particles. As a consequence, equations describing the behavior of solids are less predictive 
than their fluid counterparts. Various texts have been written on multiphase flow phenomena.75-79 
 Powder properties can vary widely. Powder features such as the physicochemical properties and 
morphology of its constituent particles and the distribution of particle sizes contribute to variability. 
Unlike liquid solutions or gas mixtures, powders are not completely homogeneous (at primary 
particulate scale) and segregation by size, a function of the action of external forces, is always a 
potential contributor to heterogeneity. The aerodynamic behavior, which has a profound effect on the 
disposition of drug from a DPI, is particularly sensitive to powder properties. This feature will 
invariably contribute to poor dose uniformity and variable efficiency and reproducibility of drug 
delivery. 
 
1.6.1. Crystallinity and Polymorphism 
Many pure organic substances, including most drugs, are crystalline. A crystal is a solid in which 
the molecules or ions are arranged in an ordered, repeating pattern (the unit cell) extending in three 
spatial dimensions. Crystalline systems are defined by the intermolecular spacing, i.e. bond lengths 
and bond angles, of the unit cell, which can be determined by X-ray diffraction.80 There are seven 
crystal classes, which yield fourteen distinct lattice structures.81  The arrangement of molecules into 
crystals is governed by noncovalent interactions, including hydrogen bonding, van der Waals forces, 
- stacking, and electrostatic interactions.82 
Nearly one third of all drugs are known to display polymorphism,83 the ability of a solid to exist 
in more than one crystal from. A prominent example of a polymorphic pharmaceutical is 
carbamazepine which has four known polymorphs, one of which was discovered almost 30 years after 
identification of the first polymorphs.84 Determination of the polymorphic forms of a drug is an 
important part of the formulation development process, because polymorphic forms are not 
equivalent. Different polymorphs are at different energy states and thus have different properties, 
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 including stability, solubility and even bioavailibility.81 Identification of all polymorphs of a drug also 
has important economic implications, because a separate patent can be granted for each polymorph.83 
It is also possible to generate noncrystalline solid. In most cases this involves cooling a fluid so 
rapidly that its molecules lose mobility before assuming their lattice positions. A noncrystalline 
material is considered amorphous because it lacks long-range order. Amorphous materials have 
higher Gibbs free energies than crystals; the laws of thermodynamics predict that in the long-term 
materials will seek to minimize their free energies by transitioning to lower energetic states (e.g. 
crystallization). Whether this will occur at a timescale that need be of concern to the pharmaceutical 
scientist, is governed by the chemical kinetics (statistical thermodynamics) of the system. 
Different polymorphs can be discerned in terms of a variety of physicochemical properties. 
Polymorphs usually differ in density, melting point, solubility and hygroscopicity. The most stable 
polymorph frequently has the highest density, melting point, and lowest solubility. Discriminating 
analytical methods to characterize polymorphs include X-ray diffraction and thermal analysis, such as 
differential scanning calorimetry.81 To reduce the risk of transformation during processing or storage, 
the most stable polymorph is typically selected for development, provided its other properties are 
manageable.  
While crystallinity refers to the geometry of the unit cell, crystal habit describes the morphology 
of particles, which can vary independently of the crystal lattice structure if growth rates (during 
precipication) vary in some dimension.85 This is shown in Figure 1.2. Crystal habit is important 
because different particle shape affects the aerodynamic behavior and, thus, the deposition in the 
lungs. Crystallization and crystal habit are influenced by a variety of factors, including identity of 
solvent,86, 87 impurities present during crystallization,88 and processing parameters, such as 
temperature, pH, and solution volume, viscosity.89  
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Figure 1.2. Crystal habit. Inhibition of growth in one of 
more spatial directions results particles with plate or 
needle morphology. 
 
Some compounds will spontaneously incorporate solvent molecules into the lattice structure upon 
crystallization or storage at certain conditions. This phenomenon has been referred to as 
pseudopolymorphism, and is relevant for many drugs, which exist as solvates or hydrates.90 It is 
important to understand the conditions that will result in hydration, because, as with true polymorphs, 
hydrates differ in their physicochemical properties. 
Knowledge of crystallization and polymorphism is still unfolding and the ability to predict 
polymorphism remains imperfect. In most solids, a large number of different intermolecular 
interactions are possible but few are actually observed.91 The difficulties involved in crystallization 
are illustrated by several reported cases of “disappearing polymorphs”. These cases were 
characterized by difficulty in resynthesis of a polymorph, after initial synthesis, despite the procedure 
and conditions appearing the same.92 Controlling crystallization is at the heart of “particle 
engineering”, a term that is used with increasing frequency in the pharmaceutical and chemical 
literature. It has been suggested that adequate control over the crystallization process could yield 
particles with precisely engineered morphology; co-crystallization (inclusion of functional impurities 
into the crystal) could then become a formulation strategy, resulting in “supramolecular 
pharmaceutics.” 90 
The recent discovery of the second aspirin polymorph has renewed interest and added new insight 
to the understanding of polymorphism. A second aspirin polymorph had long been suspected and the 
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 feasibility of it was shown computationally93 in 2004. Researchers have since reported having 
observed this polymorph after crystallization under specific conditions; the crystal was thought to be 
only transiently stable at ambient conditions.94  A second group then discovered that the polymorph 
had not truly been observed; after careful examination Bond et al. discovered aspirin's ability to exist 
in a previously unknown "intergrowth" structure in which a single crystal contains domains with both 
crystal arrangements.95 The discovery requires a new definition of polymorphism and may result in 
reexamination of other drug and excipient structures.  
 
1.6.2. Moisture Content and Hygroscopicity 
Hygroscopicity is the intrinsic tendency of materials to take on moisture from their surroundings. 
The hygroscopicity is affected by the crystallinity of the material and the morphology of the particles. 
Hygroscopic drugs present a greater risk of physical and chemical instability. Moisture uptake and 
loss due to changes in relative humidity can result in local dissolution and recrystallization leading to 
irreversible aggregation through solid bridge formation.22 This, in turn, may adversely affect aerosol 
generation and deposition of particles in the lung.96 Hygroscopicity may also alter the adhesive and 
cohesive properties or in more extreme situations induce significant increases in particle size, 
hygroscopic growth.97  The latter phenomenon, shown schematically in Figure 1.3, involves the 
uptake of moisture, which will reach equilibrium in droplets as a function of the water activity of the 
solution formed and the surrounding atmosphere of water vapor; the Kelvin-Gibbs equation describes 
the phenomenon involved.98 Hygroscopic growth has implications for the equilibrium moisture 
content of the particles in the dosage form prior to aerosol generation; it may cause either chemical or 
physical instability of the product. For aerosols the physical instability is of great significance since 
agglomeration may be irreversible and lead to an inability to generate aerosols in respirable sizes. As 
aerosol particles enter the lungs they experience a high humidity environment (99.5%RH at 37C).99 
Although they may not reach equilibrium during transit susceptible aerosol particles may be subject 
to hygroscopic growth which will increase particle dimensions and affect lung deposition.99 
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 Hygroscopic growth can be prevented by coating the drug particles with hydrophobic films.98 
However, no such approach has been successfully implemented in a marketed formulation. 
Increasing RH
 
Figure 1.3. Hygroscopic growth. Particles absorb moisture as they 
traverse the humid environment of the airways resulting in increased 
particle size. 
 
The equilibrium moisture content of a drug and excipient must be determined over a range of 
relative humidities, so that storage conditions can be defined and other protective measures 
considered. Excipients that modify the hygroscopic properties of a drug may need to be considered. 
 
1.6.3. Particle Size 
Particle size is the single most important design parameter of DPI formulations. Methods for the 
determination of particle size and distribution make use of different geometric features or 
physicochemical properties.50 Among these, aerodynamic diameter is the most relevant to lung 
delivery and ultimately to therapeutic effect. There is significant literature in industrial hygiene, 
environmental and occupational medicine in addition to pharmaceutical sciences that links the 
probability of deposition in specific sites in the lungs to aerodynamic size and size distribution. The 
statistical basis for these relationships in terms of variability in airways geometry and lung physiology 
both between individuals and within individuals has been sufficient to allow the development of 
semi-empirical models correlating particle size with lung deposition.100  
 
1.6.3.1 Aerodynamic diameter and dynamic shape factor 
Aerodynamic diameter is the most appropriate measure of aerosol particle size because it relates 
to particle dynamic behavior and describes the main mechanisms of aerosol deposition; both 
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 gravitational settling and inertial impaction depend on aerodynamic diameter. In order to reach the 
peripheral airways where drug is most efficiently absorbed, particles need to be in the 1-5 μm 
aerodynamic diameter range.101 Larger particles usually deposit in the oral cavity or pharynx, from 
which they are easily cleared. In contrast, particles smaller than 0.5m may not deposit at all, since 
they are subject to Brownian motion and settle very slowly. Moreover, they are inefficient, as a 
0.5m sphere delivers only 0.1% of the mass a 5m sphere carries into the lungs. In a series of 
studies the optimal particle size of aerosol particles was examined for several different therapeutic 
agents in patients with different disease states. Although some differences due to patient lung function 
were noted,  the optimal size was always in this 1-5m size range.102-106  
The aerodynamic diameter, dae, is defined by the diameter of an equivalent volume sphere of unit 
density deq with the same terminal settling velocity as the actual particle. For particles greater than 
about 1m the following expression describes the relationship between these dimensions. 




 o
p
eqae dd 

     (1.1)  
where p and o are particle and unit densities, and  is the dynamic shape factor. Pharmaceutical 
powders are rarely spherical and shape factors are dimensionless measures of the deviation from 
sphericity. The dynamic shape factor in particular is the ratio of the actual resistance force 
experienced by the nonspherical falling particle to the resistance force experienced by a sphere having 
the same volume.107 Dynamic shape factors are either determined experimentally or using more 
complex models that are beyond the scope of this chapter. A very thorough review of this concept 
with values for common shapes is provided by Hinds.107 
Equation 1.1 merits closer examination. As discussed, it is the aerodynamic diameter (dae) that 
determines lung disposition, irrespective of geometric particle size (to a certain point). The 
aerodynamic diameter can be decreased by decreasing particle size and particle density, or by 
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 increasing the dynamic shape factor. This concept is shown graphically in Figure 1.4, and is discussed 
in more detail below. All three of these approaches have been applied.  
 




 o
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eqae dd 

A. B.
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Figure 1.4. Strategies for altering the aerodynamic diameter. A. 
Aerodynamic diameter equation; B. Large, low density porous particles; 
C. Needle-shaped particles. Particles in both B and C are expected to have 
aerodynamic diameters that are smaller than their size would suggest. 
 
1.6.3.2 Fine Particle Fraction 
One expression that has been employed to allow general comparison of aerosols with respect to 
lung delivery is the fine particle mass/dose (dose, FPM/FPD) or fraction (usually percentage of 
nominal dose, FPF).108 The fine particle component of aerosols is usually defined as the proportion 
less than 5m (aerodynamic diameter) or in the case of particular sizing instruments a cut-off 
diameter that is close to this value. Quite often this may be in the 6-7m range. The danger of 
adopting these values as definitive measures of equivalency is associated with the significance of 
particle size on deposition.109 This is considered in more detail in section 1.6.3.3.  
 
1.6.3.3 Polydispersity 
For drug delivery it is the convention to consider the mass associated with each particle size as 
the frequency term in the distribution since this relates directly to dose. Conventional statistical 
properties apply to populations of particles (i.e. mode, mean and median). It is usual to define the 
central tendency of numbers of aerosol particles by the mass median aerodynamic diameter (MMAD) 
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 which reflects the particle size dividing the distribution in half as a function of mass. Monomodal 
distributions may conform to log-normal mathematical interpretation in which case the breadth of the 
distribution can be expressed in terms of the geometric standard deviation which is usually derived by 
dividing the particle size at the 84th percentile by the median size to achieve a dimensionless number 
greater than 1.                 
When considering particle size, the degree of polydispersity, i.e. the range of particle sizes around 
the mode, is also important. The simplest and preferred system exhibits a single mode. However, 
many pharmaceutical aerosols will exhibit more than one mode. It is conceivable that two completely 
different aerosol distributions, i.e. small median size with narrow distribution or large median size 
with broad distribution could give exactly the same fine particle fraction. However, within the FPF 
the aerosol would exhibit different sizes leading to differences in regional lung deposition resulting in 
variations in therapeutic effect. Thus, degree of dispersity is an important consideration for both 
quality and efficacy of pharmaceutical aerosols.110 The nature of the aerosol distribution must be 
established accurately if its implications for deposition and efficacy are to be understood. 
Another consideration relates to the standard DPI formulation, which is frequently bimodal since 
it contains micronized drug and substantially larger carrier particles. Recognizing the potential for 
multimodal distributions is important to the application of statistical methods to the interpretation of 
the data. Traditional methods of data interpretation, i.e. log-normal mathematical fits to 
distributions,111 may be superseded by other mathematical approaches112 or non-linear curve fitting 
using calibration data.113 
 
1.6.3.4 Particle Sizing Techniques 
Several techniques are available for the determination of particle size distributions; they have 
been described in depth elsewhere111 and will be covered, briefly, here. The techniques used for sizing 
aerosols can be classified as either (1) inertial methods, (2) light scattering methods, or (3) imaging 
methods.  
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Cascade Impactors 
Cascade impactors (CIs),114, 115 including multi-stage liquid impingers, are the most widely used 
instruments for sizing aerosols; they are recommended by both U.S. and European Pharmacopeias. 
Their utility stems from the fact that they directly measure aerodynamic size rather than equivalent 
volume diameter (based on cross-sectional area), like the other methods. The theory of CI operation 
has been described in-depth elsewhere.116 Briefly, CIs contain several stages with orifices of 
decreasing size stacked on top of each other. Particles suspended in air are drawn through the CI and 
the particles deposit on different stages based on their inertia. After each run, the CI is disassembled 
and the mass of particles deposited on each stage is determined, mostly via analytical methods 
(dissolution in solvent, followed by chromatography or UV absorbance). A cutoff diameter is 
associated with each stage of the CI. This diameter varies with airflow, thus the CI must be calibrated 
for different flowrates. This airflow dependence allows investigation of the effect of different 
inspiratory flowrates on deposition.  
At atmospheric conditions cascade impactors can only classify particles down to a size of 
approximately 0.1m. Below this size particles are close to the mean free path of air (0.066um at 
1atm and 20oC)107 and experience the air as a discontinuous medium; they experience 'slip'. The mean 
free path, λ, is the average distance traversed by air molecules between collisions with each other. 
The cutoff size range of cascade impactors can be extended downward by decreasing the air pressure, 
thereby increasing the distance between air molecules and thus the mean free path. Several low 
pressure impactors have been developed that have extended the cutoff size down to tens of 
nanometers; they have chiefly been used in the study of air pollution.117, 118  
The Electrical Low-Pressure Impactor (ELPI),119 is another rather recent modification of the CI. 
Particles passing through the ELPI are charged before traversing the cascade of stages. Their impact 
on the stages produces an electrical current that is detected and converted into particle size data that 
can be interpreted in real-time. Operating at reduced pressure the ELPI can classify particles down to 
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 a size of 30nm. The device is extensively used in experiments and is discussed in more detail in 
Chapter 4. 
 
Light Scattering – Laser Diffraction 
Light scattering methods, especially laser light scattering, are quite commonplace in formulation 
development. The operating principle of laser light scattering is depicted in Figure 1.5. An expanded 
laser beam is passed through a sample that is being drawn through a measuring zone. Different size 
particles diffract the light at different angles. A computer algorithm, which varies between 
manufacturers, interprets the diffraction pattern and calculates a particle size distribution. The 
algorithms used are based on Fraunhofer or Mie Theory from which the particle sizes are determined. 
Since the algorithms vary among the different instruments, as does instrument geometry (e.g. size and 
position of detection) comparisons are difficult particularly for pharmaceutical particles, many of 
which deviate from sphericity.   
 
Figure 1.5. Particle sizing by laser light diffraction. 
 
Image Analysis 
 The last method that is of importance in sizing particles is image analysis; it is illustrated 
schematically in Figure 1.6. An example of this method consists of taking digital images of particle 
samples, converting then to binary data, designating the key dimension, and deriving particle size 
data. The analyst can perform the steps individually or use an automated piece of equipment that 
samples particles and produces particle size distribution data. Software varies, thus conversion from 
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 binary data to particle size can produce different results. However, this technique is very powerful in 
that it has the capability to account for the shape of the particles, though images are only 2-
dimensional representations of 3-dimensional particles. Another limitation of this approach is low 
capacity. Since individual particles are imaged, it takes considerably more time than the other 
techniques.  
 
Original Image Binary Image Image Processing Particle SizeOutput
Digital Image AnalysisCa
me
ra
Figure 1.6. Particle sizing by digital image analysis. 
 
While light scattering and imaging methods are very useful in the characterization of raw 
materials, i.e. drug particles or excipient particles alone, cascade impaction is the only method that 
allows the direct determination of the FPF, an aerodynamic property. Thus, it is a better measure of 
the performance of the formulation rather than the raw materials. The different methods complement 
each other. In the early stages of the formulation development process, it is not uncommon to use all 
methods at your disposal until good process control has been established or a methodology has been 
developed that is robust enough to describe all desired features. 
 
1.6.4. Surface Area and Morphology 
Particle surfaces are important elements in particle interactions, stability and ease of dispersion. 
Since aerosol particles are small, the total surface area of a powder is very large. A large surface area 
renders the particles subject to greater potential for charging and moisture uptake. In addition, the size 
of the particles renders them more susceptible to the influence of van der Waals forces.  
 
1.6.4.1 Surface Morphology 
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 Surface area is not solely determined by particle size and shape; the surface morphology also 
contributes to surface area: corrugated (i.e. rough) particles have more surface area than smooth 
particles occupying the same volume. Thus, particle morphology can also be exploited for DPI 
formulation design.120-122 By creating drug particles with specific morphology or by selecting 
(modifying) carrier particles to obtain specific surface morphology the interparticulate forces can be 
modulated to enhance lung deposition. Ideally, the contact area and, thus, the forces should be 
adjusted to a level that provides enough adhesion between drug and carrier to provide a stable 
formulation, yet allows easy separation upon inhalation. Carrier particle surface morphology has been 
shown to affect the FPF in several studies.27, 70, 122-126 However, the influence of surface corrugation on 
the FPF has not been firmly established. Smooth surface lactose carrier particles have been shown to 
increase the FPF and dispersibility of micronized drug,27 while other studies showed that corrugated 
carrier particles increased the FPF.123-126 These results appear contradictory, but may both be correct 
since the surface force balance is dependent on a number of variables not simply surface structure.  
 
1.6.4.2 Surface area and morphology measurements 
Since surface area is highly correlated with particle interactions, measurements must be obtained 
as part of the DPI formulation development effort. Determining the powder surface area involves 
measuring the volume of gas adsorbed to the powder surface at a given pressure. Several models have 
been developed to describe gas-solid adsorption behavior, the most prominent one being the 
Brunauer, Emmett, and Teller (BET) equation.127 Another important technique for examining particle 
morphology is scanning electron microscopy (SEM), which can provide high magnification, high 
resolution images of particles. However, the technique suffers from the shortcoming, that only a small 
portion of particles can be screened. Over the last few decades, new techniques for studying surfaces 
have emerged or have been borrowed from other scientific disciplines. One particularly noteworthy 
method is inverse gas chromatography (IGC), which is used extensively for surface energy 
measurements in this research project and which is discussed in detail in Chapter 3. 
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 1.7. Interparticulate Forces of Interaction 
Particle separation is the most significant performance requirement for effective aerosol 
generation. In order to separate particles specific forces of interaction must be overcome. There are 
four major physical interactions between particles: (1) mechanical interlocking; (2) capillary forces 
from the presence of water; (3) intermolecular interactions; and (4) electrostatic forces.  
Mechanical interlocking, due to surface asperities, may prevent particles from dislodging and 
may thus prevent particle dispersion. Regular particle shapes with smooth surface morphology may 
reduce the propensity for particles to interlock. The presence of moisture, even in small quantities, 
may bring about capillary forces.128 The magnitude of these forces is related to the diameter of the 
pores between particles and the interfacial tension due to hydrogen bonding of water. Controlling 
moisture content will aid in reducing capillary forces. 
 
1.7.1. Intermolecular Interactions 
Intermolecular interactions have two contributions, Lifshitz-van der Waals (LW) interactions and 
the acid-base (AB) interactions.129 LW interactions consist of London dispersion forces, Debye 
dipole/ induced dipole forces, and Keesom dipole/dipole forces. London dispersion forces are 
independent of molecular polarity and result from natural electron cloud oscillations, which induce 
oscillations in adjacent molecules. Since London dispersion predominates LW interactions, they are 
frequently referred to as simply dispersive interactions, and the superscript 'disp' is used.  
In contrast to the ubiquitous dispersive interactions, AB interactions are present only when proton 
or electron sharing or transfer occurs between functional groups of nearby molecules or surfaces. 
These interactions are specific to each system of interacting surfaces, which is why they are more 
commonly referred to as specific interactions and are designated herein by superscript 'spec'.  
As stipulated by Fowkes, dispersive and specific interactions contribute to total intermolecular 
interactions independenty.130, 131 Consequently, work of adhesion (WA), a thermodynamic measure of 
  26
 the work needed to separate two surfaces from contact, can be represented as the sum of dispersive 
and specific contributions according to equation 1.2 132 
        (1.2) specdispA WWW 
Alternatively, work of adhesion can be defined by  
   1221  AW     (1.3)        
where 1 and 2 are the surface free energies of the individual materials that make up the interface, 
and 12 is the interfacial free energy between them.132  
Reducing the work of adhesion, , is one approach to enhancing drug-carrier particle 
separation.  can be reduced by decreasing either and/or . While dispersive forces are 
always present between adjacent molecules, they can, nevertheless, be manipulated by reducing the 
particle contact area or increasing the distance between particles. Low density, high porosity particles 
achieve this goal.133  Decreasing the specific contribution to work of adhesion requires matching the 
drug particles with a carrier particle with which it does not strongly interact. Alternatively, based on 
equation 1.3, adhesion can be modified by reducing surface free energy of the particles or increasing 
the interfacial free energy between them. While simple in theory, this approach is experimentally 
difficult because surface free energy determinations of powders are cumbersome; the commonly used 
contact angle approach requires compression of powder which could significantly alter the surface 
properties. One way to approach the problem is by inverse gas chromatography measurements which 
are discussed in detail in Chapter 3. IGC measurements allow determination of both dispersive and 
specific (acid-base) surface properties for powders. 
AW
AW
dispW specW
 
1.7.2. Electrostatic Forces 
1.7.2.1 Aerosol Electrostatics 
Electrostatic charging has been known since Ancient Greece.134 It has been studied in the context 
of powder handling,135 where it was characterized as a nuisance136-138 or explosion risk139. 
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 Electrostatic particle charging has inspired a number of industrial applications, such as the 
electrostatic precipitator, electrostatic dry powder coating, and powder separation. Electrostatic 
charging is the basis of xerography, where charged toner particles attach to the latent image on the 
drum surface to create a visible toner image.140 Despite these innovations, the electrostatic charging 
process is not fully understood, particularly for nonconducting materials; numerous factors affect the 
phenomenon and inconsistent experimental results have been reported.135 
Electrostatic forces are described by Coulomb’s Law, the natural starting point for a discussion of 
electrostatics. Coulomb’s law is experimentally determined, but often treated as a mathematically 
derived fundamental relationship.141 It states that a force between two point charges, F12, is 
proportional to the magnitude of each charge Q1 and Q2, inversely proportional to the square of the 
distance, r, between the charges, and is directed along the line connecting the charges 
2
21
12 r
QQKF E ,     (1.4) 
where the constant KE is inversely related to permittivity , via equation 1.5 
4
1EK      (1.5) 
 
In case of aerosols, the permittivity is the permittivity of vacuum, o = 8.85 · 10-12 C2/ N · m2, so that 
KE is 9.0 · 109 N·m2 / C2.  
Most atmospheric aerosol particles naturally carry a low level of charge in accordance with 
Boltzmann equilibrium charge distribution theory, which for particles greater than 0.05m, can be 
written as 
      
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 where fn is the fraction of particles of particle diameter dp having n (positive or negative) elementary 
charges 107. kB is Boltzmann’s constant. The average number of charges, n , for aerosol particles can 
be estimated by  
     pdn 37.2      (1.7) 
where dp is given in m. Equation 1.7 is an empirical relationship that is accurate to within ±5% for 
particles greater than 0.2m.107 The Boltzmann distribution predicts charges of less than ±5 
(elementary charges) for most particles with dp < 5m. Active charging mechanisms such as diffusion 
and field charging can produce particle charges 2-3 orders of magnitude larger than what is predicted 
by Boltzmann distribution.107 According to the results of Bailey 142 and Fraser 143, particle charges in 
the >100 elementary charges range can enhance the deposition of micron-size particles in the lungs.  
While the Boltzmann charge distribution gives the lower limit of charge for an aerosol, it is also 
important to consider the upper charge limits. The maximum number of negative charges that a 
particle can support, nL, is given by the equation 107  
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      (1.8) 
where dp is the particle diameter, EL is the surface field strength required for spontaneous electron 
emission (9.0 x 108 V/m), KE is the Coulomb's law constant, and e is the charge of an electron, 1.6 x 
10-19 C. The maximum number of charges is proportional to the surface area. Equation 1.8 assumes 
particles are spherical; nonspherical particles have larger surface area and would be expected to have 
higher charge limits. Since it is more difficult for a particle to emit a positive ion from its surface, the 
positive charge limit is also higher. 
Aerosol particles can acquire charge by flame charging, static electrification, diffusion charging, 
and field charging.107 Of these mechanisms, static electrification plays an important role during DPI 
actuation. Static electrification occurs when particles are detached from surfaces or the bulk phase 
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 resulting in a separation of charges. In DPIs, this occurs naturally in the form of surface charging, or 
triboelectrification.  
 
1.7.2.2 Contact Charging and Triboelectrification 
Triboelectrification is a form of contact charging in which materials come into contact and 
acquire electrical charge, which they retain after separation. Contact charging occurs due to 
differences in the work functions of different materials, i.e. electrons move from one material to the 
other more easily than in the reverse direction. When put into contact, almost any two solids will 
produce a voltage difference, referred to as a contact potential. The presence of an electric field is not 
required for charge transfer to occur.140 
For metals, the contact charging process can be explained in terms of band theory: valence and 
conduction bands overlap so that a portion of the valence electrons can move through the metal. The 
work function, , the minimum energy needed to extract an electron from a material (more precisely, 
it is the energy necessary to remove electrons from Fermi level to infinity), however differs between 
different metals. When two metals with differing work functions / Fermi levels are placed in contact, 
electrons are transferred from one to the other until the Fermi levels align. The result of the electron 
transfer is a potential difference, the material with the higher work function acquires a surplus of 
electrons and thus a negative charge. This has been experimentally validated.144 The potential 
difference remains after the metals are separated, though some backflow may occur. 
The situation is thought to be analogous for insulators.140 However, the concept of work functions 
is more abstract since energy levels are poorly defined, and Fermi levels are not occupied. Ideal 
insulators are not expected to charge at all, but real materials do display contact charging because 
impurities and morphology defects produce additional energy levels into which charge can move.145 
As stated by Bailey,146 for charge transfer to or from an insulator to occur, electron donor or acceptor 
sites need to be present at or near the surface of the material.  
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 Insulators or dielectrics are defined as materials having low conductivity, . When thinking about 
the charging properties of insulators it is also useful to consider the times necessary for charge 
transfer.147 The charge relaxation constant, , is defined as 
     
        (1.9) 
where  is the permittivity, as already defined above. The permittivity can also be expressed in terms 
of the free space permittivity, 0, by  
     0 r      (1.10) 
where r is the relative permittivity, which is also called the dielectric constant. The dielectric 
constant indicates the polarizibility of a dielectric; dielectric constants for many materials can be 
obtained from handbooks. Insulators have high dielectric constants, low conductivities and therefore 
large time constants. Charge transfer between insulators is slow compared to conductors. The time 
scale of contact must, therefore, be considered in contact electrification processes involving 
insulators.147 Charge relaxation times of insulators are in the order of seconds (0.5s for corn oil) to 104 
seconds (5.1 x 104 s for mica), though they vary widely and may differ for different presentations of 
the same material.148 
Tribocharging is a specific term applied to contact charging that results from materials being 
rubbed (tribo means “rub” in Greek) together. Friction in itself does not lead to triboelectrification, 
but increases the number of points of contact which facilitates charge transfer. Local heat gradients 
may evolve due to the rubbing, and heat also affects charging.146 It is difficult to separate the effects 
of tribocharging from simple contact electrification, which is why the terms are often combined.140 
They are used interchangeably here as well. 
Some researchers have suggested that adsorbed water and electrolytic ions play an important role 
in the surface charging process.149 While surface contaminants are always present and may affect 
charging or promote surface leakage, it has been shown that they are not necessary for charging of 
insulators to occur. As cited by Harper,149 Coehn and Lotz (1921) proved that triboelectric charging 
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 occurs after surfaces have been thoroughly cleaned and water has been rigorously expelled. 
Nonetheless, for experimental purposes, surfaces must be considered contaminated. 
Triboelectrification of insulators remains poorly understood.150 Conflicting observations have 
been reported and consistency between labs has often been lacking. Clearly, cleanliness and 
environmental conditions play an important role; this has been shown experimentally.151 However, 
discrepancies go beyond environmental control. As an example of the complexities involved in the 
charging process, consider that different crystal faces of quartz display different charging 
characteristics.149 Similarly, polycrystalline ice has been shown to charge differently from 
monocrystalline ice.152 Nonetheless, some general trends have been observed in the interaction of 
different materials; part of this information has been captured in triboelectric series, which rank 
materials in their propensity of acquiring positive (and negative) electric charge. There have been 
attempts at constructing triboelectric series for pharmaceutical materials as well.153 Some 
investigators have also classified insulators in terms of “pseudo-work functions” by measuring charge 
transfer between insulators and metal surfaces,146 a more quantitative approach to the construction of 
triboelectric series. 
 
1.7.2.3 Aerosol Electrostatics and Particle Deposition  
Electrostatics not only play a role in particle adhesion, but also in particle deposition. Computer 
simulations have indicated that electrostatic deposition is important for small particles in the lower 
lung regions, particularly the alveoli.154 The alveolar region is the site of most 2-adrenergic 
receptors42 as well as the region from which systemic absorption is most efficient. Thus, it is an 
important site for targeting therapeutic aerosols. Deposition enhancement due to electric charge was 
also shown in vivo; using rabbits and silica particles of variable size, Fraser showed that the 
deposition of particles (0.4 – 3.5 μm size range) in the respiratory system was significantly increased 
as particles were charged.143 More recently, the effect of charge on deposition of both MDI and DPI 
products was shown in experiments involving a human oral-pharyngeal-laryngeal airways cast; again 
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 deposition enhancement was observed in the presence of particle charge.155 Despite these results, 
electrostatic charging is not exploited for the delivery of medicines. 
 
1.8. Previous Work 
Electrostatic forces affect the adhesional properties and separation efficiency of particles in the 
formulation. They may influence the transport of particles and can result in undesirable adhesion of 
charged drug particles to a device or other surfaces, and they may also affect the trajectory and 
deposition of drug within the lungs. In light of these potential effects, electrostatic forces are clearly 
an important consideration in DPI formulation development. In recent years they have been the 
subject of a number of pharmaceutically relevant studies. Different techniques have been applied to 
the characterization of DPI electrostatics, with different aims and to varying degrees of success. Some 
of the important past studies of DPI charging phenomena are discussed in the context of the 
techniques that have been used. 
 
1.8.1. Faraday Cage  
The majority of studies of medicinal aerosol electrostatics have made use of Faraday cages, or 
Faraday-cage based experimental apparatus. A Faraday cage (also Faraday pail or cup) consists of 
some receiving surface contained within a cup enclosure that shields the inside from the effect of 
external electric fields. As a charged object (e.g. powder) is deposited on the receiving plate within 
the cage, it dissipates its electric charges which in turn are detected by an electrometer. One of the 
first successful aerosol electrostatic characterizations can be credited to Byron et al.,156 who 
developed an experimental apparatus based on an impinger and Faraday cage, which allowed the 
charge of DPI emissions to be measured. (Recently, more advanced impinger /Faraday cage based 
designs were described.157, 158) The study included bulk measurements of powders as well as emitted 
dose measurements of commercial DPI products. No effort was made in formulating the material; the 
study focused on triboelectification of aerosolized pure compounds. While the study suffered from 
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 these obvious drawbacks, the authors were nevertheless able to produce a triboelectric series of pure 
pharmaceutical compounds and estimate (using an overly simple assumption of mondisperse particle 
size) the per particle charge level, which was found to be high enough to affect deposition 
(approximately 200 electronic charges per aerosol drug particle). 
Bennett et al.159 used a design based on Faraday cage principles to determine the charge of 
pneumatically conveyed lactose powders. Importantly, the authors observed that the presence of 
various fractions of fine particles affected the charging propensity of the bulk powder.  
Electrostatic charge carried by a DPI aerosol cloud has also been measured using a grid probe;160 
however, the particles were large and the system was of little pharmaceutical relevance. The effects of 
particle morphology and crystallinity on triboelectrification of DPIs have been studied, but particle 
deposition was not considered.161 Moreover, use of the Faraday cage precluded analysis of different 
size fractions and charge distribution. Cassidy et al.162, 163 have also studied the propensity of different 
pharmaceutical materials to acquire charge, though their interest pertained to pneumatic conveying 
and processing; the results of their work are not relevant to respiratory drug delivery. With a slightly 
different focus, Elajnaf et al.164 recently used a corona charger with a Faraday cage based apparatus to 
study the electrostatic charge decay of charged pharmaceutical materials; the powders were 
compacted into 5mm discs, the discs were charged and the charge dissipation was measured inside a 
Faraday cage; the authors found dissipation times in the order of tens to hundreds of minutes, which 
seem extremely high and question the study's relevance to micron-size drug particles delivered from 
DPIs. 
 
1.8.2. Single Particle Impact Electrostatics 
A variation from the Faraday cage powder electrostatic measurements are the recent 
measurements of charges associated with single particle impacts.165, 166 The studies were able to shed 
some light on the charge transfer experienced during particle-wall collisions. Moreover, unlike 
regular Faraday cage methods, which measure only the net charge of a larger powder sample and 
  34
 hence may only provide rough charge-to-mass (Q/M) information, the single impact method can 
measure actual particle charges. However, the single particle method does not lend itself to particles 
in the single micron-size, and is more relevant to pneumatic conveying systems than to DPIs; as in 
previous studies the authors neglected to consider the contact charging process within the formulation 
which is a likely contribution to the aerosol charging in DPI. 
 
1.8.3. Electrical Single Particle Aerodynamic Relaxation Time (E-SPART) 
E-SPART measurements are also based on single particle measurements, but go further than the 
single particle impact device. As in previous electrical mobility measurements,167 charge is measured 
indirectly by particle behavior within an electric field. The E-SPART Analyzer has been around since 
at least the 1980s and has been applied to the characterization of many electrostatic particulate 
systems, e.g. printer toner particles.168, 169 The principles of operation are discussed elsewhere.170 
Briefly, the E-SPART samples aerosols at low flow rates (1L/min) and detects particles by laser 
Doppler velocimetry. An oscillating electric field within the device causes particles to oscillate and 
the particles' response to these oscillations supplies information on the particles' count mean 
aerodynamic diameter, and charge-to-mass ratio. Saini et al.171 recently used the E-SPART to study 
MDI and DPI particle electrostatics.  Inhalers were actuated into a collection chamber from which the 
E-SPART sampled particles over the course of several minutes. While the paper neglects to consider 
carefully the pharmaceutical implications of the experiments (e.g. it is unclear from the paper which 
drugs and inhalers were tested) the study showed differentiated and bipolar particle charging, and 
suggested charging was the result of inhaler and formulation. 
 
1.8.4. Electrical Low Pressure Impaction 
The ELPI, described briefly earlier and subject to more in-depth discussion in Chapter 4, is a 
cascade impactor in which charge depositions on the individual, electrically insulated stages can be 
measured. The ELPI can classify particle size fractions and measure the charge on each impactor 
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 stage. Unlike the E-SPART it cannot obtain charges for individual particles but rather average 
charges for mass deposited on a given impactor collection plate. Using the ELPI, tribocharging within 
the formulation was implicated as the likely cause of the drug particle charge.172  The studies also 
clearly showed for the first time that DPI charging of drug was subject to strong formulation and 
device effects.172 Furthermore, since impactor stages are electrically isolated, size specificity of 
charging could be evaluated. However, the studies left a lot of questions unanswered, which is why a 
more thorough investigation is in order. 
The studies herein rely heavily on the ELPI. They constitute a more comprehensive investigation 
of the DPI electrostatic phenomenon, with more variables, a more in-depth look at the accurate 
determination of magnitude and polarity of charge on particles in the respirable size range over time. 
Using complementary techniques the physicochemical origins of contact charging are probed.  
 
1.9. Problem Statement  
The DPI formulation presents a system that lends itself to triboelectric charging: Drug and carrier 
particles are in close contact in the formulation and are separated during actuation; the contacts can 
lead to charge transfer resulting in net particle charge. DPI formulations are usually insulating 
materials maintained at low humidities; they experience significant friction during discharge which 
may further increase triboelectric charging.  
Electrostatic charges play a significant role in the particle adhesion and separation process, as 
well as during deposition in the respiratory tract. There is evidence to suggest that tribocharging in the 
DPI is quite significant, yet the extent and the implications of DPI charging are not fully understood. 
However, it is clear that particle charging is being used in a number of other industries to control 
particle behavior. Charge may also be a design advantage for medicinal aerosols. Understanding the 
degree to which tribocharging occurs and the effect of formulation variables on the process could 
enhance the DPI formulation development process. It is postulated that triboelectric charging is a 
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 major factor in drug delivery from DPIs and that its characterization and control can be utilized to 
maximize DPI performance.  
 
1.10. Hypotheses and Specific Aims 
1.10.1. Hypotheses 
1.10.1.1 Electrostatic charging is a consequence of triboelectrification during inhaler actuation. 
1.10.1.2 Magnitude and polarity of charge on drug particles can be controlled by formulation 
variables, independently of the chemical identity of the drug being delivered. 
1.10.1.3 The acid-base characteristics of a pharmaceutical material, as determined by inverse gas 
chromatography, are directly related to its triboelectric charging characteristics and its 
position in the triboelectric series.  
1.10.1.4 By selecting formulation properties and inhaler, micronized drug can be made to acquire 
charges well beyond the Boltzmann equilibrium charge distribution theory. 
 
1.10.2. Specific Aims 
 The following specific aims will be pursued in addressing the above hypotheses. 
 
1.10.2.1 To elucidate the phenomenon of triboelectric charging during DPI actuation.  
(a) The electrostatic properties of albuterol sulphate, budesonide and three excipients (lactose 
(disaccharide), glucose (monosaccharide), and inorganic salt (e.g. calcium phosphate)), including 
different batches, size fractions, and blends will be studied using Faraday cage experiments to 
determine charge in the absence of frictional triboelectrification.  
(b) From Faraday well experiments, pseudo-work functions will be determined for the drugs, 
excipients, excipient batches and sieve fractions. 
(c) The effect of last surface of contact will be established by using different materials during Faraday 
cage discharge. 
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 (d) The electrostatic charges of the above materials will be studied using the Electrical Low Pressure 
Impactor (ELPI), in conjunction with standard flow tubes and inhaler devices to determine the 
effect of inspiratory airflow on triboelectrification. 
(e) Charge and particle size deposition will be determined and fully characterized in each case using 
the ELPI.  
 
1.10.2.2 To determine the contribution of specific formulation factors.   
(a) The effect of chemistry (drug and excipients), manufacture process, blend concentration, pressure 
drop, and materials (capsule and inhaler) on electrostatic charge will be determined in ELPI 
deposition experiments. 
(b) Materials and formulation components, including different excipient sieve fractions, and batches 
will be used to create a triboelectric series. 
 
1.10.2.3 To determine the correlation between surface acid/base properties and triboelectric charging.  
(a) The dispersive surface free energy and specific acid/base surface characteristics of select drugs, 
excipients, blends, and sieve fractions will be studied by inverse gas chromatography. 
(b) The relationship between surface acid/base parameters and pseudo-work functions will be 
investigated, i.e. acid/base parameters will be related to charge sign and magnitude. 
 
1.10.2.4 To determine if tribocharging can increase particle charge beyond Boltzmann distribution.  
(a)  Using the developed triboelectric series, drugs will be formulated to give maximal charging. 
(b) Charge during deposition studies in ELPI will be measured and compared to Boltzmann 
distribution. 
 
 
 
  38
 1.11. Conclusion 
Dry powder inhalers are increasingly important respiratory delivery devices. Particle electrostatic 
charging is used in a number of applications to bring about specific particle behavior; its use in dry 
powder inhalers has not been studied. Simulations, in vitro and in vivo studies suggest that charge can 
increase the deposition of aerosol particles in the lung. Due to their design and material characteristics 
DPI devices and formulations lend themselves to triboelectric charging. The project aim is to 
characterize particle charging in the DPI to determine if tribocharging can be utilized for DPI 
formulation development and drug delivery. The research is likely to yield secondary results that will 
further our understanding of DPI formulations and behavior.  
There have been few studies that probed aerosol electrostatics but none that has studied 
pharmaceutically relevant systems. There is no comprehensive model relating formulation variables 
with electrostatic charging and delivery. Use of the ELPI for this work has distinct advantages over 
other techniques as it allows concurrent determination of particle size and charge for particles in the 
respirable size range. Studies to date have focused on the entire discharge or on particles larger than 
what could be inhaled. 
While it has been suggested that triboelectric charging of insulators is related to the presence of 
electron donor and electron acceptor sites on the surface,146 this hypothesis has never been evaluated. 
The specific aim of linking specific surface energy data with charging holds promise to do that. If this 
hypothesis is supported by experimental data, our understanding of insulator charging would be 
significantly enhanced, and confounding data may be explained. The result would have implications 
not just to the field of pharmaceutical sciences, but could advance the entire field of particle 
electrostatics. 
 
 
 
 
  39
 1.12. Acknowledgements  
The first part of this introduction chapter is based on an article published previously in 
Respiratory Care.173 The publisher has kindly permitted use of the article in full or of passages but has 
requested that the sections not be altered. Several sections have been reproduced though the order in 
which they are presented has been changed and some sections and figures have been omitted. 
 
  40
 1.13. Literature Cited 
1. Di, L. & Kerns, E. H. Profiling drug-like properties in discovery research. Current Opinion in 
Chemical Biology 7, 402-408 (2003). 
2. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. 
Journal of Pharmacological and Toxicological Methods 44, 235-249 (2000). 
3. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Advanced Drug Delivery Reviews 23, 3-25 (1997). 
4. Timsina, M. P., Martin, G. P., Marriott, C., Ganderton, D. & Yianneskis, M. Drug-Delivery 
to the Respiratory-Tract Using Dry Powder Inhalers. International Journal of Pharmaceutics 
101, 1-13 (1994). 
5. Aswania, O. et al. Intra-subject variability in lung dose in healthy volunteers using five 
conventional portable inhalers. J Aerosol Med 17, 231-8 (2004). 
6. Cochrane, M. G., Bala, M. V., Downs, K. E., Mauskopf, J. & Ben-Joseph, R. H. Inhaled 
corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. 
Chest 117, 542-50 (2000). 
7. Smyth, H. D. C. & Hickey, A. J. Carriers in drug powder delivery: Implications for inhalation 
system design. American Journal of Drug Delivery 3 (2005). 
8. Dolovich, M. B. et al. Device selection and outcomes of aerosol therapy: Evidence-based 
guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and 
Immunology. Chest 127, 335-71 (2005). 
9. Crooks, P. A. & Al-Ghananeem, A. M. Drug targeting to the lung: chemical and biochemical 
considerations, in Pharmaceutical inhalation aerosol technology, edited by A. Hickey (M. 
Dekker, New York, 2004). 
10. Barry, P. W. & O'Callaghan, C. The influence of inhaler selection on efficacy of asthma 
therapies. Adv Drug Deliv Rev 55, 879-923 (2003). 
11. Rau, J. L. The inhalation of drugs: advantages and problems. Respir Care 50, 367-82 (2005). 
12. O'Connor, B. J. The ideal inhaler: design and characteristics to improve outcomes. Respir 
Med 98 Suppl A, S10-6 (2004). 
13. Newman, S. P. & Clarke, S. W. Bronchodilator delivery from Gentlehaler, a new low-
velocity pressurized aerosol inhaler. Chest 103, 1442-6 (1993). 
14. Ganderton, D. General factors influencing drug delivery to the lung. Respiratory Medicine 
91, 13-16 (1997). 
15. Newman, S. P. & Newhouse, M. T. Effect of add-on devices for aerosol drug delivery: 
deposition studies and clinical aspects. J Aerosol Med 9, 55-70 (1996). 
  41
 16. Giraud, V. & Roche, N. Misuse of corticosteroid metered-dose inhaler is associated with 
decreased asthma stability. Eur Respir J 19, 246-51 (2002). 
17. Borgstrom, L., Derom, E., Stahl, E., Wahlin-Boll, E. & Pauwels, R. The inhalation device 
influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care 
Med 153, 1636-40 (1996). 
18. Ashurst, I. I., Malton, A., Prime, D. & Sumby, B. Latest advances in the development of dry 
powder inhalers. Pharm. Sci. Technol. Today 3, 246-256 (2000). 
19. Norwood, D. L. et al. Analysis of polycyclic aromatic hydrocarbons in metered dose inhaler 
drug formulations by isotope dilution gas chromatography/mass spectrometry. J Pharm 
Biomed Anal 13, 293-304 (1995). 
20. Dalby, R. & Suman, J. Inhalation therapy: technological milestones in asthma treatment. Adv 
Drug Deliv Rev 55, 779-91 (2003). 
21. Newman, S. P. & Busse, W. W. Evolution of dry powder inhaler design, formulation, and 
performance. Respir Med 96, 293-304 (2002). 
22. Dunbar, C. A., Hickey, A. J. & Holzner, P. Dispersion and Characterization of 
Pharmaceutical Dry Powder Aerosols. KONA 16, 7-44 (1998). 
23. Smith, I. J. & Parry-Billings, M. The inhalers of the future? A review of dry powder devices 
on the market today. Pulm Pharmacol Ther 16, 79-95 (2003). 
24. Newman, S., Hollingworth, A. & Clark, A. Effect of different modes of inhalation on drug 
delivery from a dry powder inhaler. International Journal of Pharmaceutics 102, 127-132 
(1994). 
25. Cegla, U. H. Pressure and inspiratory flow characteristics of dry powder inhalers. Respir Med 
98 Suppl A, S22-8 (2004). 
26. Dunbar, C. A., Morgan, B., Van Oort, M. & Hickey, A. J. A comparison of dry powder 
inhaler dose delivery characteristics using a power criterion. PDA J Pharm Sci Technol 54, 
478-84 (2000). 
27. Zeng, X. M., Martin, A. P., Marriott, C. & Pritchard, J. The influence of carrier morphology 
on drug delivery by dry powder inhalers. Int J Pharm 200, 93-106 (2000). 
28. Tobyn, M., Staniforth, J. N., Morton, D., Harmer, Q. & Newton, M. E. Active and intelligent 
inhaler device development. Int J Pharm 277, 31-7 (2004). 
29. Crowder, T. M. Vibration technology for active dry-powder inhalers. Pharmaceutical 
Technology 28, 52-61 (2004). 
30. Crowder, T. M., Louey, M. D., Sethuraman, V. V., Smyth, H. D. C. & Hickey, A. J. An 
odyssey in inhaler formulations and design. Pharmaceutical Technology 25, 99-113 (2001). 
31. Crooks, P. A. & Damani, L. A. Drug Application to the Respiratory Tract: Metabolic and 
Pharmacokinetic Considerations. Respiratory Drug Delivery I 1, 61-90 (1990). 
  42
 32. Patton, J. S. & Platz, M. P. Pulmonary delivery of peptides and proteins for systemic action. 
Adv Drug Deliv Rev 8, 179-196 (1992). 
33. Byron, P. R. & Patton, J. S. Drug delivery via the respiratory tract. J Aerosol Med 7, 49-75 
(1994). 
34. Niven, R. W., Lott, F. D., Ip, A. Y. & Cribbs, J. M. Pulmonary delivery of powders and 
solutions containing recombinant human granulocyte colony-stimulating factor (rhG-CSF) to 
the rabbit. Pharm Res 11, 1101-9 (1994). 
35. Cefalu, W. T. Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes 
Care 27, 239-46 (2004). 
36. Owens, D. R., Zinman, B. & Bolli, G. Alternative routes of insulin delivery. Diabet Med 20, 
886-98 (2003). 
37. Patton, J. S., Bukar, J. & Nagarajan, S. Inhaled insulin. Adv Drug Deliv Rev 35, 235-247 
(1999). 
38. Patton, J. S. Pulmonary delivery of drugs for bone disorders. Adv Drug Deliv Rev 42, 239-48 
(2000). 
39. Roth, Y., Chapnik, J. S. & Cole, P. Feasibility of aerosol vaccination in humans. Ann Otol 
Rhinol Laryngol 112, 264-70 (2003). 
40. Tronde, A. et al. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: 
structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm 
Sci 92, 1216-33 (2003). 
41. Hickey, A. J. in Drug Delivery: Principles and Applications (eds. Wang, B., Siahaan, T. & 
Soltero, R. A.) pp 341-361 (John Wiley & Sons, Inc., Hoboken, N.J., 2005). 
42. Labiris, N. R. & Dolovich, M. B. Pulmonary drug delivery. Part I: physiological factors 
affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56, 588-
99 (2003). 
43. Howarth, P. H. Why particle size should affect clinical response to inhaled therapy. J Aerosol 
Med 14 Suppl 1, S27-34 (2001). 
44. Bergstrom, C. A. et al. Absorption classification of oral drugs based on molecular surface 
properties. J Med Chem 46, 558-70 (2003). 
45. Palm, K., Luthman, K., Ungell, A. L., Strandlund, G. & Artursson, P. Correlation of drug 
absorption with molecular surface properties. J Pharm Sci 85, 32-9 (1996). 
46. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug 
candidates. Journal of Medicinal Chemistry 45, 2615-2623 (2002). 
47. Kerns, E. H. & Di, L. Pharmaceutical profiling in drug discovery. Drug Discov Today 8, 316-
23 (2003). 
48. Barnes, P. J. A single inhaler for asthma? Am J Respir Crit Care Med 171, 95-6 (2005). 
  43
 49. Suarez, S. & Hickey, A. J. Drug properties affecting aerosol behavior. Respir Care 45, 652-66 
(2000). 
50. Snow, R. H., Allen, T., Ennis, B. J. & Litster, J. D. in Perry's Chemical Engineers' Handbook 
(eds. Perry, R. H. & Green, D. W.) (McGraw-Hill, New York, 1999). 
51. Begat, P., Young, P. M., Edge, S., Kaerger, J. S. & Price, R. The effect of mechanical 
processing on surface stability of pharmaceutical powders: Visualization by atomic force 
microscopy. Journal of Pharmaceutical Sciences 92, 611-620 (2003). 
52. Cheng, Y. S., Marshall, T. C., Henderson, R. F. & Newton, G. J. Use of a jet mill for 
dispersing dry powder for inhalation studies. Am Ind Hyg Assoc J 46, 449-54 (1985). 
53. Drogemeier, R. & Leschonski, K. Ultra fine grinding in a two stage rotor impact mill. 
International Journal of Mineral Processing 44-5, 485-495 (1996). 
54. Hu, G., Otaki, H. & Watanuki, K. Optimization of grinding performance of tumbling ball 
mill. Jsme International Journal Series C-Mechanical Systems Machine Elements and 
Manufacturing 44, 267-274 (2001). 
55. Steckel, H. & Brandes, H. G. A novel spray-drying technique to produce low density particles 
for pulmonary delivery. Int J Pharm 278, 187-95 (2004). 
56. Chawla, A., Taylor, K. M. G., Newton, J. M. & Johnson, M. C. R. Production of Spray-Dried 
Salbutamol Sulfate for Use in Dry Powder Aerosol Formulation. International Journal of 
Pharmaceutics 108, 233-240 (1994). 
57. Vidgren, M. T., Vidgren, P. A. & Paronen, T. P. Comparison of Physical and Inhalation 
Properties of Spray-Dried and Mechanically Micronized Disodium-Cromoglycate. 
International Journal of Pharmaceutics 35, 139-144 (1987). 
58. Debenedetti, P. G., Tom, J. W., Kwauk, X. & Yeo, S. D. Rapid Expansion of Supercritical 
Solutions (Ress) - Fundamentals and Applications. Fluid Phase Equilibria 82, 311-321 
(1993). 
59. Velaga, S. P., Berger, R. & Carlfors, J. Supercritical fluids crystallization of budesonide and 
flunisolide. Pharm Res 19, 1564-71 (2002). 
60. Schiavone, H., Palakodaty, S., Clark, A., York, P. & Tzannis, S. T. Evaluation of SCF-
engineered particle-based lactose blends in passive dry powder inhalers. International Journal 
of Pharmaceutics 281, 55-66 (2004). 
61. Jung, J. & Perrut, M. Particle design using supercritical fluids: Literature and patent survey. 
Journal of Supercritical Fluids 20, 179-219 (2001). 
62. Handbook of pharmaceutical excipients (eds. Rowe, R. C., Sheskey, P. J. & Weller, P. J.) 
(Pharmaceutical Press, Chicago, 2003). 
63. Steckel, H. & Bolzen, N. Alternative sugars as potential carriers for dry powder inhalations. 
Int J Pharm 270, 297-306 (2004). 
  44
 64. Tee, S. K., Marriott, C., Zeng, X. M. & Martin, G. P. The use of different sugars as fine and 
coarse carriers for aerosolised salbutamol sulphate. International Journal of Pharmaceutics 
208, 111-123 (2000). 
65. Shah, S. P. & Misra, A. Development of liposomal amphotericin B dry powder inhaler 
formulation. Drug Deliv 11, 247-53 (2004). 
66. Joshi, M. & Misra, A. N. Pulmonary disposition of budesonide from liposomal dry powder 
inhaler. Methods Find Exp Clin Pharmacol 23, 531-6 (2001). 
67. Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H. & Takeuchi, H. Design of inhalation 
dry powder of pranlukast hydrate to improve dispersibility by the surface modification with 
light anhydrous silicic acid (AEROSIL 200). International Journal of Pharmaceutics 173, 
243-251 (1998). 
68. Lucas, P., Anderson, K., Potter, U. J. & Staniforth, J. N. Enhancement of small particle size 
dry powder aerosol formulations using an ultra low density additive. Pharmaceutical 
Research 16, 1643-1647 (1999). 
69. Kawashima, Y., Serigano, T., Hino, T., Yamamoto, H. & Takeuchi, H. A new powder design 
method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface 
modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm Res 15, 
1748-52 (1998). 
70. Zeng, X. M., Martin, G. P., Marriott, C. & Pritchard, J. Lactose as a carrier in dry powder 
formulations: the influence of surface characteristics on drug delivery. J Pharm Sci 90, 1424-
34 (2001). 
71. Podczeck, F. The relationship between physical properties of lactose monohydrate and the 
aerodynamic behaviour of adhered drug particles. International Journal of Pharmaceutics 160, 
119-130 (1998). 
72. Islam, N., Stewart, P., Larson, I. & Hartley, P. Effect of carrier size on the dispersion of 
salmeterol xinafoate from interactive mixtures. J Pharm Sci 93, 1030-8 (2004). 
73. Chew, N. Y. K. & Chan, H. K. The role of particle properties in pharmaceutical powder 
inhalation formulations. Journal of Aerosol Medicine-Deposition Clearance and Effects in the 
Lung 15, 325-330 (2002). 
74. Sethuraman, V. V. & Hickey, A. J. Powder properties and their influence on dry powder 
inhaler delivery of an antitubercular drug. AAPS PharmSciTech 3, E28 (2002). 
75. Crowe, C. T., Sommerfeld, M. & Tsuji, Y. Multiphase flows with droplets and particles 
(CRC Press, Boca Raton, Fla., 1998). 
76. Kreith, F. Fluid mechanics (CRC Press, Boca Raton, Fla., 2000). 
77. Gidaspow, D. Multiphase flow and fluidization : continuum and kinetic theory descriptions 
(Academic Press, Boston, 1994). 
78. Kolev, N. I. Multiphase flow dynamics (Springer, Berlin ; New York, 2005). 
  45
 79. Johnson, R. W. The handbook of fluid dynamics (CRC Press, Boca Raton, Fla., 1998). 
80. Brittain, H. Physical characterization of pharmaceutical solids (Marcel Dekker Inc., New 
York, 1995). 
81. Brittain, H. Polymorphism in pharmaceutical solids (Marcel Dekker Inc., New York, 1999). 
82. Moulton, B. & Zaworotko, M. J. From molecules to crystal engineering: Supramolecular 
isomerism and polymorphism in network solids. Chemical Reviews 101, 1629-1658 (2001). 
83. Henck, J. O., Griesser, U. J. & Burger, A. Polymorphism of drug substances - An economic 
challenge. Pharmazeutische Industrie 59, 165-169 (1997). 
84. Grzesiak, A. L., Lang, M., Kim, K. & Matzger, A. J. Comparison of the four anhydrous 
polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 92, 2260-71 
(2003). 
85. Cartensen, J. T. Pharmceutics of solids and solid dosage forms (John Wiley and Sons, New 
York, NY, 1989). 
86. Garekani, H. A., Sadeghi, F., Badiee, A., Mostafa, S. A. & Rajabi-Siahboomi, A. R. Crystal 
habit modifications of ibuprofen and their physicomechanical characteristics. Drug 
Development and Industrial Pharmacy 27, 803-809 (2001). 
87. Stoica, C. et al. Understanding the effect of a solvent on the crystal habit. Crystal Growth & 
Design 4, 765-768 (2004). 
88. Wood, W. M. L. A bad (crystal) habit - and how it was overcome. Powder Technology 121, 
53-59 (2001). 
89. Rodriguez-Hornedo, N. & Sinclair, B. D. in Encyclopedia of Pharmaceutical Technology 
(eds. Swarbrick, J. & Boylan, J. C.) (Marcel Dekker, Inc., New York, 2002). 
90. Rodriguez-Spong, B., Price, C. P., Jayasankar, A., Matzger, A. J. & Rodriguez-Hornedo, N. 
General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv 
Drug Deliv Rev 56, 241-74 (2004). 
91. Desiraju, G. R. Chemistry beyond the molecule. Nature 412, 397-400 (2001). 
92. Dunitz, J. D. & Bernstein, J. Disappearing Polymorphs. Accounts of Chemical Research 28, 
193-200 (1995). 
93. Ouvrard, C. & Price, S. L. Toward crystal structure prediction for conformationally flexible 
molecules: The headaches illustrated by aspirin. Crystal Growth & Design 4, 1119-1127 
(2004). 
94. Vishweshwar, P., McMahon, J. A., Oliveira, M., Peterson, M. L. & Zaworotko, M. J. The 
predictably elusive form II of aspirin. Journal of the American Chemical Society 127, 16802-
16803 (2005). 
  46
 95. Bond, A. D., Boese, R. & Desiraju, G. R. On the polymorphism of aspirin: Crystalline aspirin 
as intergrowths of two "polymorphic" domains". Angewandte Chemie-International Edition 
46, 618-622 (2007). 
96. Braun, M. A., Oschmann, R. & Schmidt, P. C. Influence of excipients and storage humidity 
on the deposition of disodium cromoglycate (DSCG) in the Twin Impinger. International 
Journal of Pharmaceutics 135, 53-62 (1996). 
97. Maggi, L., Bruni, R. & Conte, U. Influence of the moisture on the performance of a new dry 
powder inhaler. Int J Pharm 177, 83-91 (1999). 
98. Hickey, A. J., Gonda, I., Irwin, W. J. & Fildes, F. J. Effect of hydrophobic coating on the 
behavior of a hygroscopic aerosol powder in an environment of controlled temperature and 
relative humidity. J Pharm Sci 79, 1009-14 (1990). 
99. Hickey, A. J. & Martonen, T. B. Behavior of hygroscopic pharmaceutical aerosols and the 
influence of hydrophobic additives. Pharm Res 10, 1-7 (1993). 
100. Rudolf, G., Gebhart, J., Heyder, J., Schiller, C. F. & Stahlhofen, W. An Empirical-Formula 
Describing Aerosol Deposition in Man for Any Particle-Size. Journal of Aerosol Science 17, 
350-355 (1986). 
101. Task Group on Lung Dynamics. Health Physics 12, 173-207 (1966). 
102. Zanen, P., Go, L. T. & Lammers, J. W. Optimal particle size for beta 2 agonist and 
anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51, 977-80 
(1996). 
103. Zanen, P., Go, L. T. & Lammers, J. W. J. The Optimal Particle-Size for Beta-Adrenergic 
Aerosols in Mild Asthmatics. International Journal of Pharmaceutics 107, 211-217 (1994). 
104. Zanen, P., Go, L. T. & Lammers, J. W. J. The Optimal Particle-Size for Parasympathicolytic 
Aerosols in Mild Asthmatics. International Journal of Pharmaceutics 114, 111-115 (1995). 
105. Zanen, P., Go, L. T. & Lammers, J. W. J. Optimal particle size for beta(2) agonist and 
anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51, 977-980 
(1996). 
106. Usmani, O. S., Biddiscombe, M. F., Nightingale, J. A., Underwood, S. R. & Barnes, P. J. 
Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J 
Appl Physiol 95, 2106-12 (2003). 
107. Hinds, W. C. Aerosol technology : properties, behavior, and measurement of airborne 
particles (Wiley, New York, 1999). 
108. Hickey, A. J., Martonen, T. B. & Yang, Y. Theoretical relationship of lung deposition to the 
fine particle fraction of inhalation aerosols. Pharm Acta Helv 71, 185-90 (1996). 
109. Martonen, T. B., Katz, I., Fults, K. & Hickey, A. J. Use of analytically defined estimates of 
aerosol respirable fraction to predict lung deposition patterns. Pharm Res 9, 1634-9 (1992). 
  47
 110. Chew, N. Y. K. & Chan, H. K. Effect of powder polydispersity on aerosol generation. Journal 
of Pharmacy and Pharmaceutical Sciences 5, 162-168 (2002). 
111. Hickey, A. J. in Pharmaceutical inhalation aerosol technology (ed. Hickey, A. J.) 345-384 
(Marcel Dekker, New York, 2004). 
112. Dunbar, C. A. & Hickey, A. J. Evaluation of probability density functions to approximate 
particle size distributions of representative pharmaceutical aerosols. Journal of Aerosol 
Science 31, 813-831 (2000). 
113. Raabe, O. G. A general method for fitting size distributions to multicomponent aerosol data 
using weighted least-squares. Environ Sci Technol 12, 1162-1167 (1978). 
114. Marple, V. A. et al. Next generation pharmaceutical impactor: a new impactor for 
pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min. J 
Aerosol Med 17, 335-43 (2004). 
115. Mitchell, J. P. & Nagel, M. W. Cascade impactors for the size characterization of aerosols 
from medical inhalers: their uses and limitations. J Aerosol Med 16, 341-77 (2003). 
116. Marple, V. A., Rubow, K. L. & Olson, B. A. in Aerosol Measurement: Principles, Techniques 
and Applications (eds. Baron, P. A. & Willeke, K.) 229-260 (Wiley Interscience, New York, 
2001). 
117. Hering, S. V., Flagan, R. C. & Friedlander, S. K. Design and Evaluation of New Low-
Pressure Impactor .1. Environmental Science & Technology 12, 667-673 (1978). 
118. Hering, S. V., Friedlander, S. K., Collins, J. J. & Richards, L. W. Design and Evaluation of a 
New Low-Pressure Impactor .2. Environmental Science & Technology 13, 184-188 (1979). 
119. Keskinen, J., Pietarinen, K. & Lehtimaki, M. Electrical Low-Pressure Impactor. Journal of 
Aerosol Science 23, 353-360 (1992). 
120. Fults, K. A., Miller, I. F. & Hickey, A. J. Effect of particle morphology on emitted dose of 
fatty acid-treated disodium cromoglycate powder aerosols. Pharm Dev Technol 2, 67-79 
(1997). 
121. Hickey, A. J., Fults, A. K. & Pilliai, R. S. Use of particle morphology to influence the 
delivery of drug from dry powder aerosols. J. Biopharm. Sci 3, 107-113 (1992). 
122. Young, P. M. et al. Characterization of a surface modified dry powder inhalation carrier 
prepared by "particle smoothing". J Pharm Pharmacol 54, 1339-44 (2002). 
123. Chew, N. Y. K. & Chan, H. K. Use of solid corrugated particles to enhance powder aerosol 
performance. Pharmaceutical Research 18, 1570-1577 (2001). 
124. Chew, N. Y. K., Tang, P., Chan, H. K. & Raper, J. A. How much particle surface corrugation 
is sufficient to improve aerosol performance of powders? Pharmaceutical Research 22, 148-
152 (2005). 
  48
 125. Heng, P. W., Chan, L. W. & Lim, L. T. Quantification of the surface morphologies of lactose 
carriers and their effect on the in vitro deposition of salbutamol sulphate. Chem Pharm Bull 
(Tokyo) 48, 393-8 (2000). 
126. Chan, L. W., Lim, L. T. & Heng, P. W. Immobilization of fine particles on lactose carrier by 
precision coating and its effect on the performance of dry powder formulations. J Pharm Sci 
92, 975-84 (2003). 
127. Martin, A. Physical Pharmacy (Lippincott Williams & Wilkins, Baltimore, MD, 1993). 
128. Israelachvili, J. N. Intermolecular and surface forces (Academic Press London, London, 
1991). 
129. Sun, C. H. & Berg, J. C. A review of the different techniques for solid surface acid-base 
characterization. Advances in Colloid and Interface Science 105, 151-175 (2003). 
130. Fowkes, F. M. Determination of Interfacial Tensions, Contact Angles, and Dispersion Forces 
in Surfaces by Assuming Additivity of Intermolecular Interactions in Surfaces. Journal of 
Physical Chemistry 66, 382-& (1962). 
131. Fowkes, F. M. Attractive forces at interfaces. Ind. Eng. Chem. 56, 40-52 (1964). 
132. Mukhopadhyay, P. & Schreiber, H. P. Aspects of Acid-Base Interactions and Use of Inverse 
Gas-Chromatography. Colloids and Surfaces a-Physicochemical and Engineering Aspects 
100, 47-71 (1995). 
133. Edwards, D. A. et al. Large porous particles for pulmonary drug delivery. Science 276, 1868-
1871 (1997). 
134. Castle, G. S. P. Industrial applications of electrostatics: the past, present and future. Journal 
of Electrostatics 51, 1-7 (2001). 
135. Matsusaka, S. & Masuda, H. Electrostatics of particles. Advanced Powder Technology 14, 
143-166 (2003). 
136. Yao, J. & Wang, C.-H. Granular size and shape effects on electrostatics in pneumatic 
conveying systems. Chemical Engineering Science 61, 3858-3874 (2006). 
137. Adhiwidjaja, I., Matsusaka, S., Tanaka, H. & Masuda, H. Simultaneous phenomenon of 
particle deposition and reentrainment: Effects of surface roughness on deposition layer of 
striped pattern. Aerosol Science and Technology 33, 323-333 (2000). 
138. Adhiwidjaja, I., Matsusaka, S., Yabe, S. & Masuda, H. Simultaneous phenomenon of particle 
deposition and reentrainment in charged aerosol flow - effects of particle charge and external 
electric field on the deposition layer. Advanced Powder Technology 11, 221-233 (2000). 
139. Jones, T. B. & King, J. L. Powder handling and electrostatics - Understanding and preventing 
hazards (Lewis, London, 1991). 
140. Hendricks, C. D. in Electrostatics and its applications (ed. Moore, A. C.) 57-85 (John Wiley 
& Sons, New York, 1973). 
  49
 141. Hendricks, C. D. in Electrostatics and its applications (ed. Moore, A. C.) 29-56 (John Wiley 
& Sons, New York, 1973). 
142. Bailey, A. G., Hashish, A. H. & Williams, T. J. Drug delivery by inhalation of charged 
particles. Journal of Electrostatics 44, 3-10 (1998). 
143. Fraser, D. A. The deposition of unipolar charged particles in the lungs of animals. Arch 
Environ Health 13, 152-7 (1966). 
144. Inculet, I. I. in Electrostatics and its applications (ed. Moore, A. C.) 86-114 (John Wiley & 
Sons, New York, 1973). 
145. Murtomaa, M., Harjunen, P., Mellin, V., Lehto, V. P. & Laine, E. Effect of amorphicity on 
the triboelectrification of lactose powder. Journal of Electrostatics 56, 103-110 (2002). 
146. Bailey, A. G. Charging of Solids and Powders. Journal of Electrostatics 30, 167-180 (1993). 
147. Hendricks, C. D. in Electrostatics and its applications (ed. Moore, A. C.) 8-28 (John Wiley & 
Sons, New York, 1973). 
148. Lectures of Electromagnetism, Chapter 7. Conduction and Electroquasistatic Charge 
 Relaxation, http://web.mit.edu/6.013_book/www/book.html 
149. Harper, W. R. Contact and frictional electrification (Oxford University Press, London, 1967). 
150. Castle, G. S. P. Contact charging between particles; some current understanding. Proc. ESA 
Annual Meeting on Electrostatics, 1-3 (2008). 
151. Eilbeck, J., Rowley, G., Carter, P. A. & Fletcher, E. J. Effect of contamination of 
pharmaceutical equipment on powder triboelectrification. Int J Pharm 195, 7-11 (2000). 
152. Shio, H. Triboelectrification between polycrystalline and monocrystalline ice. Journal of 
Electrostatics 53, 185-193 (2001). 
153. Elajnaf, A., Carter, P. & Rowley, G. Electrostatic characterisation of inhaled powders: effect 
of contact surface and relative humidity. Eur J Pharm Sci 29, 375-84 (2006). 
154. Balachandran, W., Machowski, W., Gaura, E. & Hudson, C. Control of drug aerosol in 
human airways using electrostatic forces. Journal of Electrostatics 40-1, 579-584 (1997). 
155. Ali, M., Mazumder, M. K. & Martonen, T. B. Measurements of Electrodynamic Effects on 
the Deposition of MDI and DPI Aerosols in a Replica Cast of Human Oral-Pharyngeal-
Laryngeal Airways. J Aerosol Med Pulm Drug Deliv (2008). 
156. Byron, P. B., Peart, J. & Staniforth, J. N. Aerosol electrostatics I: Properties of fine powders 
before and after aerosolization by dry powder inhalers. Pharm Res 14, 698-705 (1997). 
157. Chow, K. T., Zhu, K., Tan, R. B. & Heng, P. W. Investigation of Electrostatic Behavior of a 
Lactose Carrier for Dry Powder Inhalers. Pharm Res (2008). 
  50
 158. Zhu, K., Ng, W. K., Shen, S., Tan, R. B. & Heng, P. W. Design of a device for simultaneous 
particle size and electrostatic charge measurement of inhalation drugs. Pharm Res 25, 2488-
96 (2008). 
159. Bennett, F. S., Carter, P. A., Rowley, G. & Dandiker, Y. Modification of electrostatic charge 
on inhaled carrier lactose particles by addition of fine particles. Drug Dev Ind Pharm 25, 99-
103 (1999). 
160. Murtomaa, M., Strengell, S., Laine, E. & Bailey, A. Measurement of electrostatic charge of 
an aerosol using a grid-probe. Journal of Electrostatics 58, 197-207 (2003). 
161. Murtomaa, M. et al. Effect of particle morphology on the triboelectrification in dry powder 
inhalers. International Journal of Pharmaceutics 282, 107-114 (2004). 
162. Carter, P. A., Cassidy, O. E., Rowley, G. & Merrifield, D. R. Triboelectrification of 
fractionated crystalline and spray-dried lactose. J Pharm Pharmacol 4, 111-115 (1998). 
163. Cassidy, O. E., Carter, P. A., Rowley, G. & Merrifield, D. R. Triboelectrification of spray-
dried lactose prepared from different feedstock concentrations. J Pharm Pharmacol 52, 13-7 
(2000). 
164. Elajnaf, A., Carter, P. & Rowley, G. The effect of relative humidity on electrostatic charge 
decay of drugs and excipient used in dry powder inhaler formulation. Drug Dev Ind Pharm 
33, 967-74 (2007). 
165. Watanabe, H., Ghadiri, M., Matsuyama, T., Ding, Y. L. & Pitt, K. G. New instrument for 
tribocharge measurement due to single particle impacts. Rev Sci Instrum 78, 024706 (2007). 
166. Watanabe, H. et al. Triboelectrification of pharmaceutical powders by particle impact. Int J 
Pharm 334, 149-55 (2007). 
167. Knutson, E. O. & Whitby, K. T. Aerosol classification by electric mobility: apparatus, theory, 
and applications. J Aerosol Sci 6, 443-451 (1975). 
168. Kitabatake, Y. Charge Spectra Measurement of Toner-Particles for Copier by E-Spart 
Analyzer. Sharp Technical Journal, 83-86 (1988). 
169. Kutsuwada, N. et al. Tribocharging of Monocomponent Toner for Analyzing Charge-
Distributions by E-Spart Analyzer. Is&Ts Eighth International Congress on Advances in 
Non-Impact Printing Technologies, 126-128, 529 (1992). 
170. Mazumder, M. K. et al. E-Spart Analyzer - Its Performance in Real-Time Measurements of 
Particle-Size and Charge-Distributions. Aerosol Science and Technology 2, 240-240 (1983). 
171. Saini, D., Biris, A. S., Srirama, P. K. & Mazumder, M. K. Particle size and charge 
distribution analysis of pharmaceutical aerosols generated by inhalers. Pharm Dev Technol 
12, 35-41 (2007). 
172. Telko, M. J., Kujanpaa, J. & Hickey, A. J. Investigation of triboelectric charging in dry 
powder inhalers using electrical low pressure impactor (ELPI). Int J Pharm 336, 352-60 
(2007). 
  51
   52
173. Telko, M. J. & Hickey, A. J. Dry powder inhaler formulation. Respir Care 50, 1209-27 
(2005). 
 
 
  
 
2. MATERIAL PREPARATION AND PHYSICOCHEMICAL CHARACTERIZATION 
 
2.1. Introduction 
Understanding triboelectrification in DPI formulations requires consideration of the interactions 
of the constituent materials, i.e. the drug and the excipient particles. Drugs vary from product to 
product. In the early stages of development, drug substance is usually in short supply, physical 
properties are estimated from limited testing and may then be modified in a narrow range, e.g. salt 
selection, to address regulatory, safety, and stability requirements more than formulation needs. The 
drug itself typically offers little flexibility in terms of formulation variables. The choice of excipient 
is, therefore, critically important. Carrier particles usually make up 98% or more of the product by 
weight, which makes them a crucial determinant of overall DPI performance.  
As described in Chapter 1, a range of drug and carrier particle properties are considered to ensure 
bioavailability and stability. For aerosolized drugs, primary particle size and size distribution most 
profoundly affect aerosolization, delivery and availability to the target organ. Crystallinity, 
polymorphism, and moisture content are important with respect to drug stability. Carrier particles can 
moderate drug stability, handling, and aerosolization properties by manipulation of particle size and 
surface characteristics. Electrostatic particle interactions are thought to play a role as well, but are not 
routinely characterized in product preparation.  
This chapter discusses the selection and characterization of the model drugs and excipients, and 
the preparation of the model formulations. The formulations are used in deposition studies which are 
described in detail in Chapter 4. Drugs and excipients are characterized in terms of their particle size, 
their thermal profiles (to establish their polymorphic makeup), and their electrostatic properties using 
Faraday cage experiments. Drugs are characterized in terms of their particle size and shape. To 
control for particle size related effects, excipients are sieved prior to blending with the drugs. 
Formulations are tested for content uniformity. 
 
2.1.1. Selection of Drugs 
Two drugs were selected for study, albuterol sulfate and budesonide. Albuterol (USAN) or 
salbutamol (INN) is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasms 
in asthma and COPD. Albuterol (MW 239.3) is a common inhaled medicine and a frequently used 
model drug in medicinal aerosol research. Albuterol sulphate was the sole drug substance studied in 
the preliminary experiments.  
Budesonide (MW 430.5) is a glucocorticoid steroid for the treatment of asthma, non-infectious 
rhinitis, and allergies. Budesonide is marketed as Pulmicort® with a Turbohaler DPI by AstraZenaca1 
and was selected because it is a different therapeutic category of drug and is structurally distinct from 
albuterol. While albuterol is a polar and hydrophilic drug, budesonide is hydrophobic. Since 
budesonide is protected from development as a patented product, few studies of its formulation for 
DPIs have been published. Select properties of albuterol and budesonide that pertain to this research 
project are summarized in Table 2.1. 
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Table 2.1. Select properties of albuterol sulfate and budesonide 
 
Drug Albuterol sulfate Budesonide 
Chemical Name1 
α1[(tert-Butylamino)methyl]-4-hydroxy-
mxylene- α, α ´-diol sulfate 
(RS)-11, 16 α, 17, 21-
tetrahydroxypregna-1, 4-diene-3, 20-
dione cyclic 16, 17-acetal with 
butyraldehyde 
Proprietary name 
and manufacturer 
Generic, various manufacturers, e.g. 
Ventolin®, GlaxoSmithKline 
Proventil®, Schering-Plough 
ProAir®, Teva 
Pulmicort®, Astra-Zeneca 
Therapeutic 
Category 
Short-acting β2-adrenergic receptor 
agonist 
Glucocorticoid steroid 
Indication1 Bronchodilation, relief of bronchospasms. Asthma, COPD 
Anti-inflammatory. Asthma, non-
infectious rhinitis. 
Dose range1 120 g 0.25- 1.0 mg 
Empirical Formula C13H21NO3  (C13H21NO3)2•H2SO4 C25H34O6 
Structure 
 
N
HO
HO
OH
2
H2SO4
HO
OH
O
O
O
O
 
Molecular Weight 
(g/mol) 
576.7  
(239.3, albuterol) 430.5 
pKa 5.9 2 High 
Partition 
Coefficient (log P) 1.0 
3 3.2 4 
Aq. Solubility5 Soluble, 3mg/L  Insoluble 
Melting point (oC) 1 230-235   (151,5 albuterol) 
221-232 5 
(2596) 
True density 
(g/cm3) 1.34 
7 1.25 8 
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2.1.2. Selection of Excipients 
Lactose is the sole conventional carrier excipient used in DPI formulations in the United States 
and is, therefore, a primary focus of study. It has been shown that minute changes in morphology or 
particle size of lactose can produce dramatically different product performance. It is not surprising, 
therefore, that despite best efforts in process control, many problems with DPI performance have 
been associated with batch-to-batch variability of the excipient. Lactose material properties, including 
particle size, morphology, method of processing, crystallinity, surface energy have been studied in the 
context of elucidating batch-to-batch variability. The results of these studies have recently been 
discussed in two comprehensive publications.9, 10 Since lactose is so important to DPI formulation 
development, it is available in different qualities (having undergone different manufacturing 
processes) from a number of different manufacturers. These differences are investigated in this 
research project using different lactose products as well as different batches of the same product. The 
products selected consist of the most stable polymorph α-lactose monohydrate. 
Glucose is the only the other excipient employed in marketed inhaled drug products11 and, thus, is 
an important alternative excipient to study. However, like lactose, glucose is a carbohydrate. While 
one is a disaccharide and the other a monosaccharide, they share some chemical features.  
In order to provide a more pronounced contrast, calcium phosphate (CP) was also employed. As 
an inorganic salt, it is physico-chemically an entirely different material from the sugars described 
previously. While CP is a physiologically biocompatible salt that is widely used in the formulation of 
oral dosage forms, it has not been used in DPI formulations. Nonetheless, as reported by Garcia-
Contreras et al., CP has been used for lung delivery in animal studies with no adverse effects, and 
there is evidence to suggest it may be safe to use in humans as well.12 However, it should be noted 
that any excipient is not intended to enter the lungs to any significant extent. Relevant 
physicochemical properties of the studied excipients are listed in Table 2.2. 
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Table 2.2. Selected material properties of excipients used in these studies 
 
Excipient Lactose monohydrate Glucose monohydrate Calcium Phosphate 
Proprietary name 
and manufacturer 
Respitose®,  
DMV-Fonterra 
Lycadex® HD,  
Roquette 
A-TAB®,  
Innophos 
Chemical Name 
4-(-D-galactosido)-D-glucose 
monohydrate 
D-(+)-Glucose monohydrate Calcium hydrogen 
phosphate;  
Dicalcium phosphate, 
anhydrous 
Empirical 
Formula C12H22O11.H20 C6H12O6.H2O CaHPO4 
Molecular Weight 
(g/mol) 360.3 198.2 136.1  
Melting point 13 
201-202°C for α-lactose 
monohydrate 
223°C for anhydrous α-
lactose 
252.2°C for anhydrous -
lactose 
83°C  for glucose 
monohydrate 
146°C for anhydrous 
glucose 
148-155°C for anhydrous -
D-dextrose 
~1670°C 
Decomposes at ~425°C to 
form calcium 
pyrophosphate.  
 
Polymorphism 13 
Several crystalline and 
amorphous forms. 
Differential scanning 
calorimetry can effectively 
be used to characterize the 
composition.  
α -lactose monohydrate 
becomes anhydrous at 
120°C and has a melting 
point of 201-202°C; 
endothermic peaks occur at 
approximately 150°C and 
vary depending on particle 
size. 
Below 50°C α -D-dextrose 
monohydrate is the stable 
crystalline form produced, 
above 50°C the anhydrous 
form is obtained, at still 
higher temperatures -D-
dextrose is formed. 
Often contains other 
calcium phosphates, e.g. 
Ca3(PO4)2.  
True density 13 
(g/cm3) 1.55 1.54 3.14 
Specific Surface 
Area (m2/g)* 
0.3 – 0.4 (SV)  
0.9 (ML) 0.2 – 0.3 20-30 (A-Tab) 
Aq Solubility 13 Soluble  (0.05-0.1g /mL at 20°C) 
Highly soluble  
(0.9 g/ml at 25°C) Sparingly soluble 
Solubility in 
solvent 13 
Practically insoluble in 
alcohol 
Soluble in alcohol  
(0.017g /ml at 20oC) 
Practically insoluble in 
alcohol 
* Manufacturer furnished information 
 
2.2. Materials  
2.2.1. Drugs 
Milled albuterol sulfate (median particle size 2µm) was obtained from Chemaco (Beetsterzwaag, 
NL) from drug manufactured by P.F.C. Italiana S.r.1, (Caronno Pertusella, Italy). Budesonide was 
obtained from Sigma-Aldrich (St. Louis, MO), and was jet-milled to a single-micron size range 
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(verified using laser diffraction light scattering). In accordance with manufacturer recommendations, 
both drugs were stored in glass bottles at ambient conditions (which are closely monitored within the 
laboratory and fluctuate modestly around 23±0.5oC and 30±5%RH throughout the year). 
 
2.2.2. Excipients 
Lactose monohydrate, Respitose™, was provided by DMV-Fonterra Excipients (Goch, 
Germany). Two batches of milled (ML001, batches 10136780 and 10138058), and two batches of 
sieved (SV003, batches 10134131 and 10135425) lactose were evaluated. Dextrose (D-glucose), 
LycadexTM, batch KDTLT, was provided by Roquette (Keokuk, IA). Calcium hydrogen phosphate, 
anhydrous, A-TabTM (granular grade), lot WL00014930, was obtained from Innophos (Cranbury, NJ). 
In accordance with manufacturer recommendations, the excipients were stored in double-lined PE 
bags at ambient conditions  23±0.5oC and 30±5%RH. 
 
2.3. Methods 
2.3.1. Excipient Sieving and Powder Preparation 
Excipients were sieved (Hogentogler & Co, Columbia, MD) prior to characterization and 
blending with micronized drug. This serves three purposes: (1) removal of fine particles which may 
confound later electrostatic analysis; (2) control of effects related to particle size between different 
excipients and (3) determination of particle size effects within a given batch of excipient. 
The following sieve fractions are obtained: 45 – 75 µm, 75 – 105 µm, 106 – 150 µm. The sieves 
used were No. 100, 140, 200, and 325. In previous studies, milled lactose was shown to contain some 
fraction of surface-associated fines, which detached during DPI actuation and deposited on the stages 
of the ELPI. To remove these fine particles, simple sieving did not suffice and an element of 
fluidization was introduced; after sieving each size fraction was confined between two #325 sieves 
and sprayed with compressed air for 2 minutes. This facilitated dislodgement and removal of fine 
excipient particles that were associated with the surface of larger particles. 
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2.3.2. Particle Size Analysis 
Assuming a cuboidal particle shape (i.e. rectangular prism), sieves retain particles whose second 
largest dimension exceeds the size of the sieve opening. Given that the excipient particles are of 
different and at times non-uniform shape, the mean volumetric or aerodynamic particle size of a sieve 
fraction is not necessarily confined to the size range of the sieves used. A dispersed sizing method 
provides mean volumetric particle sizes. It may also provide similarly turbulent conditions that 
separate particles and thus facilitate determination of the presence of fines, which can deposit on the 
stages of the ELPI. A microscopic method provides validation of the experiments and a visual 
assessment of the surface morphology. 
 
2.3.2.1 Laser Light Diffraction 
To ascertain the size distributions of the sieve fractions and determine the level of fines after 
sieving, drugs and excipients were sized by Fraunhofer laser diffraction analysis (Malvern Series 
2600c Droplet and Particle Sizer, Malvern, UK) using the liquid stir cell in the particle-in-liquid 
mode. A small quantity (~5mg) of drug or excipient were suspended in 2mL of non-solvent (light 
mineral oil or chloroform), stirred, then gradually added to the liquid-stir cell until obscuration 
reached approximately 15%. Depending on the expected particle size range, either the 63mm, 
100mm, or 300mm focal length lens was used, corresponding to size ranges of 1.22 – 188 m,1.9 – 
188m, 5.8 – 564m (interval upper limits). Prior to addition to the liquid cells drug suspensions 
were sonicated for 10 seconds to promote deagglomeration into primary particle sizes. 
 
2.3.2.2 Scanning Electron Microscopy (SEM) 
To complement the results of the laser diffraction light scattering measurements and to 
independently assess the particle size and morphology, electron micrographs were obtained for the 
micronized drugs and the excipient sieve fractions. To visualize the blend uniformity a number of 
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formulation blends were also assessed by SEM (Hitachi S-4700 Cold Cathode Field Emission 
Scanning Electron Microscope). An electron beam with an accelerating voltage of 2.0 kV was used at 
magnifications of 100x, 500x, 2000x, and 5000x (only micronized drug at this magnification). The 
powders were placed on double-sided adhesive carbon tabs (Ted Pella, Inc., Redding, CA) which 
were adhered to aluminum stubs (Ernest F. Fullam, Inc., Latham, NY) and were coated with gold-
palladium alloy to a thickness of 3nm using a sputter-coater (Polaron 5200, Structure Probe Supplies, 
West Chester, PA) operating at 0.1 mmHg (under argon) for approximately 3min. The sputter coating 
conditions are commonly used and are not expected to result in drug evaopration from the lactose 
surface. 
 
2.3.3. Thermal Analysis: Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) is a useful tool for discerning polymorphs and the 
presence of amorphous material in pharmaceutical solids. Thermal analyses (DSC-6, Perkin Elmer, 
Waltham, MA) were performed on the lactose, glucose and drugs. Samples of 3 mg were enclosed in 
crimped aluminum pans. Albuterol sulfate was scanned at a rate of 10oC/min under nitrogen purge to 
a temperature of 400oC, budesonide was scanned to 280oC. 
Lactose samples were scanned at 5oC/min and from 30oC to 250oC under nitrogen purge to show 
the dehydration at approximately 140oC and melting at 210oC, and possibly thermal events at 170oC 
or 240oC, which would be indicative of the presence of unstable α-lactose and -lactose.14 Glucose 
samples were scanned at 5oC/min from 30oC to 160oC to include the melting temperature of the -
glucose. CP was scanned at 5oC/min from 30oC to 450oC (max allowed with instrument).  
 
2.3.4. Electrostatic Material Characterization: Faraday well experiments 
Faraday well experiments were conducted to determine the intrinsic electrostatic charge carrying 
propensity of drugs and excipients. A Faraday well was custom-manufactured at the UNC Dept of 
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Chemistry instrument shop. The well consists of a receiving pan contained within a metal enclosure 
that is open on top. The grounded enclosure shields the pan from the effects of external electric fields. 
The receiving pan is connected to a load resistor (current-to-voltage conversion) and transistor 
(amplification); when charges are deposited on the pan, the current generates a voltage difference 
which is then amplified. The amplified voltage signal is captured via a DI-154RS analog-to-digital 
converter (Dataq, Akron, OH) and recorded on a computer using Windaq data acquisition system 
(Dataq). Acquisition files are saved as a voltage vs. time binary code and then analyzed in Microsoft 
Excel. Charges were integrated to give the total electric charge for the sample of material deposited in 
the well. The circuit for the Faraday well and a picture of the device are shown in Appendix A. 
Since the Faraday well was newly built and had no commercial equivalent, the first step in its use 
was developing a procedure that allowed materials to be characterized successfully. This type of 
characterization is not a standard technique and instrument and procedure are only poorly described 
in the literature; most experiments seem to have been conducted with improvised Faraday well type 
devices.15-17 The limited work conducted in this area was summarized in Chapter 1.  
Extensive initial trials were conducted to establish the charge measurement procedure. The initial 
trials differed in quantity of material, in the procedure for feeding the material, in use of grounding, 
and surface of last contact. The final procedure which results in a comparatively high level of 
reproducibility consists of weighing 50mg of material onto weighing paper and adding it to the 
Faraday well in a slow and steady manner. This procedure gave a high degree of reproducibility. 
Experiments were conducted at least three times in a randomized order over the course of several 
days.  
 
2.3.5. Formulation Manufacture and Content Uniformity Determination 
Due to a limited supply of materials, the difficulty involved in preparing the raw materials, and 
the large number of experiments designed, formulations were manufactured in 1.0g batch sizes. This 
small batch size limited the methods and equipment that could be used for preparation. Formulations 
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were prepared using a combination of geometric dilution and tumbling within a vial. Drug and 
excipient were weighed out in appropriate quantities. Drug was distributed on a mixing pan and 
geometrically diluted with the excipient, then blended using a small stainless steel spatula for one 
minute. The blend was transferred to a 20mL glass vial, then tumbled for an additional two minutes 
by axial rotation of the vial. 
Content uniformity of the blends was ascertained by withdrawing three samples (~15mg each) 
from different locations in the powder bed contained in the vial using a small stainless steel spatula; 
the powder was tumbled after each sample withdrawal. The samples were weighed and dissolved in 
3mL water (albuterol formulations) or methanol (budesonide formulations). UV absorbance of the 
solutions was assessed at a wavelength of 225.5nm (albuterol) or 244nm (budesonide) (Shimadzu 
160U spectrophotometer, Shimadzu Scientific Instruments, Columbia, MD). Excipients are either 
insoluble or have negligible absorbance at these wavelengths. Drug concentration and variability 
between samples were calculated; blend concentrations within 10% of nominal concentration and 
with relative standard deviation less than 10% were accepted, samples outside this range were 
remanufactured. 
 
2.4. Results and Discussion 
2.4.1. Particle Size Distribution 
The particle size distributions of micronized albuterol and budesonide, obtained by laser 
diffraction light scattering are shown in Figure 2.1. The particles meet the size requirement of being 
in the unit-micron size range. Albuterol had an approximately log-normal distribution with a median 
diameter of 2.5m and a geometric standard deviation of 1.4. Budesonide, which was previously jet-
milled in the laboratory, had a highly monodisperse distribution with virtually all particles in the 1.9-
2.6m range and a d50 of 2.1m. Note that the particle size distribution here, as in the following 
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figures, is not normalized for the width of the interval; this results in a distribution slightly skewed in 
favor of larger sizes. This presentation is simpler. Distribtions are based on volume. 
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Figure 2.1. Particle size distribution of budesonide (blue) and albuterol (red). Figure 2.1(a) shows the fraction 
of drug recovered on the midpoint of the given stage. Figure 2.1(b) shows the cumulative undersize at each 
interval. 
 
The excipient sieve fractions showed particle size distributions that extended outside the range of 
the sieves. As described earlier, this result is expected for sieved non-spherical particles (i.e. particles 
with an aspect ratio greater than 1). The sieves classify particles based on their second largest 
dimension, while light scattering methods determine mean particle diameters based on the assumption 
of sphericity. As a result, particles with diameters outside the boundaries of the sieves show up in a 
given sieve fraction. This is shown for the case of CP in Figure 2.2, where the particle size 
distributions of the entire sample and the constituent sieve fractions are shown. The dashed lines 
indicate the sieve boundaries. It is also evident, that each of the distributions is bimodal with a sizable 
fraction of fine particles. This observation cannot be explained by the sieving process. Rather, it 
suggests there is a portion of ultra-fine particles (in the single micron range) which are associated 
with the surface of the larger particles. They do not dislodge during sieving but detach from the 
surfaces of the larger particles after suspension and stirring in liquid media. The observation of 
surface associated fine particles has been made before, and has been described in the literature.18  
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Figure 2.2. Particle size distribution of CP sample and the constituent sieve fractions after simple sieving, 
i.e. without additional fluidization. All samples clearly show the presence of very fine, single micron size 
particles. Dashed lines show the sieve fraction pore sizes. 
 
Figure 2.2 also highlights the need for the additional processing step of "sifting" the sieve 
fractions. The result of this step is shown in Figure 2.3, for the same sieve fractions shown in Figure 
2.2; clearly the presence of these fine particles has been greatly reduced. 
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Figure 2.3. Particle size distribution of whole calcium phosphate sieve fractions after sieving and sifting. 
Compared to Figure 2.2, the proportion of fine particles is greatly reduced. Dashed lines show the sieve 
fraction pore sizes. 
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 The behavior of other excipients with respect to sieve sizes was similar to that of CP, though it was 
somewhat less pronounced for lactose batches. The particle size distributions of the different sieve 
fractions are summarized by d10, d50, and d90 values, span, and fraction of particles smaller than 10m 
in Table 2.3.  
 
Table 2.3. Particle size distribution summary for the different excipient sieve fractions obtained (after 
sifting). Values are based on results from laser light diffraction experiments (average of n=3 ± 
standard deviation). The d10, d50, and d90 measures were determined through linear data interpolation, 
with no model assumptions.  
 
Excipient 
Excipient 
Sieve 
Fraction 
d10 (m) d50 (m) d90 (m) d90 / d10  % < 10m 
45-75m 44.9 ± 2.8  63.3 ± 1.9 80.5 ± 3.7 1.8 ± 0.2 1.4 ± 1.7 
75-105m 71.3 ± 8.6 102.2 ± 5.6 153.1 ± 8.4 2.2 ± 0.4 0.6 ± 0.4 Calcium Phosphate 
105-150m 115.8 ± 2.7 141.4 ± 3.0 183.5 ± 9.5 1.6 ± 0.1 0.0 ± 0.1 
45-75m 37.9 ± 6.3 73.7 ± 4.8 115.4 ± 1.8 3.1 ± 0.5 2.2 ± 0.4 
75-105m 78.8 ± 3.8 124.5 ± 4.0 199.4 ± 4.0 2.5 ± 0.1 1.2 ± 0.2 Glucose 
105-150m 110.2 ± 1.2 181.4 ± 3.0 316.3 ± 18.9 2.9 ± 0.2 0.8 ± 0.0 
45-75m 43.0 ± 1.3 64.3 ± 4.8 84.0 ± 6.9 2.0 ± 0.1 2.0 ± 0.2 
75-105m 82.8 ± 9.4 116.0 ± 5.4 165.5 ± 16.7 2.0 ± 0.0 1.2 ± 0.3 Lactose ML80 
105-150m 121.8 ± 2.0 167.9 ± 4.4 248.0 ± 15.8 2.0 ± 0.1 0.7 ± 0.1 
45-75m 45.0 ± 0.7 63.6 ± 3.2 86.6 ± 13.6 1.9 ± 0.3 1.8 ± 0.2 
75-105m 84.8 ± 7.5 116.9 ± 5.8 172.9 ± 3.7 2.0 ± 0.2 1.0 ± 0.2 Lactose ML58 
105-150m 123.5 ± 1.2 170.7 ± 3.7 258.0 ± 14.0 2.1 ± 0.1 0.4 ± 0.3 
Lactose     
SV425 45-75m 44.8 ± 0.1 66.1 ± 3.9 85.0 ± 6.5 1.9 ± 0.1 1.5 ± 0.3 
Lactose    
SV94 45-75m 47.3 ± 2.1 71.1 ± 4.8 97.9 ± 12.5 2.1 ± 0.2 1.4 ± 0.2 
 
2.4.2. Size and Shape Characterization of Powders 
SEM micrographs were obtained to: (1) ascertain that drug particles and excipients sieve fractions 
were in fact of the right particle size and thus independently verify the results of the laser light 
scattering experiments; (2) assess the results of the excipients fines removal procedure; and (3) assess 
the distribution of drug within the formulation blends. Figure 2.4 shows high magnification (5000x) 
images of micronized albuterol and budesonide. The particles appear to be in the required single 
micron range, which is consistent with the laser diffraction light scattering experiments. Albuterol had 
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a more disperse particle size distribution; particles from 1 to 5m in size are visible in the 
micrographs. Budesonide is more uniformly distributed; particles have regular, approximately 
spherical shapes, and are in the 1-2m range. These results are also consistent with laser diffraction 
light scattering. 
  
Figure 2.4 Micronized drug particles at 5000x magnification. (a) Albuterol sulfate, (b) budesonide. 
 
Figures 2.5(a) through (f) show the 45-75m sieve fraction for each excipient at 500x 
magnification. Lactose particles display the characteristic tomahawk shape, glucose particles appear 
as flakes, while CP appears granular. These observations are consistent with what is known of the 
excipients. Compared to other SEM images of the same lactose excipients,18 the fluidization 
procedure shows some success in removing surface associated fines. However, higher magnification 
images of lactose particles, SV94 shown in Figure 2.6, show the presence of some surface fines which 
might account for the approximately 1% of single-micron particles observed in most batches during 
laser light scattering experiments (shown in Table 2.3). 
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(a) ML80 lactose particles (45-75m sieve fraction). (b) ML58 lactose particles (45-75m sieve fraction). 
 
(c) SV94 lactose particles (45-75m sieve fraction). (d) SV 425 lactose particles (45-75m sieve 
fraction). 
 
(e) Glucose particles (45-75m sieve fraction). (f) CP particles (45-75m sieve fraction). 
Figure 2.5. Electron micrographs showing the 45-75m sieve cut, each at a magnification of 500x. 
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 Figure 2.6. Lactose SV94 particles at 15,000x magnification. Fine particles in the single micron range are 
present at the particle surface. 
 
In addition to a chemical assessment of formulation drug content uniformity (via UV assay), a 
number of blends were visually inspected by SEM for the presence of unique particle distribution 
patterns; none were noted. As shown in Figure 2.7, drug distribution across the surface of particles 
was uniform although distribution of drug across the population of different particles varied, i.e some 
excipient particles had a lot of drug on their surface, while other particles had little. 
  
Figure 2.7. Representative drug blends. (a) 1% albuterol on ML58 lactose particles (b) 0.5% Budesonide on CP 
particles. Drug was quite evenly distributed. 
 
 68
2.4.3. Differential Scanning Calorimetry 
The results of the thermal analysis of the drugs are shown in Figure 2.8. The DSC thermogram of 
the micronized budesonide showed a single endothermic melting transition at 256°C, which is in 
agreement with values reported in the literature.6, 19 Various melting temperatures and thermograms 
can be found in the literature for albuterol sulfate. The manufacturer reports the melting point as 230-
235oC,1 so initially, albuterol sulfate  was scanned to a temperature of 250oC which should have 
revealed this melting point. Instead, the thermogram revealed a sharp mixed endo/exo/endothermic 
event with a maximum endothermic peak at 206oC. This also contradicted other published results, e.g. 
a melting temperature of 185-195oC described by El Fattah et al.20 Another sample of albuterol sulfate 
was scanned to a temperature of 400oC. This revealed two further endothermic peaks at 286 and 
329oC, in agreement with observations made by Larhrib et al.21 The explanation for the thermogram 
was recently provided by Palacio et al.; albuterol exists as two polymorphs, and the peaks show a 
decomposition pathway for the more stable Form I.22  
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Figure 2.8. DSC thermograms of albuterol sulfate and budesonide used in formulations. 
 
The DSC thermograms of the excipients are presented in Figure 2.9. All materials had thermal events 
as expected. Glucose monohydrate melts at 80oC. Slight curvature in the thermogram at 115oC 
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indicates the presence of some anhydrous glucose. Lactose monohydrate shows two endothermic 
events: the first endothermic transition corresponds to the loss of water of crystallization while the 
second transition shows the melting of the anhydrous material followed by its decomposition. These 
thermograms are in agreement with published data, e.g. Larhrib et al.21 CP was scanned to 450oC, 
which is the highest temperature attainable on the DSC instrument used; as expected decomposition 
was observed at 425oC, which constituted the only thermal event. This is in agreement with Miyazaki 
et al., which have recently described the physical properties of dibasic calcium phosphate anhydrate 
and dehydrate.23 
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Figure 2.9. DSC thermograms of lactose ML58, ML80, SV94, SV425, and glucose. Samples were scanned at at 
5oC/min from 50oC to 250oC. 
 
2.4.4. Electrostatic Material Characterization 
All materials, drugs and all excipient sieve fractions, were evaluated for their electrostatic 
properties. Experiments were randomized and conducted in triplicates (n=3) at 23oC/24%RH. 
Significant differences were observed in the charging behavior of drugs and excipients. Figure 2.10 
summarizes the findings. Both CP and glucose consistently delivered a negative charge, in both cases 
in the order of -0.2 – -0.3 nC/g. By contrast, all lactose batches delivered positive charges to the 
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Faraday well, in the order of 0.4-0.6nC/g. While some differences between the lactose batches were 
noted, they were comparatively small and statistically insignificant. The micronized drugs showed the 
largest charges, whereby albuterol charged highly positive and budesonide charged highly negative. 
There were no significant differences between the size fractions of the excipients, except for ML58 
lactose, where the finer sieve fractions delivered larger charges.  
Since contact with the insulating paper was brief and affected only a small number of particles, 
the charges recorded are the result mostly of contact with the glass bottles, in which the formulations 
were stored. Thus, the charges are a relative measure of the effective work functions of the bulk 
materials; the negatively charged particles have acquired an excess of electrons from their 
environment; thus they have higher work functions than the positively charged materials which have 
given up their electrons.  
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Figure 2.10. Electrostatic charge recorded after deposition of the powders in the Faraday well. Experiments 
were randomized and performed at a 23oC/24%RH ambient conditions. Averages of n=3 experiments with 
standard deviations in the error bar are shown. 
 
Measurements were repeated for 45-75m sieve fraction excipients at higher RH conditions (23oC, 
37%RH). The same trend was observed at the higher RH conditions, with both CP and glucose 
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charging negative, and the lactose batches charging positive; the rank-order was even preserved 
among the lactose batches. 
The results of the Faraday well experiments lend themselves to the creation of a triboelectric 
series. The series are presented, with the recorded charges, for different excipient fractions in Table 
2.4.  
Tables 2.4. Triboelectric series, by excipient sieve fraction, from most negative charge (left) to most 
positive charge (on right). Note that rank order is preserved across every sieve fraction. 
 
  ------------------------------ Q (nC/g) ------------------------------ 
Particle Size Budesonide Glucose CP   ML80 ML58 SV425 SV94 Albuterol 
Micronized -1.169 ± 0.260 - - 0±0 - - - - 
+0.736 ± 
0.378 
45 - 75m - -0.252 ± 0.025 
-0.230 
± 0.043 0±0 
+0.403 
± 0.031 
+0.551 
± 0.061 
+0.556 
± 0.161 
+0.601 
± 0.107 - 
75-105m - -0.352 ± 0.049 
-0.197 
± 0.070 0±0 
+0.352 
± 0.049 
+0.459 
± 0.015 - - - 
105 - 150m - -0.206 ± 0.060 
-0.172 
± 0.019 0±0 
+0.263 
± 0.015 
+0.470 
± 0.059 - - - 
 
While variability in the behavior clearly occurs, the results of the Faraday well experiments are highly 
consistent in a rank-order across the different sieve cuts. Assuming the sieved lactose batches were 
available in other larger sizes and fell into the same pattern, one general triboelectric series can be 
constructed as follows: 
-   Budesonide << Glucose ≤ CP < Paper/Glass < ML80 < ML58 < SV425 < SV94 < Albuterol + 
Based on this series, we expect the strongest particle interactions to occur between albuterol and 
glucose as well as budesonide and SV94 lactose.  
A number of drug/ excipient blends were also evaluated with the Faraday well method. The 
presence of drug, budesonide or albuterol, did not have a consistent effect on the bulk powder 
charging properties. This is not surprising as the drug content in the formulations is at or below 1% in 
all formulations. 
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2.5. Summary 
The drugs and excipients in this study were carefully selected based on their relevance to 
respiratory drug delivery. Albuterol and budesonide are representatives of two important therapeutic 
categories, 2-receptor adrenergic agonists and glucocorticosteroids, respectively. Lactose 
monohydrate and glucose are the sole DPI excipients in use. Calcium phosphate is a physiological 
salt that offers a useful contrast. The drugs were micronized and their particle size was independently 
confirmed using laser light scattering and scanning electron microscopy. To control for particle size 
effects that might confound later analysis, excipients were sieved into three sieve fractions. To aid the 
removal of surface-associated fines, excipients underwent fluidization procedures. Particle size and 
shape were verified by laser diffraction light scattering and scanning electron microscopy. The 
polymorphic makeup of the drugs and excipients was ascertained using differential scanning 
calorimetry. Excipients and drugs were combined in formulations by small-scale blending procedures. 
The blends were assayed for content uniformity and distribution of drug was assessed using SEM. 
The electrostatic properties of the materials were then characterized in Faraday well experiments and 
a triboelectric series was created. The triboelectric series follows the order (from most negative to 
most positive charge): Budesonide < glucose < calcium phosphate < milled lactose < sieved lactose < 
albuterol. Although the charging behavior was variable and the differences between the excipients 
were small, the charge behavior, in particular the rank-order, was preserved even as the experiments 
were repeated at different environmental conditions (higher RH). 
Knowing the triboelectric series is of limited utility. However, the series will be helpful in 
determining the charging behavior of drug after release from the DPI formulation. This in turn will 
help test the hypothesis that aerosol charging is the result of contact charging between drug and 
excipient within the formulation. Based on the established triboelectric series, we can predict that 
albuterol will be most highly, positively charged when it is formulated with glucose and/or calcium 
phosphate and will be least positively charged when combined with sieved lactose. It is postulated 
that the reverse will be demonstrated with budesonide.  
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While the triboelectric series offers a chance to establish a causal relationship it does not explain 
why materials may behave one way or another. This question will be addressed in the next chapter 
after material characterization using inverse gas chromatography. Chapter 4 then presents the DPI 
actuation and deposition studies, in which the electrostatic properties of aerosolized drugs are probed. 
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3. SURFACE ENERGY MEASUREMENTS 
 
3.1. Introduction 
A principal goal of this project is to elucidate the triboelectrification process between the 
constituent particles of a DPI formulation. Contact charging is well understood for conducting 
materials, such as metals, where it is the result of electron transfer between materials of differing 
work functions. A work function is the minimum energy needed to extract an electron from a material 
(more precisely, it is the energy necessary to remove electrons from Fermi level to infinity at 0 K). 
Contact charging is less well understood for nonconducting materials, including most drugs and 
excipients, which have unoccupied Fermi levels and, thus no work functions, yet clearly are subject to 
contact charging.  
The current theory, first proposed four decades ago by Harper1, is that the presence of crystal 
lattice defects, adsorbed gases, and impurities on the insulator surface produces additional energy 
levels into which charge can move.2 This leads to the concept of an "effective" work function3 or 
"pseudo-work function",4 which is a material surface property rather than an intensive bulk 
physicochemical property. Stated more specifically, for charge transfer to or from an insulator to 
occur, electron donor or acceptor sites need to be present at or near the surface of the material.4   
The important role of the material surface to contact charging highlights the need for specific 
surface characterization techniques. Inverse gas chromatography (IGC) permits powder surfaces to be 
studied without prior treatment (e.g. compression, as required in contact angle measurements). IGC 
methodology has been developed for characterizing the surface's tendency to interact with adjacent 
molecules, and to act as either an electron acceptor (acid) or electron donor (base) in the process. 
 
3.2. IGC Theory and Experimental Considerations 
IGC is a technique for studying particulate or fibrous solids or films using gas chromatography 
(GC) principles. The technique was used extensively in the characterization of polymers and fibers5 
before being applied to pharmaceutical material characterization. IGC is an effective technique for 
determining surface energy and surface acid/base properties and for the study of surface area,6 
porosity,5 polymorphism,7 and a host of other physical properties. It has some important advantages 
over other methods, which make IGC especially suitable for pharmaceutical work: the technique can 
be performed with small quantities of material; it is non-destructive, versatile and inexpensive, as it 
can be conducted with a standard gas chromatograph. Use of IGC in this work is tied primarily to the 
determination of surface energy and surface acid/base properties.  
Use of the IGC technique has been extensively reviewed elsewhere.8-11 Briefly, the technique is 
based on interactions of gaseous probe molecules with stationary phase in packed column which give 
a characteristic net retention volume, VN. When measured at infinite dilution (where probe-probe 
interactions are negligible), VN can be related to free energy of adsorption, which in turn can be used 
to calculate other thermodynamic parameters.  
 
3.2.1. Surface Free Energy 
Surface free energy is a critical determinant of particle adhesion, which is an important factor in 
the performance of several pharmaceutical systems, including DPI formulations. Surface free energy 
is due the Lifshitz-van der Waals (LW) forces and acid-base interactions.12 The LW component of 
surface energy is primarily due to dispersion forces and may be considered an intrinsic material 
property. Acid-base interactions are considered “specific” as they are only evident when surfaces 
interact with other molecules. Following Fowkes’ reasoning that different phenomena contribute to 
intermolecular forces independently,13, 14 surface energy can be represented as the sum of dispersive 
and nondispersive (specific) contributions as  
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S
disp
SS         (3.1) 
where stands for the total surface free energy of the solid, designates the dispersive surface 
free energy, and the specific surface energy. (Note that  is sometimes referred to as ; 
given the above rationale, the parameters are interchangeable.) Equation 3.1 is analogous to equation 
1.2, which gives work of adhesion as a sum of its constituents.  
S dispS
spec
SspecS ABS
 
3.2.2 Dispersive and Specific Energy by Inverse Gas Chromatography 
From IGC measurements at infinite dilution (i.e. zero surface coverage of the adsorbent), Gray et 
al. 15, 16 proposed a relationship between the dispersive component, , and the retention volumes 
of a series of n-alkanes (which only interact through dispersive forces). Using the work of adhesion 
concept and the Fowkes relationship,13 Schultz et al. 17 expanded on this approach and derived an 
equation between net retention volume, VN and free energy of adsorption 
disp
S
   CVRTG NA  )ln(      (3.2) 
    CaN dispL
disp
SA  2     (3.3) 
where NA is Avogadro’s number, a is the effective surface area of the probe molecule, and 
are dispersive free energies of interacting solid and probe, and C is a constant that depends on 
the chosen reference state. Given that effective surface area and increase linearly for the 
homologous series of alkanes, a plot of  versus 
disp
S
disp
L
disp
L
NVRT ln
disp
LA aN 2 , shown in Figure 3.1, 
yields a straight line with slope dispS . The dispersive surface energy, , is the square of the 
slope of this line.  
disp
S
The specific free energy is determined from the retention of polar probes. When  is 
plotted versus 
NVRT ln
D
lA aN 2  for a polar probe the distance of the point from the n-alkane line is the 
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specific free energy of adsorption, , between the surface of the stationary phase and the 
respective probe (shown in Figure 3.1). Other methods of determining  from retention 
volumes have also been described and were shown to give equivalent results.18  
specG
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Equation of Line:
y  1.837
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Figure 3.1. Plot used to determine the dispersive and specific surface energy of 
the solid, Sd and Ssp, respectively. 
 
The specific free energies of different probes can be determined and correlated with the character 
of the interacting surface. This is most commonly done by way of the acid/base approach to 
molecular interactions,19 based on which specific interactions are classified as either electron donor or 
acceptor type interactions. The approach allows the specific surface free energy values of any number 
of probes to be consolidated into two general parameters that characterize the tendency of the surface 
to act as an electron donor and acceptor. Donor and corrected acceptor numbers, DN and AN*, have 
been determined for many different solvents; these values represent the ability of a probe to donate or 
accept electrons from reference acceptors and donors, respectively. Gutmann defined the DN as the 
molar enthalpy of a given substance with SbCl5, a reference acid, in 1.0 mM dichloroethane solution 
( , kJ/mol).19 AN* was defined as the molar enthalpy of adduct formation of a 
substance with (CH3CH2)3PO, a reference base (
5SbClD
HDN 
OPEtAHAN  3* , kJ/mol).20 This corrected the 
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initial AN definition by Gutmann.19 Using said approach, the surface can be characterized by two 
constants related to the acid/base interactions via the equation 
        (3.4) *ANKDNKH BA
sp
A 
where is the specific enthalpy of adsorption, and KA and KB are the acid (acceptor) and base 
(donor) parameters of the studied surface, respectively. Equation 3.4 is based on work to predict 
enthalpies of adduct formation21 that was later extended to solid adsorption phenomena.17, 22 It is a 
semi-empirical relationship, based on the observation that acid-base interactions are directly linked to 
changes in enthalpy. It was shown that heat of adsorption of basic probes onto an acidic surface can 
be accurately and quantitatively predicted based on acid/base parameters.23 Since KA and KB of the 
absorbent are analogous to the DN and AN* of the probes (which as shown are defined by enthalpy), 
they have the same reference. 
sp
AH
Ticehurst et al.24 and others 8, 25-31 have used an alternative expression based on surface free 
energy given by equation 3.5.  
        (3.5) *ANKDNKG BA
sp
A 
The early literature stated that equation 3.5 is an approximation based on the assumption of negligible 
entropic effects. However, most subsequent papers no longer state this assumption, and in some cases 
erroneously cite the original Schultz et al. article as the source of this equation.  
Use of equation 3.5 instead of 3.4 has important experimental consequences. Using equation 3.5 
instead of 3.4 the experimenter can quickly determine KA and KB from one set of data at a single 
temperature, by plotting /AN* versus DN/AN* for a number of acidic and basic probes. By 
contrast, determination of KA and KB from equation 3.4 requires the IGC experiments to be repeated 
at several temperatures so that values can first be determined for the different probes from the 
intercept of the plot of versus temperature (by Gibb’s equation). After that, KA and KB are 
determined from the slope and intercept of /AN* versus DN/AN* for the probes. 
sp
AG

sp
AG
sp
AH
sp
AH
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In preliminary work, the two approaches to characterizing surface acid/base interactions using 
IGC were compared and the validity of the assumptions behind equation 3.5 was evaluated.32 Using 
the same set of data, the simplified approach (where G of adhesion is assumed to be equal to H) 
that has been popular in the pharmaceutical literature was compared with a more rigorous approach 
for the determination of surface acid/base properties. While assuming ≈ results in 
experimental simplification, it reduced the correlation since it depends strongly on method and 
experimental conditions. The values obtained were internally inconsistent and did not agree with 
those obtained in the rigorous analysis. This was an important result which justifies the rigorous 
approach applied in these studies. The study resulted in a publication,32 which is included in 
Appendix B. This paper also provides a more detailed discussion of the methodology of the IGC 
approach.  
spec
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3.3. Materials and Methods  
 
3.3.1. Materials  
 
Two batches of milled (ML001, batches 10136780 and 10138058), and two batches of sieved 
(SV003, batches 10190094 and 10135425) Respitose™, lactose monohydrate, were selected for 
evaluation. (For convenience, the batches are referred to as ML80, ML58, SV94, and SV425, 
respectively.) Dextrose (D-glucose) monohydrate (batch KDTLT) LycadexTM, was provided by 
Roquette (Keokuk, IA). Calcium phosphate, CalipharmTM (powder grade) was obtained from Rhodia 
(Cranbury, NJ).  
The IGC experiments utilized a number of apolar and polar probe vapors. The alkane probes used 
for dispersive free energy determination were hexane (>99%, Aldrich), heptane (>99%, Aldrich), 
octane (>99.5%, Fluka), nonane (>99%, Aldrich), and decane (>99%, Aldrich). Polar probes were 
chosen to cover a wide DN/AN* range. The polar probes used were tetrahydrofuron (THF) (EM 
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Science, 99.99%), chloroform (100%, Mallinkrodt), acetone (99.7%, Mallinkrodt), ethyl acetate 
(99.9%, Mallinkrodt), diethyl ether (99%+, Acros), and ethanol (100%, Aaper).  
 
3.3.2. Inverse Phase Gas Chromatography Methodology 
IGC experiments were conducted with a Hewlett-Packard 5890 Series II GC with flame 
ionization detector. The chromatograph was modified to allow installation of 205mm, 4mm ID glass 
columns. Carrier gas employed was dry N2 at a flowrate of 30mL/min. Lactose was packed into 
deactivated33 glass columns and plugged with silanated glass wool. Corrections were made for 
pressure drop across column and temperature effects on flow rate. Injector and detector temperatures 
were set to 200oC to ensure immediate and complete probe evaporation and prevent eluted probe 
condensation at the detector. After installation and temperature changes, packed columns were 
allowed to equilibrate for at least 1 hour before subsequent injections were made. Injections were 
made with a 10L-Hamilton syringe. Infinite dilution was ensured by detector response, detector 
signals below 10x limit of detection were permitted; this corresponds to injection volumes <0.01L. 
The injection volumes were obtained by dipping the syringe needle briefly into the probe, and then 
waiting a few seconds for evaporation prior to injection. Each injection was made 2-3 times; the 
relative standard deviations in the retention times of these injections were <3% in each case. Each 
excipient was evaluated using three different packed columns. Since even inert probes can be 
somewhat retarded,34 dead-times were calculated using a least squares approach involving the 
retention times of heptane, octane, nonane and decane.5  
 
3.3.2.1 Lactose Monohydrate 
The oven temperatures used for analysis of the lactose samples were 60oC, 45oC, and 30oC, in 
that order. Previous experiments had shown that 60oC is the highest feasible temperature for 
analyzing lactose; prolonged exposure to higher temperatures can bring about polymorphic 
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transformations. The lowest temperature that can reliably be maintained in the GC oven without 
introducing an active cooling element is 26C. However, operation at this temperature requires the 
oven door to remain opened, which creates air turbulence (generated by the oven fan) which in turn 
affects the stability of the FID signal. 30oC was chosen because it can be maintained in the GC oven 
with the oven door closed.  
 
3.3.2.2 Glucose Monohydrate 
An IGC method for glucose was required as all previous work had been conducted using lactose. 
α -D-dextrose monohydrate is stable below 50°C, but may become anhydrous or form -D-dextrose 
at higher temperatures.35 As a result, in the initial experiments the oven temperatures for analysis 
were set to 48oC, 36oC, and 26oC, in that order to maximize the temperature range to obtain the most 
accurate ΔH value recognizing that 26C may result in some data variability.  
 
3.3.2.3 Calcium Phosphate 
In addition, the oven temperatures for calcium phosphate analysis required evaluation. Having a 
larger specific surface area than the other excipients (~20m2/g) CP was expected to have longer 
retention times. Since the material is stable at higher temperatures, IGC experiments were performed 
at oven temperatures of 100oC, 80oC, and 60oC, in that order.  
 
3.3.3. Differential Scanning Calorimetry 
To assure that IGC experimental conditions did not induce physical instability, thermal analyses 
were performed on samples prior to and after the IGC experiment. Analyses were performed using 
DSC-6 (Perkin Elmer, Waltham, MA). Samples of 3 mg were enclosed in crimped aluminum pans 
and scanned across the relevant temperature ranges at a rate of 10o/min. (see Chapter 2 for details).  
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3.3.4. Data Analysis 
Dead times, net retention times, and surface free energies at each temperature, and enthalpies 
were calculated in Excel 2003 (Microsoft Corp, Seattle, WA) in accordance with equations 3.1 
through 3.3. Surface acid and base parameters, KA and KB respectively, were calculated using SPSS 
16 (SPSS, Chicago, IL); enthalpy data for three columns was pooled and linear regression was 
performed. Results were plotted using Excel 2003. Differences between lactose batches were probed 
for statistical significance using the two-sample t-test for independent samples with unequal variances 
(Satterthwaite’s method). Probe surface areas used in the analyses were obtained from Schultz et al.17 
Other properties, including surface tension, are readily available in chemistry handbooks.36 Table 3.1 
summarizes the relevant probe properties that were used in the calculations.   
 
Table 3.1. Properties of IGC Probes, values used in all IGC calculations 
 
Probe 
Molecular 
Surface Area 
(Å2) 
DN (kJ/mol) AN* (kJ/mol) DN/AN* Character 
n-Hexane 51.5 0 0  Neutral 
n-Heptane 57.0 0 0  Neutral 
n-Octane 62.8 0 0  Neutral 
n-Nonane 68.9 0 0  Neutral 
n-Decane 75.2 0 0  Neutral 
THF 45 83.7 2.1 40.0 Base 
Diethyl Ether 47 80.4 5.9 13.7 Base 
Chloroform 44 0.0 22.6 0.0 Acid 
Acetone 42.5 71.2 10.5 6.8 Amphoteric 
Ethyl Acetate 48 71.6 6.3 11.4 Amphoteric 
Methanol 42 83.7 50.2 1.7 Amphoteric 
Ethanol 57 83.7 43.1 1.9 Amphoteric 
Surface tension data as the relevant temperatures was obtained from CRC Handbook 
of Thermophysical and Thermochemical Data.36 
 
3.4. Results and Discussion 
3.4.1. Analysis of Lactose Monohydrate Batches  
The dispersive surface free energies of the two ML and two SV batches were determined at 60, 
45, and 30oC. Using DSC, the lactose samples were examined for physical changes after the IGC 
experiments but none were detected. While there do not appear to be any significant differences in the 
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dispersive surface free energies of the four batches at any of the temperatures, the milled and the 
sieved batches appear different when studied across the temperature range. This is evident in Figure 
3.2. The slopes, which represent surface entropy, are larger for the sieved than the milled batches. As 
a result, higher surface enthalpies are obtained for the sieved than the milled lactose batches (106-110 
mJ/m2 versus 98-101 mJ/m2).  
: y = -0.224x + 110  R2 = 1.000
: y = -0.186x + 98    R2 = 0.998
: y = -0.210x + 106  R2 = 0.999
: y = -0.197x + 101  R2 = 0.989
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Figure 3.2. Dispersive surface free energies of sieved and milled lactose monohydrate vs. temperature. Relative 
standard deviation was < 2.5% in each case (n=4). While there are no statistically significant differences in 
dispersive surface free energy at any of the temperatures, the slope of the ML lactose batches (dashed lines) 
appears different from the two SV batches, resulting in lower slopes (entropy) and lower intercepts (enthalpy). 
 
Examination of the specific interactions reveals differences between the milled and the sieved 
batches, and among the two sieved and two milled batches. These differences are presented in Table 
3.2. In general, the batches appear to be quite similar, which is expected given that they are the same 
material from a single manufacturer (DMV-Fonterra). Since KA and KB values are unitless, 
differences between KA and KB for a material cannot be interpreted directly as signifying a more 
acidic or more basic surface. However, comparing KA and KB for different batches and materials 
allows these comparisons to be made. Lactose is known to be an acidic material and the differences in 
acidic parameter are small but significant as the sieved batches are similar to one another (0.146) but 
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differ from the milled batches (0.156 and 0.167). The differences in KA between milled and sieved 
lactose batches are statistically significant (p<0.05). The differences in KB are marked and indicative 
of material variations. Since lactose is an acidic material, the differences in KB are likely tied to 
surface properties, perhaps the presence of impurities or certain crystal faces at the surface. However, 
due to the variability in this parameter, these differences lack statistical significance. 
 
Table 3.2.  Surface acid/base parameters of lactose monohydrate batches, SV and ML (mean ± standard error of 
n  3 experiments) with corresponding square of correlation coefficient. The milled batches differ from the 
sieved batches in KA; they have more acidic surface. Sieved and milled batches differ from one another in KB 
though variability in this parameter is high. 
 
Lactose 
Batch KA KB R
2 KA / KB 
SV     
094 0.146 ± 0.006 0.419 ± 0.104 0.964 0.35 
425 0.146 ± 0.003 0.357 ± 0.052 0.990 0.41 
ML     
58 0.167 ± 0.003 0.374 ± 0.053 0.995 0.45 
80 0.156 ± 0.004 0.311 ± 0.061 0.990 0.50 
 
 
3.4.2. Analysis of Glucose Monohydrate  
A number of experimental IGC conditions were evaluated to determine the procedure best-suited 
for characterizing the surface energy of glucose. Initial experiments were performed at a maximum 
temperature of 48oC, below the temperature of 50oC at which polymorph instability may arise. Yet 
DSC experiments at the conclusion of the IGC experiment indicated that the material had been 
completely dehydrated and had formed anhydrous -D-dextrose which has a melting temperature of 
148-155°C (endotherm peak recorded at 151oC). This is shown in Figure 3.3. Experiments were 
repeated with 36oC as the highest temperature, but these conditions also resulted in dehydration of 
glucose monohydrate (though no -D-dextrose formation); the melting endotherm characteristic of 
anhydrous glucose is observed at 146oC in Figure 3.3. Dehydration was so rapid, it could be observed 
during the experiments; changes in retention time of a given probe were noted in as little as ten 
minutes. Experiments were repeated with the injector temperature lowered to 50oC; dehydration of 
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the material persisted though the rate decreased. IGC measurements at 26oC with the injection 
temperature lowered to 50oC did not result in physical instability, but constitute a single temperature 
reading, which precludes determination of the surface enthalpy. As a result, KA and KB could not be 
determined using the conventional approach based on equation 3.4. Instead, the evaluation of the 
surface acid/base properties of glucose monohydrate is based on a single temperature setting and is 
qualitative in nature. 
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Figure 3.3. Thermogram of glucose monohydrate before (blue) and after (blue) the IGC experiment. Prolonged 
exposure of glucose monohydrate packed into IGC column at 48oC results in dehydration and formation of -D-
dextrose. Prolonged exposure of glucose monohydrate at 36oC results in dehydration of the material. Glucose 
monohydrate has a melting point of ~80oC, glucose anhydrate melts at ~145oC, while -glucose melts at 
~150oC. 
 
At 26oC, glucose monohydrate has a dispersive surface free energy of 38.1 ± 0.4 mJ/m2; this 
value is approximately 10% lower than that of the lactose monohydrate batches. Table 3.3 
summarizes the specific surface free energies of glucose monohydrate at 26oC compared to milled 
lactose monohydrate batch ML58, which had previously been determined using the same IGC 
method. Dispersive effects have been accounted for and have been subtracted; the specific free energy 
values listed account solely for specific interactions between the excipient and the given probes. The 
probes are listed along with their acidic/basic properties (DN/AN* numbers). Comparing the values 
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of glucose and ML58 lactose, we can see that glucose has weaker interactions with the acidic 
chloroform probe but stronger interactions with the amphoteric and basic probes. This suggests that 
the glucose surface is itself more acidic or electron-accepting compared to lactose. Assuming the 
entropic contribution to the free energy were approximately the same for lactose and glucose, the 
results would imply higher KA and lower KB values for glucose than for this lactose batch.  
 
Table 3.3. Specific surface free energies (average ± standard deviation of n=3 columns) of adsorption 
between glucose monohydrate and the vapor probes listed in the table. 
 
 ----------          ΔGsp (kJ/mol)          ---------- 
Probe          
(DN / AN*, 
kJ/mol) 
Chloroform 
(0.0 / 22.6) 
Acidic 
Methanol 
(83.7 / 50.2) 
Amphoteric 
Ethanol 
(83.7 / 43.1) 
Amphoteric 
Acetone 
(71.2 / 10.5) 
Amphoteric 
Ethyl Ac. 
(71.6 / 6.3) 
Amphoteric 
THF 
(83.7 /2.1) 
Basic 
Glucose 
monohydrate 0.28 ±0.07 8.13 ±0.38 5.40 ±0.22 5.30 ±0.12 5.94 ±0.10 5.45 ±0.09 
Lactose 
monohydrate 
ML58 
0.77 ± 0.02 6.16 ± 0.05 3.59 ± 0.02 3.81 ± 0.08 4.56 ± 0.05 3.87 ± 0.12 
 
To estimate KA and KB numerically, equal entropic contribution was assumed and applied to the 
enthalpy of adsorption calculation of glucose. The entropic contribution to surface free energy of each 
lactose batch had already been estimated as part of the KA and KB calculation for the lactose batches. 
It was noted that the differences between the lactose batches were minor (max. difference was 20%) 
and the mean for all lactose batches and each probe was calculated. ΔHsp for each probe and glucose 
was then estimated, and KA and KB were calculated based on the ΔHsp /AN* vs DN/AN* best fit line. 
The parameter estimates were KA= 0.18 and KB=0.32, respectively, which does imply a more 
electron-withdrawing surface compared to lactose, recognizing that the differences are relatively 
minor.  
 
3.4.3. Analysis of Anhydrous Calcium Phosphate  
After preliminary studies to establish the IGC experimental conditions, the method described in 
section 3.3.2.3 was applied to the analysis of CP; IGC experiments, i.e. probe injections, were 
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performed at 100oC, 80oC, and 60oC. (The conditions that had been applied to lactose had resulted in 
extremely high retention times with severe peak spreading for all probes.) As shown in Figure 3.4, the 
dispersive surface free energies obtained varied from 40.7 ± 0.8 mJ/m2 at 60oC to 35.5 ± 0.6 mJ/m2 at 
100oC. The 60oC free energy of 40.7 mJ/m2 is significantly higher than that of lactose, ca. 36mJ/m2 
across the different batches. Linear regression of the data provides the enthalpy of adsorption, 
approximately 84 mJ/m2.   
y = -0.130x + 84.154
R2 = 1.000
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Figure 3.4. Dispersive surface free energy of calcium phosphate from 60oC to 100oC. 
 
Injections of polar probes provided some unexpected results. While the injections of the n-alkane 
probes and chloroform resulted in the usual sharp chromatogram peaks, eluted after  6 minutes, all 
other polar probes did not elute at all. After the injections were repeated with increasing injection 
volumes (moving away from infinite dilution), extreme peak broadening, or rather solvent front 
development, were observed in the range of 10 minutes at 100oC to 40 minutes at 60oC. In each case 
the peak broadening was so severe, reliable and reproducible retention times could not be obtained, 
for either of the amphoteric or basic probes. Moreover, the condition of infinite dilution no longer 
applied to these chromatograms.  
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A survey of the literature did not provide any description, or explanation, of this observed 
retention behavior, with regard to calcium phosphate or other inorganic salts. Thus, the following 
explanation is proposed: The calcium phosphate material is highly acidic in nature and strongly 
interacts with the amphoteric and basic polar probes. Adsorption is clearly very strong resulting in 
extremely high retention times and severe dispersion and spreading. At low injection volumes, the 
spreading renders the concentrations at elution too low to be discerned from background effects.  
The CP surface readily accepts electrons from the electron-donating probe vapors. Chloroform, 
on the other hand, which is an acidic probe with AN* and DN of 22.6 and 0.0, respectively, does not 
interact strongly and is, thus, eluted after a short retention time. Specific free energies of adsorption 
were calculated for chloroform at each of the temperatures and an enthalpy of adsorption was thus 
obtained; it is 4.8 ± 0.2 kJ/mol. Based on this one data point (albeit at the origin), the KB was 
estimated from the y-intercept of the /AN* versus DN/AN* graph; it is 0.213 ± 0.007. KA 
could not be determined but based on the very strong interactions of CP with the amphoteric and 
basic probes, it is clear that KA is very high, higher than for either lactose monohydrate or glucose 
monohydrate. DSC performed on the CP samples prior to and after the IGC runs showed no 
differences, indicating no physical instability. 
sp
AH
 
3.4.4. Discussion 
Physical adsorption, the principle of IGC, is a manifestation of interactions between molecules in 
the vapor probe and those in the solid surface.37 The magnitude of the interactions is reflected in the 
adsorption processes, which in turn determine the retention times. While the IGC analysis did not 
result in KA and KB values for each surface studied, retention data provided sufficient information for 
a classification of the surface characteristics. The inability to generate KA and KB for glucose and KA 
for CP was a result of experimental limitations due to the nature of the materials; it is not a failure of 
the technique or approach itself. The KA and KB data are summarized in Table 3.4. 
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Table 3.4. Summary of KA and KB data obtained in the IGC experiments. 
 
Excipient KA KB 
Lactose SV094 0.146 ± 0.006 0.419 ± 0.104 
Lactose SV425 0.146 ± 0.003 0.357 ± 0.052 
Lactose ML 58 0.167 ± 0.003 0.374 ± 0.053 
Lactose ML 80 0.156 ± 0.004 0.311 ± 0.061 
Glucose 
monohydrate Higher than lactose
About the same as 
lactose 
Calcium Phosphate High 0.213 ± 0.007 
 
 
Based on these results, a rank-order correlation for the expected behavior of the excipient as 
either an electron donor or electron acceptor can be proposed. While the lack of precise data for 
calcium phosphate and glucose precludes an entirely quantitative comparison of the excipients, the 
results provide enough information to determine an ordinal, rank-order, comparison. Based on the 
results of the experiments, calcium phosphate, followed by glucose would be expected to act most 
electron withdrawing (acidic) in contact with other materials, such as drug. Based on KA and KB, 
sieved lactose (SV094, followed by SV425) is expected to be least electron-withdrawing and most 
electron donating. The following rank-order is thus given, from least to most electron withdrawing 
species: 
SV094 < SV 425 < ML58 ≈ ML80 < Glucose < Calcium Phosphate 
If the surface acid / base properties are predictive of contact charging processes, drugs co-formulated 
with these respective excipients would be expected to charge in the following order: 
Negative drug charge - SV094 < SV 425 < ML58 ≈ ML80 < Glucose < CP - Positive drug charge 
Note that this order is largely consistent with the order proposed based on Faraday well experiments 
at the conclusion of Chapter 2. The next chapter will demonstrate the charging of drugs when 
delivered from DPI formulations consisting of interactive blends with these excipients. The results of 
this chapter will be revisited in light of those findings. 
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3.5. Summary and Conclusion 
The IGC methodology was applied to the studied excipients, four batches of lactose 
monohydrate, glucose monohydrate, and anhydrous calcium phosphate. The technique was subject to 
several experimental limitations, most notably the physical instability of glucose monohydrate at 
elevated temperatures, and the extremely strong interactions of some probes with calcium phosphate. 
While these limitations have precluded a determination of all surface acid and base parameters for 
glucose and calcium phosphate, the experiments provided sufficient information to rank-order the 
excipient surfaces in their ability to act as electron donors or electron acceptors in physicochemical 
processes. The trend is in agreement with that proposed from Faraday well experiments in Chapter 2. 
The next chapter will demonstrate if the relationship is predictable of formulation behavior. 
A principal goal of this project is to elucidate the triboelectrification process between the 
constituent particles of a DPI formulation. While Faraday well experiments in Chapter 2 provided a 
macroscopic view of bulk powder charging, and Chapter 4 will examine drug particle charging upon 
delivery from a DPI, this chapter has focused on the explanation of the charge transfer phenomenon 
by linking it with material surface properties. Inverse gas chromatography (IGC) permits the 
characterization of a surface's tendency to interact with adjacent molecules, and to act as either an 
electron acceptor (acid) or electron donor (base) in the process. 
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4. AERODYNAMIC AND ELECTROSTATIC PROPERTIES DETERMINED BY 
ELECTRICAL LOW PRESSURE IMPACTION 
 
4.1. Introduction 
DPI formulations and devices have characteristics that can give rise to surface charging, or 
triboelectrification, as described in Chapter 1. When the patient actuates a DPI the formulation is 
fluidized and dispersed; drug and carrier particles separate from each other. Charges can be 
transferred during this process resulting in net particle charges which may affect particle trajectory 
and deposition. Particles experience significant friction during DPI discharge which tends to amplify 
these effects.  
Chapter 2 describes Faraday well experiments which provide the bulk material charging 
properties of the drugs and excipients. This chapter describes the aerodynamic and electrical property 
experiments required for elucidating the aerosol behavior of the formulation. Using the electrical low 
pressure impactor (ELPI), the experimental apparatus permits the simultaneous determination of 
particle size and charge distribution of the fine particle fraction of the emitted aerosol, which are 
important prerequisites for understanding formulation behavior and testing hypotheses 1, 2, and 4. 
 
4.1.1. The Electrical Low Pressure Impactor (ELPITM) 
The experimental apparatus relies on the Electrical Low Pressure Impactor (ELPITM, Dekati Ltd, 
Tampere, Finland), an aerodynamic particle sizer that detects particles by charge.1 The ELPI has 
primarily been used in the automotive industry2-5 and in industrial hygiene applications.6, 7 Only 
recently has it been applied to the evaluation of electrostatic phenomena in medicinal aerosols, 
including MDIs8 and DPIs9.  
A detailed discussion of the ELPI is available elsewhere.10 Briefly, the ELPI is composed of a 
low-pressure cascade impactor and a unipolar corona aerosol charger that charges the incoming 
aerosol uniformly prior to entry into the cascade impactor. Operating at a reduced pressure (10kPa on 
the final stage) the ELPI collects particles down to size of 30nm, the cutoff diameter of the bottom 
stage (stage 1). The cutoff diameters of the other 12 stages are 10.2, 6.56, 4.09, 2.52, 1.66, 1.02, 0.66, 
0.41, 0.27, 0.17, 0.11, and 0.06m, respectively. As is the case in other impactors, deposition inside 
the ELPI is dependent on particle aerodynamic diameter. But unlike conventional cascade impactors 
which are disassembled after operation for chemical or gravimetrical assay of the stages, an ELPI 
detects particle deposition by measuring the current resulting from dissipation of the particles’ 
electrical charges. The collected particles can be measured simultaneously on all stages using a 
multichannel electrometer and reported in real-time on a computer. Thus, when operated with charger 
turned on, the ELPI functions as a real-time particle sizer; this is the standard ELPI configuration and 
it is shown in Figure 4.1(a).  
 
Inlet 
  
Figure 4.1. (a) Standard ELPI configuration with 
corona charger in place. The aerosol particles are 
charged uniformly prior to deposition within the 
impactor, for real-time particle size determination. 
(b) Modified ELPI configuration with charger turned 
off. When the incoming aerosol is not charged 
uniformly, the ELPI determines native particle 
charges and records a charge distribution. 
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The ELPI can also be operated with the charger turned off, as shown schematically in Figure 
4.1(b). In this configuration, the incoming aerosol is not charged within the ELPI and the electrometer 
measures only native particle charges. Since each impactor stage is electrically isolated from the next, 
charges can be measured across individual stages, allowing the evaluation of size specific charging 
with accurate determination of charge magnitude and polarity on particles in the respirable size range 
over time.  
 
4.1.2. Preliminary Data 
Studies of medicinal aerosol electrostatics have been attempted previously. Electrostatic charge 
carried by a DPI aerosol cloud has been measured using a grid probe;11 however, the particles were 
rather large and the system was of little pharmaceutical relevance. The effects of particle morphology 
and crystallinity on triboelectrification of DPIs have also been studied, but particle deposition was not 
considered.12 Moreover, the studies relied solely on Faraday cage charge measurements, which 
precluded analysis of fine particle sizes and size-dependent charge distribution.  
A preliminary analysis of DPI electrostatics in a pharmaceutically relevant system was conducted 
by the author and has recently been published; it is included in Appendix C.9 The preliminary studies 
provide the foundation for the work described in this chapter, and can be summarized as follows: 
 
(1) An experimental apparatus was developed that allowed inhalers to be tested at an airflow rate of 
60L/min, as recommended by the FDA and US Pharmacopeia13, and the electrical charge of the 
respirable fraction to be determined. The same setup is used in the present work. 
(2) Initial experiments assessed the ability of the ELPI to classify therapeutic aerosols consistently 
and in accord with a conventional inertial impactor, i.e. the Andersen eight stage nonviable 
impactor. ELPI particle size distributions were in agreement with those determined from ACI 
deposition measurements. 
 99
(3) The particle size distributions acquired by ELPI were compared to those obtained from 
gravimetric analysis of the stages; agreement was good with almost superimposable particle size 
distributions and same d25, d50, and d75 values. The ELPI system proved more precise and 
reproducible in the lower particle size ranges due to the limited resolution of the analytical 
balance used in the gravimetric analysis. 
(4) The study showed that particle deposition within the ELPI was consistent and reproducible for a 
given set of conditions. However, deposited particle charge was shown to vary significantly 
between different particle size fractions of a given formulation as well as between formulations.  
(5) The study revealed that pharmaceutical product properties such as excipient, inhaler type, and 
metering system (capsule material) significantly affect the extent to which formulations 
experience triboelectrification. Both charge magnitude and polarity were affected consistently. 
 
The experiments constituted the most comprehensive study of DPI triboelectrification phenomena 
to date. They proved unequivocally that triboelectrification is a significant phenomenon in DPI 
actuation. Yet, the study had several shortcomings that needed to be considered in follow-up work. 
Charging effects are confounded by particle size distribution and mass depositions since the stages of 
the ELPI were not assayed for drug and excipient deposition during individual actuations. Moreover, 
excipients contained sizeable proportions of fine particles that were deposited together with the 
micron-size drug after formulation actuation. As a result, it is unclear which material contributed to 
charge on each stage; tribocharging could not be conclusively linked with fine particulate drug, and 
the magnitude of particle charge could not be established. However, this information is needed to 
determine whether particles carry sufficient charge to affect delivery.  
 
4.2. Experimental Design 
The goal of the experiments was to elucidate the phenomenon of electrostatic charging in a DPI 
(specific aim 1) by simultaneously studying charge and mass deposition following DPI actuation. 
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Establishing which formulation variables contribute to charging (specific aim 2) has consequences for 
product development. However, the number of possible variables to study in this context was 
potentially large. The choice of a discriminating experimental design with appropriate input factors 
and responses was critical. 
 
4.2.1. Design Factors 
Preliminary experiments suggested which factors might merit closer scrutiny. At the same time 
the scope of the study needed to be expanded to consider previously neglected factors that might 
allow generalized conclusions. The Ishikawa (cause-and-effect) diagram in Figure 4.2 lists the factors 
that affect the performance of a DPI. The following section describes which of these factors were 
selected for study and how the experimental design was developed to test the contribution of the 
factors to triboelectric charging: 
 
Drug
Formulation
Emitted Dose
Fine Particle Mass
Particle Size Distribution
Electrostatic Charge
Excipient
Size fraction
Micronization
Capsule
Load
Composition
Time
Temperature
Humidity
Geometry
Flow rate
Shear
Dosage
DeviceStorage
Figure 4.2. Ishikawa (cause-and-effect) diagram describing the function of dry powder inhalers. 
 
 
 (1) Drugs: Albuterol sulfate, Budesonide 
 Albuterol (USAN) or salbutamol (INN) is a short-acting β2-adrenergic receptor agonist used for 
the relief of bronchospasms in asthma and COPD. Albuterol (MW 239.3) is a commonly inhaled 
medicine, available in many drug products, and frequently used as a model drug in medicinal 
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aerosol research. Albuterol sulfate was the sole drug substance studied in the preliminary 
experiments.  
 A second model drug, budesonide, was selected to determine if preliminary results could be 
extended beyond albuterol alone. Budesonide (MW 430.5) is a glucocorticoid steroid for the 
treatment of asthma, non-infectious rhinitis, and allergies. Budesonide is marketed as Pulmicort® 
with a Turbohaler DPI by AstraZenaca.14 It was selected because it is a different therapeutic 
category of drug and is structurally very distinct from albuterol. Since it is a newer and still 
patented product, budesonide has not been studied to a large extent. 
(2) Excipients: Lactose monohydrate, Glucose, Calcium Phosphate (CP) 
 Lactose is the most common excipient in DPI formulations. It was the only excipient used in the 
preliminary experiments and is the primary excipient in the formulations tested in this study. In 
addition to lactose, glucose was tested. It is the only other excipient employed in DPI 
formulations,15 and is thus a relevant substance to compare. CP was chosen for study because it is 
chemically an entirely different material (inorganic salt), which offers a contrast. While it is a 
physiological salt that is widely used in the formulation of oral dosage forms, it has not been used 
in DPI formulations. 
(3) Excipient Sieve Fractions: 45–75 µm, 75–105 µm, 105-150 µm 
 Different excipient sieve fractions were obtained and used in individual formulations. Since 
different size fractions of micronized albuterol have shown different charging characteristics in 
preliminary experiments, it is postulated that excipients may also show size dependent behavior. 
Three sieve fractions were selected because they were size ranges available for most excipients 
(all but the sieved lactose batches, where all particles are smaller than 75 µm). A lower limit of 
45µm was selected to allow the most complete removal of excipient fines which might otherwise 
be deposited on the stages of the ELPI, confounding the analysis.  
(4) Excipient Batch-to-Batch Variability (Lactose only): 2 milled (ML) 2 sieved (SV) lactose 
products 
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 Since batch-to-batch variability is a well-known problem, several lactose products and batches 
were used to make formulations. Sieved lactose batches (SV) have undergone sieving as the only 
process step after crystallization while milled batches (ML) have been milled after crystallization 
at the manufacture site. 
(5) Drug Concentration: 0.25%, 0.50%, 1.0% 
 DPI formulations are interactive powder blends containing low drug concentrations, often at the 
0.5-2% mass/mass range. These concentrations ensure that drug particles remain separated from 
one another and, thus, maintain their primary particle size, i.e. they do not aggregate significantly. 
Drug concentrations are an important determinant of drug/carrier particle interactions. The drug 
concentration was examined at three levels to evaluate particle separation and charging. Carrier 
particle surfaces are heterogeneous with a number of particularly energetic “active sites”;16 using 
different drug concentrations these active sites may be probed. The presence of active sites would 
likely be manifested in particle association resulting in deposition differences that are in non-
linear with respect to drug concentration.  
(6) Dose: 10mg, 20mg, 30mg, 40mg 
 The dose range is relevant to DPI formulations. Nonlinear responses of charging and drug 
deposition to changes in dose may elucidate the fluidization and charging pattern.  
(7) Fluidization Conditions: Standard Entrainment Tubes  
 Preliminary studies were conducted using two different inhaler devices, the Rotahaler® 
(GlaxoSmithKline, RTP, NC) and the Inhalator® (Boerhinger Ingelheim, Germany) single 
capsule inhaler, were a high pressure drop and a low pressure drop device, respectively.17 The 
study results indicated a strong correlation between choice of inhaler and both magnitude and 
polarity of acquired charge. However, this correlation could not be firmly linked to a change in 
pressure drop or device resistivity, because the devices also differed in material and operational 
principles, which confounded comparisons between the devices. To eliminate this source of 
variability, standardized entrainment tubes (SETs) replaced DPI devices as aerosol dispersion 
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systems. SETs are simple steel tubes of specific dimensions in which well characterized air flow 
patterns are established.18 
(8) Product Batch-to-Batch Variability (variability in manufacture) 
 Manufacture of select batches was repeated to determine if the observed phenomena were the 
result of fundamental material properties (as postulated) or whether they were the result of 
environmental or random effects that might arise in the process of manufacture. 
 
4.2.2. Study Design 
Having established the design factors and their most useful levels, experiments must be structured 
to satisfy the study’s aims. The mere combination of excipient, batch, and sieve fractions results in 14 
different excipient building blocks. Were each of these to be tested at two levels, the total number of 
individual formulations would be 14 x 2 (drugs) x 2 (conc) = 56 formulations. Tested at 2 doses and 2 
fluidization conditions would require 224 experiments which does not account for the allocation of 
replicates (to test reproducibility and manufacture consistency). Were all levels discussed above 
tested the study would require 14 x 2 x 3 x 4 x 3 x 4 x 3 = 12,096 experiments (again excluding 
allocations for reproducibility and manufacture consistency). Efficient experimental allocation is 
crucially important. 
In determining the appropriate statistical design, several competing objectives were weighed. 
Picking a standard design scheme, such as a fractional factorial or central composite design is 
attractive because it provides the ability to interpret all generated data simultaneously using well 
established statistical tools and generate response surfaces that may allow interpolation and 
extrapolation. However, given the large number of factors (in particular categorical factors such as 
the 14 different excipient building blocks) this design would be difficult to construct and in the end 
would still require sufficient trials to be impractical. Consequently a different approach was required.  
The experimental design developed was a series of experiments in a design framework rather than 
a purely statistical design scheme. While it contains elements of both half and full-factorial designs it 
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was structured to test specific (if conditional) hypotheses rather than to determine a multidimensional 
response surface. Using this experimental framework the results cannot be interpreted generally but 
must be considered discretely. Specific hypotheses, represented by the design factors listed in section 
4.2.1 were tested using a 2-level design with a number of intermittent or extreme points at various 
positions to gauge the response surface curvature where it appeared to play a role. The design, which 
is shown schematically in Figure 4.3, is based on the assumption that most factors are independent, 
and that marginal effects are more important than interaction effects. While many effects in this 
design can only be considered conditionally, understanding the system may allow more general 
statements to be formulated. In all, the design required 33 formulations to be tested in 63 experiments, 
which provided sufficient time for the repetition of a sizable portion of experiments, thereby 
increasing statistical power. In figure 4.3, each circle denotes an experiment, for which three sets of 
electrical charge data and one set of mass deposition data were determined.  
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Figure 4.3. Experimental framework developed to study the electrostatic effects of the variables. Each circle 
denotes a different experimental setting. The framework contains elements of factorial and central composite design 
but was developed to test specific hypotheses. The main elements of the design are denoted by red boxes. The 
design is described in detail in the text. 
 
The design is built around a central set of experiments that compares each excipient in a standard 
formulation (0.5% albuterol in 45-75μm sieve fraction of excipient) to the other five excipients using 
a common set of actuation conditions (40mg, SET A). There are two full-factorial experimental sets 
using the two milled lactose batches (ML80 and ML58) aimed at gauging the effects of drug 
concentration (0.5% and 1.0%), fluidization conditions (SET A vs. SET C), and dose (20mg vs. 
40mg), and half-factorial designs for each of the other excipients. The purpose of collecting 2 full-
factorial sets for ML80 and ML58 is that the differences between the batches are assumed to be 
minute (batch-to-batch variability), much smaller than the differences expected between the different 
materials. A full-factorial design has greater potential to discriminate differences. Using ML80 only, 
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the effects of drug concentration (0.25% albuterol), fluidization conditions (SET D), and dose (10mg, 
30mg) were further investigated. These experiments were to provide insight on the response surface 
curvature with respect to these variables. The central design (triangular prism) with a full-factorial 
assessment around ML80 is repeated for budesonide; this should allow a comprehensive comparison 
of drug identity for each excipient, as well as confounded effects (interactions between drug, drug 
concentration, fluidization conditions, and dose) for ML80 lactose formulations. Finally, the cube on 
the left provides comparisons of the different sieve fractions for each of the four excipients for which 
the larger sieve fractions are obtainable, that is the two milled lactose batches (ML80, ML58), 
glucose, and CP. Once again, using ML80 lactose, the confounding effects of sieve fraction and drug 
concentration may be examined. While this is one of the afore-mentioned conditional tests, if an 
effect is observed it may well exist for some of the other excipients.  
Of the 63 experiments that were conducted in this framework, 28 involve ML80 lactose (12 out 
of 33 formulations). Thus, a very thorough study of ML80 lactose behavior is obtained, allowing a 
complete examination of all possible interactions of the different variables. Examinations of the other 
excipients are less comprehensive. ML80 lactose stands at the center of this study because it presents 
the pharmaceutically most relevant excipient.   
To ensure that formulations would be tested within a week after manufacture, the order of the 
formulations was randomized first, and then the different actuations were randomized within blocks 
of ~5 formulations. Formulations were then manufactured. This ensured that formulations were not 
subject to different storage effects. 
To evaluate the reproducibility and possible storage effects, 20 of the 63 experiments were 
randomly selected for retesting, several of these would be retested several times after varying periods 
of storage. To evaluate the variability associated with the manufacture seven formulations were 
randomly selected for remanufacture and were subsequently retested using the same experimental 
conditions and settings. In addition, several formulations were selected to check the effect of 
environmental conditions, including the effect of high RH and the effect of the last surface of contact. 
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4.3. Materials and Methods 
The following discussion focuses on the description of the materials and methods directly related 
to the actuation experiments. A complete discussion of drug and excipient and formulation 
preparation (sieving, particle size analysis, etc.) and characterization is provided in Chapter 2. 
 
4.3.1. Materials 
4.3.1.1 Excipients 
Lactose monohydrate, Respitose™, was provided by DMV-Fonterra Excipients (Goch, 
Germany). Two batches of milled (ML001, batches 10136780 and 10138058), and two batches of 
sieved (SV003, batches 10190094 and 10135425) lactose were evaluated. (For convenience, the 
batches will be referred to as ML80, ML58, SV94, and SV425, respectively.) Dextrose (D-glucose), 
LycadexTM, was provided by Roquette (Keokuk, IA). Calcium phosphate, A-TabTM was obtained 
from Innophos (Cranbury, NJ). To control for differences in particle size in the experiments, all 
excipient batches were sieved prior to use in the formulations and experiments. 
 
4.3.1.2 Drugs 
Milled albuterol sulfate (median particle size 2µm) was obtained from Chemaco (Beetsterzwaag, 
NL) from drug manufactured by P.F.C. Italiana S.r.1, (Caronno Pertusella, Italy). Budesonide was 
obtained from Sigma-Aldrich (St. Louis, MO), and was jet-milled to a single-micron size range 
(verified using laser light scattering, described in Chapter 2). 
 
4.3.1.3 Dispersion Devices 
To understand the effects of fluid dynamics on triboelectrification three standard entrainment 
tubes (SET) were used, giving low, intermediate, and high specific resistance values of 0.021, 0.046, 
and 0.140 cm H2O ½ / (L/min), respectively 18. The relevant properties of these SETs in comparison 
with the two previously tested devices are shown in Table 4.1; SETs A, C, and D provide high, low 
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(corresponding to Inhalator and Rotahaler), and very low resistivity devices, likely to provide 
evidence of a range of performance of the formulations in response to airflow conditions. 
 
Table 4.1. Relevant fluid dynamic properties (at 60L/min) of standard entrainment tubes used in studies 
compared with previously used and commercially available inhalers. 
 
Specific Resistance (RD) ΔP Power Shear Stress 
SET 
cm H2O0.5 / (L/ min) 
Re  
(N/m2) (Watt) (N/m2) 
A 0.140 18440 6920 6.92 13.14 
C 0.046 11070 747 0.747 2.20 
D 0.021 7720 156 0.156 0.62 
Rotahaler 0.040 N/A    
Inhalator 0.180  N/A       
 
4.3.2. Methods 
4.3.2.1 ELPI Experimental Apparatus 
The experimental apparatus was developed during preliminary studies to overcome two major 
obstacles, (1) operation at 30L/min and (2) pre-separation of large agglomerates (of no therapeutic 
importance). (1) The ELPI operates at 30L/min, but DPIs are typically tested at 60L/min airflow rates 
which more closely approximates the inspiratory air flowrate; (2) unlike the ACI (ThermoAnderson, 
Smyrna, GA), the ELPI does not have a pre-separator capable of removing large quantities of coarse 
material. However, initial trials made clear that failure to remove carrier particles and agglomerates 
from the aerosol prior to introduction into the ELPI could result in flooding the top stages after a 
single inhaler actuation. The setup that was devised to address these issues is shown in Figure 4.4. An 
SET is connected to the standard USP induction throat, which is connected to the ACI pre-separator 
(loaded with 15mL water or methanol) (cut-off size of 8.6m at 60L/min). A custom-manufactured 
aluminum connector from the pre-separator split the 60L/min stream in two equal streams; 40cm 
TygonTM tubing (R3603) was used to connect the two outlets with ELPI and ACI, each employing a 
vacuum pump operating at 30L/min. Tygon tubing is commonly used in aerosol research because, 
unlike other materials, Tygon has negligible electrostatic effects.19 Deposition of drug in different 
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parts of the experimental apparatus was determined in preliminary studies; deposition in the custom-
made part and tubing accounted for <5% of deposition in the ELPI and ACI. To prevent particle 
bounce ACI collection plates were coated with silicone oil. Coated aluminum foils were used with the 
ELPI stages. The apparatus was leak tested prior to each experiment. In accordance with 
manufacturer recommendations, the ELPI was switched on at least 1 hour prior to measurement. Inlet 
air was not filtered and baseline measurements of charge were collected.  
 
 
Figure 4.4. Experimental set-up, adapted from Telko et al. 2007.  
 
4.3.2.2 Actuations 
Formulations were weighed on an analytical balance, dispensed onto weighing paper and placed 
in front of the entrainment tube for actuation into the experimental apparatus. Preliminary studies 
indicated that three actuations were required to ensure sufficient material deposited on all ELPI 
stages. To determine the charge contribution of excipient only, for each experimental setting the three 
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formulation actuations were preceded by three actuations of excipient only. In sequence, for each 
setting, the apparatus was turned on, the electrometer channels were zeroed, and once the signal 
stabilized, the actuations proceeded in the order: placebo; active formulation; placebo; active 
formulation; placebo; and active formulation. All active and placebo formulations were weighed out 
prior to the experiment and approximately 10 seconds were allowed between actuations. Electrical 
charge across twelve stages during actuations was recorded using the ELPI V acquisition software. 
 
4.3.2.3 Analysis of Drug Deposition on ELPI Stages 
After each set of three actuations for a given formulation the ELPI was turned off and the 
apparatus was disassembled and washed. The coated aluminum foils were removed from the ELPI 
stages and washed with 3mL water (albuterol formulations) or 3mL methanol (budesonide 
formulations). CP formulations (limited aqueous and methanol solubility) were centrifuged to 
separate any undissolved excipient. UV absorbance of the supernatant solutions was assessed at a 
wavelength of 224.5nm (albuterol) or 244nm (budesonide) using a Shimadzu 160U 
spectrophotometer. The excipients have negligible absorbance at this wavelength. 
 
4.3.2.4 Environmental conditions 
The extent to which triboelectric charging occurs depends, in part, on the environmental 
conditions. Triboelectrification is only observed at relative humidities of less than 65%.20 Hence, 
conditions must be monitored closely. The experiments were performed in the climate-controlled 
laboratory over the course of several months; the conditions during blending, storage, and actuation 
were constant at a temperature of 23 ± 0.5oC and a relative humidity of 35 ± 5%. 
 
4.3.2.5 Environmental Effects Study 
When a patient actuates an inhaler and the drug particles enter the airways, they are entering a 
high humidity (100% RH) environment. High RH is known to inhibit triboelectrification. However, it 
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is unclear if the environmental conditions in the airways, to which drug particles are briefly exposed 
can also dissipate the particles’ charges. This was determined using a modified apparatus which is 
similar to Figure 4.4 with an ultrasonic humidifier (Vicks V-5100, Procter & Gamble, Cincinnati, 
OH) generating water vapor immediately next to the SET inlet, so that humid air instead of ambient 
air is drawn into the apparatus. 
 
4.3.2.6 Surface Effects Study 
Triboelectrification is a surface effect; different surfaces interact with materials and result in 
specific charging behavior. It is important to understand the choice of surface from which the 
formulation is actuated. Two formulations were actuated into the experimental apparatus from a 
series of different surfaces, including weighing paper, PE weighing dish, aluminum weighing dish, a 
gelatin capsule, carageenan capsule. Only the ELPI charge deposition data was recorded for these and 
was subsequently compared.  
 
4.3.2.7 Storage 
Raw materials were stored in double-lined PE bags and PE containers. Once the excipients were 
sieved, they were stored in 60mL Wheaton glass bottles with plastic snap caps. After blending 
formulations were stored in 20mL Wheaton glass vials with PE-lined screw caps. Since ambient 
conditions in the laboratory were well controlled, no specific storage conditions were used. For 
consistency, drug/excipient blends were stored no longer than one week between manufacture and 
initial actuation. 
 
4.3.2.8 Data Analysis 
Charge data were collected by the ELPI data acquisition software, ELPIVI 4.0 (Dekati, Tampere, 
Finland). Raw data were transferred to, and analyzed using Excel software (Microsoft, Seattle, WA). 
Each actuation was isolated and charge was integrated over the time the actuation had occurred. Since 
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there were three actuations of active formulation for each experiment, the charges were averaged and 
standard deviations determined. Drug deposition was determined from chemical assay of  the ELPI 
stages and plotted in Excel.  
The set of 63 experiments provides a large dataset. However, the data represents a custom design; 
containing elements of factorial and central composite design. Data were transferred to statistical 
software SPSS 16.0 for Windows (SPSS Inc., Chicago, IL) and analyzed using the general linear 
model multivariate analysis feature. The response elements examined included d25, d50, d75, fine 
particle fraction, as well as total charge magnitude and polarity (summed across all stages), absolute 
magnitude of the charges recovered, and charges recovered on stages 1-3, 4-6, 7-9, 10-12. Another 
response variable tested was charge/fine particle mass. Assuming the particles were perfect spheres of 
a uniform size at the midpoint between two stages, the average particle charge was determined and 
adapted as a response variable. All of the response variables were examined with respect to each of 
the formulation factors in a series of statistical tests.  
 
4.4. Results and Discussion 
4.4.1. Reproducibility of ELPI Experiments 
Preliminary experiments had shown good reproducibility of charge distribution profiles for a 
given formulation performed at constant conditions.21 Using the same formulation/ capsule/ inhaler 
combination gave consistent charge distributions, which differed from those of other formulation/ 
capsule/ inhaler combinations. This consistency was also observed in the current trials, as is 
highlighted in Figure 4.5. 20mg of 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, was 
actuated from SET A three times (separated by actuations of placebo formulation); the procedure was 
repeated 9 days later. As is evident in Figure 4.5, the actuations were consistent within a given day, 
and consistent over the course of several days. There were some differences in magnitude, by as 
much as 20%, but some portion of this is a result of drug concentration variations in the blend. 
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Moreover, even as differences in magnitude are observed, polarity and rank/order of the stages was 
retained in all trials. 
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Figure 4.5. Six actuations of 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, 20mg actuated 
from SET A. The first three were performed on one day separated only by actuations of excipient, the 
next three performed 9 days later, also separated by excipient actuations (excipient actuations have 
been removed from this graph). Double line indicates temporal discontinuity. In each case, deposition 
on stages is complete in about 6 seconds. While there is some variability with regards to magnitude, 
the overall rank/order and polarity is highly preserved in each trial.  
 
In some instances, the variability was in excess of the approximately 20% shown in Figure 4.5. 
However, even where the variability was greater, the charge deposition patterns remained discernable 
for given formulations actuated at specific conditions (compared to other formulations and/or 
conditions).  
The two experiments shown in Figure 4.5 were separated by nine days of storage. However, since 
the current experimental plan was completed over the course of months rather than days the 
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consistency was evaluated in more detail, including an assessment of the reproducibility of charge 
and particle size distribution after storage. Storage times of less than two weeks generally resulted in 
highly reproducible charge and particle size distributions with variability similar in magnitude to 
intra-experimental variability observed when experiments were performed in sequence (on the same 
day). Figure 4.6 represents a case, where a formulation was retested five days after the original 
sample was examined; this formulation (0.5% albuterol in 45-75μm ML80 lactose) showed very good 
reproducibility in both mass deposited (FPM and FPF) and charge distributions.  
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Figure 4.6. Formulation (0.5% albuterol in 45-75μm ML80 lactose, 40mg) actuated from SET A (three times) on 
different days, separated by 5 days of storage. The differences in deposition (actual quantities shown) are minimal. 
Differences in charge distribution mirror the differences in deposition, and are within a standard deviation from 
one another. 
 
However, variability in mass and charge deposition profiles increased after more than two weeks 
of storage (at ambient but constant conditions). In many cases, the differences observed after storage 
were so dramatic that the replicates were no longer representative of the original system. In other 
words, many of the formulations were subject to significant storage effects. Surprisingly, in most 
cases, the dispersion of drug had improved upon storage. A complete discussion of the storage effects 
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is given in Appendix D. As a result of these effects, all replicates subject to storage effects, i.e. those 
with storage times exceeding two weeks, were excluded from the experimental analysis. 
 
4.4.2. Remanufactured Product Variability 
Another aspect of variability that requires elucidation is the variability associated with the 
manufacture. While the same process of manufacture is applied to all formulations, the major 
processing step of blending is by its nature a random process. If the variability associated with the 
product manufacture results in significant differences in formulation behavior, variability from other 
factors would be difficult to discern. In light of the observations made with respect to storage, 
understanding the variability of the manufacture process is essential.  
Figure 4.7 shows the mass and charge deposition profiles for a formulation (0.5% albuterol, 
ML58 lactose, 75-106μm sieve fraction) manufactured twice. Both mass and charge deposition 
profiles are almost superimposable, indicating a high level of reproducibility. 
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Figure 4.7. Remade formulation (0.5% albuterol in 75-106μm ML58 lactose) actuated from SET A (three times). 
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Figure 4.8 compares two batches of product, one actuated soon after manufacture (blue) as well 
as after 36 days of storage (red) and a remanufactured formulation actuated two days after 
manufacture. Clearly, the remanufactured formulation is more similar to the original formulation than 
to the formulation that has undergone storage. This suggests that the variability in the process is not 
significant, and that the storage effects are real.  
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Figure 4.8. Same formulation (0.5% budesonide in 45-75μm SV425 lactose) actuated from SET A (three times) on 
different days, separated by 36 days of storage. Also shown remade formulation, actuated day after it was made. 
The remade formulation has FPF similar to the old formulation without storage, while storage results in higher 
deposition. Charge deposition profiles are similar for all. 
 
4.4.3. Surface Effects 
Two formulations were actuated into the experimental apparatus from a series of different 
surfaces, including weighing paper, a polyethylene (PE) weighing dish, a gelatin capsule, and a 
carageenan capsule. Figure 4.9 shows the results of one of these experiments, charge depositions over 
time for a formulation of 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, 20mg actuated from 
SET A; the formulation had been dispensed onto each of the different surfaces and  had been kept 
there for at least 30 minutes prior to actuation. The choice of surface did not appear to have a 
significant effect on the charging properties of the FPF within the ELPI in either case; the charging 
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recorded on the individual stages follows the same pattern in each case, and the differences in overall 
magnitude are in the order of inter-actuation variability. 
 
Figure 4.9. 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, 20mg actuated from SET A, off different 
surfaces. The eight actuations were performed in a row with intermittent placebo actuations. There are minor 
magnitude differences but the charge deposition profiles are largely the same. This supports the hypothesis 
that the charges observed are the result of triboelectrification during actuation, when particles have undergone 
charge transfer and those charges are exposed.  
  
The results in Figure 4.9 are important because they support the hypothesis that the electrical charges 
are the result of tribocharging, i.e. charge transfers between the particles of the formulation. These 
charges are the result of electron transfer during particle contact which occur during and after the 
blending process; the charges are exposed when the particles are separated from one another during 
the actuation process. This point in particular can be deduced from the fourth actuation shown, in 
which the blend was actuated from weigh paper after it had been treated with Zerostat® antistatic gun, 
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which removes static charges by releasing a stream of bipolar ions. This treatment ensures that the 
system as a whole is uncharged. The charges, shown in Figure 4.9 were integrated over time and 
summed across the stages; the results of this are shown in Table 4.2. Differences in charge (actual and 
absolute magnitude) are within the normal variability. 
 
Table 4.2. Effect of last surface of contact on total charge (sum across all stages, and sum of absolute 
magnitudes across all stages) for 1% albuterol in ML58 lactose, 45-75 μm sieve fraction formulation, 20mg 
actuated from SET A, shown in Figure 4.9. Range is given, except in last row which gives actuation average ± 
standard deviation. 
 
Last Surface of Contact 
Sum of 
Charges (pC) 
Charge Magnitude 
(pC) 
Paper  (n=1) 559 663 
Carageenan Capsule 646 – 714 758 – 813  
PE Dish 781 – 821  886 – 908  
Paper w/ Zerostat  (n=1) 806 922 
Gelatin Capsule 829 – 860  934 – 941  
AVERAGE 752 ± 104 853 ± 100 
 
As shown in Figure 4.10 and Table 4.3, another formulation containing budesonide in sieved lactose 
displayed the same behavior, i.e. charge distribution was independent of the surface of last contact, 
even as the actual charging was very different from the previous formulation. In this case, highly 
negative charges were recorded for all actuations, suggesting that the milled budesonide had a higher 
pseudo work function than the sieved lactose leaving its particles with an excess of electrons after 
separation from the sieved lactose. 
 
 119
 
Figure 4.10. 0.5% budesonide in SV425 lactose, 45-75 μm sieve fraction, 20mg actuated from SET A, off 
different surfaces. The eight actuations were performed in a row with intermittent placebo actuations. There 
are minor magnitude differences but the charge deposition profiles are largely the same. This supports the 
hypothesis that the charges observed are the result of triboelectrification during actuation, when particles 
have undergone charge transfer and those charges are exposed.  
 
 
Table 4.3. Effect of last surface of contact on total charge (sum across all stages, and sum of absolute 
magnitudes across all stages) for 0.5% budesonide in SV425 lactose, 45-75μm sieve fraction formulation, 40mg 
actuated from SET A. Range is given, except in last row which gives actuation average ± standard deviation. 
 
Last Surface of Contact 
Sum of 
Charges (pC) 
Charge Magnitude 
(pC) 
Paper  (n=1) -795 834 
Carageenan Capsule -1080   – -1086  1125 – 1136  
PE Dish -1209  –  -1426  1254 – 1447  
Paper w/ Zerostat (n=1) -1077 1129 
Gelatin Capsule -822  –  -959  873 – 1003  
AVERAGE -1057 ± 205 1100 ± 199 
 
4.4.4. Environmental Effects 
When drug particles enter the airways during inhaler acutuation they are entering a high humidity 
environment. Although high RH can inhibit triboelectrification, it is unclear if brief exposure is 
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sufficient to dissipate particle charges. To determine the effect of high RH during aerosol transport, 
an ultrasonic humidifier was operated adjacent to the SET inlet, so that humid air was drawn into the 
apparatus. Actuations of 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, 20mg actuated from 
SET A (same as Figure 4.9) were performed. The charges recorded on the stages of the ELPI are 
shown in Figure 4.11. The first two peaks show previous experiments performed at ambient humidity 
(35% RH), the next three were performed at high humidity (95% RH). Then the humidifier was 
turned off and another two actuations were performed at ambient humidity. While the high humidity 
greatly increases the noise on the stages, the actuations are essentially unchanged. Charge distribution 
and magnitude are the same as in a low humidity environment. This confirms that charging is a 
relevant phenomenon during clinical DPI use. Whether there is sufficient triboelectrification to affect 
particle trajectory and deposition will be determined in later experiments. 
Figure 4.11. 1% albuterol in ML58 lactose, 45-75 μm sieve fraction, 20mg actuated from SET A, actuated at 
low RH, high RH, and then again at low RH. Brief exposure to high RH as might be experienced in a patient’s 
lung does not lead to a dissipation of electrical charges. 
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 4.4.5. Experimental Design Analysis: Effect of Formulation Factors on Fine Particle Mass (FPM) 
and Particle Size Distribution 
As discussed in the introduction (Section 4.1.2), mass depositions for individual actuation were 
not determined in the preliminary studies.9 Instead, a number of initial screens were performed and 
assumptions about deposition applied to the other actuations. This was a valid approach given the 
goal of the study was to assess the overall prevalence of electrostatic charging. However, in the 
absence of accurate deposition data, the effects of the formulation variables on the charging 
characteristics are confounded by presumed differences in mass deposition. In order to understand 
how particle charge is affected by formulation and actuation factors the charge levels need to be 
considered relative to the mass of the deposited aerosol particles. In the current project charge 
distributions were recorded using the ELPI, then the mass deposition on each stage were determined 
by chemical assay. (Since the single depositions were close to the limit of detection on some stages 
mass was assayed for a pooled set of 3 subsequent depositions of the same formulation and averaged.) 
As a result we can discern how the formulation variables affect drug deposition and apply the results 
to the analysis of charging. 
After each actuation experiment, the ELPI was disassembled and the stages assayed. The mass on 
each individual ELPI stage was determined, total deposited mass and FPF were calculated, and 
particle size distributions (PSDs) were generated. These measures are used in conjunction with the 
charging data, but it is also instructive to consider them individually, since they present a rich data set 
of formulation effects on PSD. The PSDs are first discussed qualitatively, then in context of the 
statistical analysis. 
 
4.4.5.1 Qualitative Analysis 
The effects of drug concentration, fluid dynamic conditions, excipient, and excipient sieve 
fraction on particle size were evaluated. While the fine particle mass (FPM) varied for many of these 
variables (as might be expected), only the fluidization conditions (pressure drop or Re) had a visible 
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effect on the particle size distribution of the deposited drug. This is shown in Figure 4.12, in which 
different albuterol in ML80 lactose formulations (0.25%, 0.50%, 1.0%) actuated under different fluid 
dynamic conditions represented by SET A (Re=18440), SET C (Re=11070), and SET D (Re=7720) 
are shown. Table 4.4 gives the corresponding d25, d50, and d75 values. The figure and table show 
clearly that the actuation conditions affect the particle size distribution; more intense actuation 
conditions (SET A, triangles) shift the particle size distribution to lower values by dislodging and 
delivering more fine drug particles (in the 1μm range), which may not separate under less turbulent 
conditions. Mass depositions were higher under the more vigorous conditions which supports this 
conclusion. In turn, the very low pressure drop actuation conditions (SET D, rectangles) shift the 
particle size distribution to a higher size range. The concentration of drug does not appear to have 
any effect on the relative particle size distribution, though higher concentrations resulted in 
correspondingly more drug on the stages of the ELPI (as expected). The effect of sieve fraction or 
the excipient was more difficult to discern and is discussed in the context of the experimental design 
analysis.  
 Table 4.4. Particle size distribution proxies for 
albuterol in 45-75μm ML80 lactose formulations, 
shown in Figure 4.12. 
 Formulation & 
Actuation 
Conditions 
d25 
(m) 
d50 
(m) 
d75 
(m) 
 
0.25%A, SET A 0.86 1.32 1.88 
 
0.50%A, SET A 0.94 1.37 1.92 
 
0.50%A, SET C 0.98 1.49 2.13 
 
0.50%A, SET D 1.24 1.83 2.47 0.0
0.1
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0.4
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0.25% A, 40mg, SET A
0.50% A, 40mg, SET A
0.50% A, 40mg, SET C
0.50% A, 40mg, SET D
1.00% A, 40mg, SET A
1.00% A, 40mg, SET C
 
 
1.0%A, SET A 0.98 1.39 1.94 
1.0%A, SET C 0.97 1.52 2.20 
    
    
Figure 4.12. Effects of drug concentration and 
actuation conditions (high pressure drop (SET A), 
low pressure drop (SET C) and very low pressure 
drop (SET D)) on the particle size distribution of 
albuterol in 45-75μm ML80 lactose formulations.  
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4.4.5.2 Statistical Analysis: General 
For the experimental design analysis, the PSD data were reduced to a smaller number of 
descriptive parameters consisting of d25, d50, d75, (determined by linear interpolation of the particle 
size distribution data) and FPF which were evaluated by multivariate statistics. 
 An initial evaluation of the entire data set showed very strong codependency of the results on the 
identity of the drugs. This is expected, since, as shown in the preliminary analysis (Chapter 2), the 
drugs have different primary particle sizes. As a result, all significant effects contained the drug as a 
cofactor. Moreover, since the two drugs differed in their behavior and response to formulation 
variables the statistical software (SPSS) could not find a converging model that accounted for all 
effects on both drugs simultaneously. To circumvent this problem, the datasets for the two drugs were 
analyzed separately. The results of this analysis are summarized in Table 4.5 (budesonide) and Table 
4.6 (albuterol). 
Table 4.5 summarizes the significant effects of the formulation variables on the particle size and 
mass distribution of budesonide actuated from different formulations. Since the table follows the 
same format and gives the same kind of information as the subsequent results tables, a short 
description of the procedure is in order:  
The first two rows in the table describe the data in terms of the mean (± standard deviation) and 
the range for the entire data set. Subsequent rows show the results of the statistical analysis. The 
statistical analysis was conducted in SPSS using the general linear model (GLM) multivariate 
procedure. The procedure provides regression analysis and analysis of variance (ANOVA) for the 
dependent variables (i.e. d25, d50, d75, and FPF) by factor variables (i.e. excipient, drug conc., 
fluidization conditions). The effects of factor variables on the means of dependent variable groupings 
were tested, and the interactions between factors and the effects of individual factors were probed. 
Only the effects of individual factors are reported in Table 4.5 and subsequent result tables, because 
these are general and apply to different systems. The tables also provide effect size estimates based on 
the unbalanced full factorial model (unbalanced because, as described above, certain factor 
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combinations were not tested). The effect size describes the proportion of total variability attributable 
to a given factor. The confidence interval for each test is also given; the significance level was set to 
α=0.05, and only effects with lower p-values are reported. For each category of factor (underlined) 
the cells to the right indicate weather the effect on the given response was significant. Where the 
effects are statistically significant, the p-value is indicated and the rows below give the individual 
factor contribution (parameter) estimates; again, where these contributions are significantly different 
from the other variables of the category, the p-value is indicated. One of the variables serves as a 
basis of comparison in each case and is assigned a contribution of 0; the effects of the other variables 
are given relative to it. The basis of comparison is SV94 lactose, 45-75m sieve fraction, 1.0% drug 
concentration, and the highly turbulent actuation conditions (SET A, Re=18440). The model intercept 
is also given in the tables. This intercept provides the default response value in absence of the factor 
effects. Thus, to highlight an example from Table 4.5, the d25 of budesonide after release from a 
0.25% drug in ML80 formulation, actuated at Re=18440 is expected to be 0.96-0.16+0.28+0.00= 
1.08μm; this result is consistent with the raw data: the actual recorded value from experiments is 
1.08±0.03μm. 
 
4.4.5.3 Statistical Analysis: Budesonide 
Table 4.5 shows that the particle size distributions and FPFs have wide ranges. Yet neither 
excipients nor drug concentrations of the formulation have a significant effect on the particle size 
distribution of the deposited drug. Only d25 is affected by the excipient, suggesting that the particle 
size distribution is most sensitive to formulation and actuation conditions in the smallest particle size 
range. Use of ML80 lactose and CP excipients results in the most dramatic shift in the d25 to a higher 
particle size (compared to SV94 lactose), suggesting relatively less separation of smaller drug 
particles. When considering the FPF of CP, which is significantly higher than that of the other 
excipients, one can see that the shift in the particle size is likely due to an overall increase in the 
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release of drug, most of which is larger in size. Varying the drug concentration, on the other hand, 
does not have a statistically significant effect on the d25 of budesonide.  
 
 
Table 4.5. Effect of excipient (all 45-75μm sieve cut), drug concentration and fluidization conditions on the 
PSD (using d25, d50, d75 as surrogate markers) and FPF of deposited budesonide. In the model, created by SPSS 
software, the default value is given by the model intercept and the contribution for each factor is given in each 
column. Thus, for example, the d25 of budesonide from a 0.25% drug in ML80 actuated at Re=18440 would be 
expected to be 0.96-0.16+0.28+0.00= 1.08μm (actual recorded value from experiments is 1.08±0.03μm (n=2)). 
 
Factor    /    Response d25 (μm) d50 (μm) d75 (μm) FPF 
Data Average ±  1.38 ± 0.28 1.99 ± 0.22 2.73 ± 0.31 0.056 ± 0.061 
Data Range 1.04 – 2.05 1.75 – 2.56 3.34 – 2.39 0.002 – 0.219 
Model Intercept 0.96 1.83 2.59 0.093 
Excipient Significant (p=0.034) Not Sign. Not Sign. 
Significant 
(p=0.001) 
     Lactose, SV94 0   0 
     Lactose, SV425 + 0.19   - 0.042 
     Lactose, ML58 + 0.22   - 0.056 
     Lactose, ML80 + 0.28 (p=0.028)   - 0.054 
     Glucose             + 0.11   + 0.037 
     Calcium Phosphate + 0.38 (p=0.005)   
+ 0.127 
(p=0.001) 
     
Drug Concentration Not Sign. Not Sign. Not Sign. Not Sign. 
     
Fluidization Conditions Significant (p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.019) Not Sign. 
     Re = 18440 0 0 0  
     Re = 11070 + 0.25 + 0.29  + 0.55  
     Re = 7720 + 0.73 + 0.70 + 0.89   
 
As could be gauged from Figure 4.12 and Table 4.4, the fluidization conditions shift the entire 
particle size distribution; Table 4.5 confirms that d25, d50, and d75 of budesonide are all affected. Use 
of less turbulent (less energetic) actuation conditions, represented by a lower Re, results in the release 
of fewer fine particles and consequently an increase of all three particle size indicators to higher 
values. Remarkably, the actuation conditions did not have statistically significant effects on the FPF 
of budesonide, though this is in part the result of relatively few data points and high data variability 
for budesonide formulations. Changing the excipient appears to be a more reliable way of increasing 
the FPF than increasing the pressure drop during DPI actuation. The effects of excipient size fraction 
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on budesonide delivery were not considered since only 45-75m sieve fractions were used for all 
excipients. (They were, however, examined for albuterol formulations.) The d50 value observed in the 
experiments (~2m) was in good agreement with the primary particle size measured by light 
scattering, described in Chapter 2. 
 
4.4.5.4 Statistical Analysis: Albuterol 
The same analysis of particle size and FPF effects was conducted for albuterol; the results are 
shown in Table 4.6. As explained in Section 4.2.2 more experiments in the experimental design 
involved albuterol formulations, and excipient particle size was varied as well; hence the additional 
rows in the results table and more effects. Varying the excipient, has a significant effect on each of 
the response variables, the entire particle size distribution as well as the FPF. For d25 and FPF, the 
observed trends are largely in agreement with those observed for budesonide. Again, some of the 
most significant increases in particle size and FPF are observed for CP, indicating more efficient 
release of drug compared to the other excipients. Glucose provides another interesting result; the 
entire particle size distribution is shifted to higher particle sizes, while the FPF registers a decrease. 
This suggests that separation of fine particulate drug is limited, which supports prior suggestions that 
the small particles are most strongly affected by formulation changes. While the size fraction of the 
excipient does have statistically significant and consistent effects, the effects on the particle size are 
relatively minor. Use of the intermediate excipient sieve fraction (75-106m) appears to result in 
higher FPF in most cases. The concentration of drug has a significant effect on the FPF, with the 1% 
drug concentration resulting in significantly higher FPF than the 0.5% concentration. (The 
comparison to 0.25% is less significant, perhaps once more due to the limited number of experiments 
using 0.25% drug concentration.) This result supports the active site hypothesis, whereby the drug 
first adheres to the most energetic ("active") sites of the carrier particles, and then (after active site 
saturation) distributes around the less energetic sites of the carrier particle. Thus, at higher drug 
concentrations active sites have been saturated and a larger fraction of drug is in contact at less 
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energetic carrier surface sites, from which it can detach more easily. In contrast to budesonide, for 
which particle size and FPF were barely affected, albuterol formulations are significantly affected by 
the fluidization conditions. Using more turbulent actuation conditions (higher Re) gives reliably 
smaller particle size and higher FPF. This result suggests once more that primarily the separation of 
small particles is enhanced during actuation.  
 
Table 4.6. Effect of excipient, excipient sieve fraction, drug concentration, and fluidization conditions on the 
PSD (using d25, d50, d75 as surrogate markers) and FPF of deposited albuterol. In the model, created using SPSS 
software, the default value is given by the model intercept and the contribution for each factor is given in each 
column.  
 
Factor    /    Response d25 (um) d50 (um) d75 (um) FPF 
Data Average ±  0.94 ± 0.18 1.47 ± 0.16 2.10 ± 0.25 0.101 ± 0.051 
Data Range 0.64 – 1.24 1.29 – 1.97 1.80 – 3.12 0.015 – 0.194 
Model Intercept 1.05 1.32 1.80 0.193 
Excipient Significant (p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.004) 
     Lactose, SV94 0 0 0 0 
     Lactose, SV425 + 0.30 + 0.29 (p=0.003) - 0.08 - 0.036 
     Lactose, ML58 + 0.01 + 0.03 + 0.05 + 0.134 (p=0.014) 
     Lactose, ML80 - 0.11 + 0.05 + 0.10 - 0.019 
     Glucose             + 0.17  +0.31 (p=0.033) 
+ 0.58 
(p=0.006) - 0.088 
     Calcium Phosphate + 0.49 (p=0.054) 
+ 0.46 
(p=0.001) 
+ 0.65 
(p=0.001) + 0.051 
     
Excipient Size Fraction Not Sign. Significant (p=0.015) 
Significant 
(p=0.001) 
Significant 
(p=0.006) 
         45-75 m  0 0 0 
       75-106 m  - 0.02 - 0.04 + 0.090 (p=0.005) 
     106-150 m  + 0.04 + 0.09 + 0.025 
     
Drug Concentration Not Sign. Not Sign. Not Sign. Significant (p=0.003) 
     1.00%    0 
     0.50%    - 0.149 (p=0.001) 
     0.25%    - 0.041 
     
Fluidization Conditions Not Sign. Significant (p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.015) 
     Re = 18440  0 0 0 
     Re = 11070  + 0.18 (p=0.065) 
+ 0.35 
(p=0.013) - 0.041 
     Re = 7720    + 0.46 (p=0.000) 
+ 0.57 
(p=0.000) 
- 0.109 
(p=0.000) 
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4.4.6. Experimental Design Analysis: Effect of Formulation Factors on Electrostatic Charging of 
Drug 
4.4.6.1 Qualitative Analysis 
As in the previous case, it is instructive to first look at the effects on drug charging qualitatively. 
Figure 4.13 (a) though (f) show the effects of varying the excipient on the mass deposition and the 
charge deposition of 0.5% albuterol in 40mg of 45-75um sieve fraction excipient formulations, 
actuated from SET A (at high sheer conditions). Figure 4.14 (a) though (f) show the same effects for 
budesonide formulations. The mass depositions of drug are shown in yellow diamonds (left axis), and 
the charge distribution (right axis) in shown in red squares. 
From Figures 4.13 (a) through (f) it is evident that the FPM and the deposited charges vary 
significantly from excipient to excipient. While the charge deposition is largely positive for albuterol 
drug actuated from milled lactose (a and b) and glucose (e), sieved lactose formulations (Figures c 
and d) and the CP formulation (f) show bipolar charging. Clearly the mass depositions vary, but the 
overall shapes of the particle size distributions are similar (as might be expected, since it is the same 
drug). Yet the charge distribution is unique for each formulation. This clearly shows that the 
formulation has a profound effect on the charging behavior of the drug. Figure 4.14 makes the same 
point for formulations containing budesonide. The conditions are the same as in Figure 4.13, i.e. 0.5% 
budesonide in a 45-75m fraction of the excipient, 40mg actuated from SET A. Note that in this case, 
the charge is mostly negative, with some bipolar charging observed for the formulation containing 
CP. Milled lactose formulations also show slight positive peaks in the 0.5m range, which, however, 
are likely due to the deposition of some residual excipient particles in that size range (actuations of 
excipient only are shown in blue triangles). Unlike albuterol, the charge distributions of the different 
budesonide formulations are much more similar to one another, suggesting that the formulation has a 
smaller impact.  
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Figure 4.13. Effect of formulation excipient on FPM and charge distribution of albuterol. Mass depositions of 
drug (g, yellow diamonds, axis on left), charge distribution of formulation (fC, red rectangles, n=3 ± , axis on 
right), and excipient charging (fC, blue triangles, right axis) are shown. Each formulation is 0.5% albuterol in 
45-75m fraction of the excipient, 40mg actuated from SET A. Lines drawn between points for better visibility. 
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(a) 0.5% albuterol in 45-75um sieve fraction ML80 
lactose, 40mg, actuated from SET A. 
(b) 0.5% albuterol in 45-75um sieve fraction ML58 
lactose, 40mg, actuated from SET A. 
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(c) 0.5% albuterol in 45-75um sieve fraction SV425 
lactose, 40mg, actuated from SET A. 
(d) 0.5% albuterol in 45-75um sieve fraction SV94 
lactose, 40mg, actuated from SET A. 
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(e) 0.5% albuterol in 45-75um sieve fraction glucose, 
40mg, actuated from SET A. 
(f) 0.5% albuterol in 45-75um sieve fraction Calcium 
phosphate, 40mg, actuated from SET A. 
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Figure 4.14. Effect of formulation excipient on FPM and charge distribution of budesonide. Mass depositions 
of drug (g, yellow diamonds, left axis), charge distribution of formulation (fC, red rectangles, n=3 ± , axis on 
right), and excipient charging (fC, blue triangles, right axis) are shown. Each formulation is 0.5% albuterol in 
45-75m fraction of the excipient, 40mg actuated from SET A. Lines drawn between points for better visibility. 
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(a) 0.5% budesonide in 45-75um sieve fraction ML80 
lactose, 40mg, actuated from SET A. 
(b) 0.5% budesonide in 45-75um sieve fraction ML58 
lactose, 40mg, actuated from SET A. 
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(c) 0.5% budesonide in 45-75um sieve fraction SV425 
lactose, 40mg, actuated from SET A. 
(d) 0.5% budesonide in 45-75um sieve fraction SV94 
lactose, 40mg, actuated from SET A. 
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(e) 0.5% budesonide in 45-75um sieve fraction glucose, 
40mg, actuated from SET A. 
(f) 0.5% budesonide in 45-75um sieve fraction Calcium 
phosphate, 40mg, actuated from SET A. 
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4.4.6.2 Charging Differences between Polydisperse Particles  
One striking feature observed throughout Figures 4.13 and 4.14 is that different drug particle size 
fractions show differences in charging behavior. The charging behavior does not follow the particle 
size distribution, and cannot be explained by mass depositions on the given stages. For instance, when 
delivered from SV425 lactose (Figure 4.13(c)), albuterol particles smaller than ~0.5m charge 
positive, particles between 0.5 and 1.0m charge negative, whereas particles above 1m charge 
positive again. Based on the small size of the error bars (showing standard deviation of n=3 
actuations), this charging pattern is quite reproducible. The effect is not related to the deposition of 
fine excipient particles either, which is minimal as shown by the blue graphs in the figures. Clearly, 
different drug size fractions have different charging properties.  
The phenomenon of charging between particles within a polydisperse mixture of a material 
having the same chemical composition (and thus presumably the same effective work function) has 
been observed in other natural and industrial settings.22-24 In polydisperse mixtures with many surface 
contacts, it was found that smaller particles typically acquire an excess of negative charge while the 
larger particles tend to charge more positive.23-25 The phenomenon has recently been explained using 
a largely statistical argument in conjunction with particle dynamics simulations;26 it was postulated 
that high energy electrons are initially uniformly distributed, and during a mixing process concentrate 
on the surface of the smaller particle fraction, leaving the smaller particles with an excess of electrons 
relative to larger particles in the mixture.  
However, this explanation does not adequately describe the DPI system, where the larger drug 
particles are not necessarily more positively charged. Moreover, in the DPI formulation, the drug 
particles are primarily in contact with the excipient. Both drug and excipient are somewhat disperse 
within some defined particle size ranges (in the figures it is 0.1-8m for the drug, and ~45-75m for 
the excipient particles). The bimodal charging phenomena observed in this study are more 
complicated and no adequate explanation can be offered. However, given the small drug particle size 
and the low concentration, the drug particles cannot be controlled directly. Instead, the formulation 
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components and variables offer the better opportunity for drug particle control so we now turn to the 
statistical analysis of the contributions of the formulation variables to drug triboelectrification. 
 
4.4.6.3 Statistical Analysis: General 
As was the case for the particle size and mass depositon data, the charge distribution data 
(consisting of charge distribution data for each ELPI stage over time) were consolidated into a smaller 
number of descriptive parameters and analyzed using SPSS. As before, the general linear model 
multivariate procedure was applied. The data in the results tables, Tables 4.7 (budesonide) and 4.8 
(albuterol) are organized as previously discussed as well. As in the previous results tables, the average 
and the data range are shown in the first two rows. Note that the data average is just the simple, non-
weighted average of all measurements of a given response. This is important to remember because the 
statistical design is unbalanced, that is more experiments were conducted around a central set of 
conditions (e.g. milled lactose excipient) than for the other formulations and conditions; this explains 
part of the variability.  
It is clear that for both budesonide and albuterol formulations the data variability is very large. 
Some of this variability is due to the natural variability of the observed phenomena, i.e, the random 
element in charging phenomena. However, it is important to recognize that some of the extreme data 
points may be subject to experimental error. Nonetheless, to prevent the introduction of bias into the 
analysis, no data points were removed from the analysis. Since the dataset is extensive, the analysis 
should not be overwhelmed by the influence of outliers.  
Two important response variables were the total charge and the dominant polarity. However, to 
understand the strength of the charging phenomena it is important to determine charge effects relative 
to the quantity of drug that is delivered. Charge deposition was recorded using the ELPI and 
deposition of drug was determined from chemical assay of the ELPI stages. Having this data, there 
are a number of different ways in which the two measures could be correlated. Several different 
response factors were evaluated in this analysis. Each response variable correlates charge to quantity 
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of drug in a different way using a different set of assumptions; as discussed below the response 
variables used are normalized for mass (sum of charge per mass, average per particle charge), or 
normalized for surface area (charges per surface area). The different response factors are described in 
detail: 
(1) Polarity of Charge is determined by summing all the charges recorded for a given deposition 
across all the stages and then, depending on the polarity of the charge, assigned a -1 or a +1. This 
response variable is very simple and requires no assumptions. However, since the value can only 
be either +1 or -1, the response is nominal and thus not scalable.  
(2) The total of absolute charge (Sum |Q|), given in units of nC, is simply the total of the absolute 
values of charge recorded across the different ELPI stages. This response does not take into 
account the quantity of material delivered. It is nevertheless considered as a first step, since the 
charging phenomena could also turn out to be a property of the actuation process, relatively 
independent of mass. 
(3) Absolute charge per mass (Sum |Q| / m), given in units of C/g, is determined by summing all the 
absolute values of the charges recorded across all the ELPI stages and then dividing by the total 
mass that was recovered from all the stages. The calculation makes no assumptions, but may 
oversimplify and skew the charging response, which depends more on surface area than mass. 
(4) Charges/Area, given in elementary charges (1 e- = 1.6 x 10-19C) per m2 is the sum of charges 
divided by the surface area of the deposited drug particles. This response variable assumes that 
the deposition of drug on each stage consists of spheres with particle size exactly at the midpoint 
between the cutoff sizes of the corresponding and the previous stage. Clearly, this is an 
oversimplification; the drug particles are not uniform spheres, but are prismatic in shape and 
present a distribution of sizes. The assumption of sphericity underestimates the true surface area, 
which is likely to be a factor larger; thus, the true charges / area measures are likely to be smaller. 
But this inaccuracy should not affect the outcome of the analysis, since it applies the simplifying 
assumption to all size fractions for each drug. The two drugs are not analyzed jointly, so 
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differences in particle shape should not bias the outcome of the statistical analysis either. Since 
charging is a surface effect, differences in the magnitude of this measure are probably the most 
physically meaningful indications of charging strength. 
(5) Average charges per particle (stages 7-10) is the estimated per-particle charge (in elementary 
charges) for drug deposited on stages 7-10, which includes particles from 0.655m (cutoff size of 
stage 7) to 4.09m (cutoff size of stage 11). These four stages account for at least 70% (and in 
most cases over 85%) of total drug deposited inside the ELPI. Due to the high material 
depositions on these stages there is a high level of confidence associated with the mass 
determinations. Using the material densities (1.3g/cm3 for albuterol, 1.25g/cm3 for budesonide)27 
and basic geometric assumptions (particles are uniform spheres of average size for a given stage) 
the mass depositions on each stage are converted into numbers of particles. The charge collected 
on each stage is divided into elementary charges, which are divided by the number of particles. 
This measure is an oversimplification and is likely a source of some error, though the approach is 
uniform and does not introduce any bias into the statistical analysis. While the charge density 
(charge per area, in (4)) is physically the most important response, the per particle charge is 
probably the most clinically relevant measure. It is, after all, the total charge on a particle that 
determines how the particle experiences the forces of other charges, including image forces of 
neutral surfaces, and how it is affected in its trajectory and deposition. Furthermore, this measure 
is an important intermediate in addressing Hypothesis 4, as will be discussed in more detail in the 
next section.  
While the three normalized response variables (3-5) use different assumptions and correlate data 
in different ways, they follow the same basic trends in most cases. As a result, not all of them need to 
be discussed individually in detail.  
 
4.4.6.4 Statistical Analysis: Budesonide 
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Table 4.7 summarizes the effects of formulation variables on the charging behavior of budesonide 
particles. The drug consistently charged negatively and the polarity was not affected by the identity of 
the excipient. On the other hand, every single other response was significantly affected by the choice 
of excipient, the concentration of the drug, the fluidization conditions and even the dose. The 
effects of drug concentration, fluidization conditions, and dose on the absolute magnitude of the 
charge are expected and are related in part to the larger drug depositions. However, as the mass 
normalized charge measures show, the effects are smaller than might be expected based on mass 
depositions alone. On a per particle basis, the milled lactose batches result in the strongest (negative) 
charging of the drug particles, while glucose and CP result in least charge per particle. The lower 
drug concentrations of 0.25% and 0.50% produce higher particle charges than the higher 1% drug 
concentration formulations. This may be the result of stronger contact charging due to closer drug-
excipient contact in lower concentration drug blends. (The smallest charge contribution of the 0.25% 
formulation does not support this conclusion, though the effect of this variable is variable and lacks 
statistical significance.) The charge contribution associated with the drug concentration is minor 
compared with the effects of excipient or fluidization conditions. Fluidization conditions 
significantly affect the charge. The parameter estimates for this effect are counterintuitive: the 
analysis reveals higher per particle charges for the less intense fluidization conditions (Re=11070 and 
7720) than the more turbulent conditions (Re=18440). A possible explanation is that when fewer 
particles are dispersed, the likelihood of contact and charge backflow in transit is smaller, i.e. it is less 
likely that opposite charges cancel each other. This explanation is supported by the fact that the 
smaller actuation dose also gives rise to more highly charged particles. Additionally, as shown in the 
previous section, the lower Re fluidization conditions result in the release of fewer fine particles 
shifting the distribution to larger particles, which have larger surface areas and can accommodate 
more charges. 
To see if these results hold for albuterol, we turn to the results of the statistical analysis of the 
albuterol formulations. 
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Table 4.7. Formulation variables contributing to the charging of budesonide. Effect of excipient, excipient size 
fraction, drug concentration, fluidization conditions, and dose on the charging behavior of fine particulate 
albuterol. In the model, created using SPSS software, the default value is given by the model intercept and the 
contribution for each factor is given in each column. Also shown is the significance level of the formulation 
variable (from ANOVA), as well as the level of significance for each individual variable level (where p ≤ 0.05). 
 
Factor    /    Response (1) Polarity of Charge 
(2) Sum |Q|  
(nC) 
(3) Sum |Q| / 
m (C/g) 
(4) 
Charges/Area 
(e-/m2) 
(5) Avg charges 
per particle 
(stages 7-10) 
Data Average ±  -1 ± 0 0.73 ± 0.27 64.8 ± 76.4 1333 ± 2003 6112 ± 7930 
Data range -1 0.35 – 1.31 6.9 – 304.1 70 - 8054 363 - 32312 
Model Intercept -1 1.20 -8.8 -294 -296 
Excipient Not Sign. Significant (p=0.008) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.003) 
     Lactose, SV94  0 0 0 0 
     Lactose, SV425   + 0.11 + 23.3 (p=0.006) 
+ 379 
(p=0.005) 
+ 1640 
(p=0.039) 
     Lactose, ML58  + 0.00 + 40.7 (p=0.001) 
+ 759 
(p=0.000) 
+ 3210 
(p=0.005) 
     Lactose, ML80  + 0.11 + 38.6 (p=0.001) 
+ 762 
(p=0.000) 
+ 2690 
(p=0.011) 
     Glucose  - 0.31 (p=0.020) - 9.8 - 104 - 971 
     Calcium Phosphate  + 0.24 (p=0.047) - 7.6 - 76 - 874 
      
Drug Concentration Not Sign. Significant (p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
1.00%  0 0 0 0 
0.50%  - 0.43 (p=0.010) 
+ 25.4 
(p=0.008) 
+ 487 
(p=0.003) 
+ 1690 
(p=0.056) 
0.25%  - 0.90 (p=0.000) + 0.2 - 156 + 773 
      
Fluidization Conditions Not Sign. Significant (p=0.003) 
Significant 
(p=0.006) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
Re = 18440  0 0 0 0 
Re = 11070  - 0.37 (p=0.010) + 10.2 
+ 258 
(p=0.022) 
+ 2040 
(p=0.018) 
Re = 7720  - 0.52 (p=0.004) 
+ 248.8 
(p=0.000) 
+ 7100 
(p=0.000) 
+ 2820 
(p=0.000) 
      
Dose Not Sign. Significant (p=0.003) 
Significant 
(p=0.006) 
Significant 
(p=0.010) 
Significant 
(p=0.041) 
40mg  0 0 0 0 
20mg  - 0.33 (p=0.028) + 2.0 + 38.6 + 158 
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4.4.6.5 Statistical Analysis: Albuterol 
Table 4.8. Formulation variables contributing to the charging of albuterol. Effect of excipient, excipient size 
fraction, drug concentration, fluidization conditions, and dose on the charging behavior of fine particulate 
albuterol. In the model, created using SPSS software, the default value is given by the model intercept and the 
contribution for each factor is given in each column. Also shown is the significance level of the formulation 
variable (from ANOVA), as well as the level of significance for each individual variable level (where p ≤ 0.05). 
 
Factor    /    Response (1) Polarity of Charge 
(2) Sum |Q|  
(nC) 
(3) Sum |Q| / 
m (C/g) 
(4) 
Charges/Area 
(e-/m2) 
(5) Avg charges 
per particle 
(stages 7-10) 
Data Average ±  0.74 ± 0.68 0.77 ± 0.52 6.3 ± 12.9 142 ± 80 542 ± 381 
Data Range -1 – +1 0.89 – 2.12 1.5 – 30.5 16.5 – 395.3 43 - 2092 
Model Intercept 0 0.72 - 6.1 - 49.9 -277 
Excipient Significant (p=0.011) 
Significant 
(p=0.013) 
Significant 
(p=0.001) 
Significant 
(p=0.000) 
Significant 
(p=0.000) 
  Lactose, SV94 -1 0 0 0 0 
   Lactose, SV425 ± 0 + 0.26 + 10.6 (p=0.008) 
+ 127.2 
(p=0.002) + 138 
   Lactose, ML58 + 1 (p=0.000) 
+ 2.10 
(p=0.009) 
+ 16.2 
(p=0.026) 
+ 207.3 
(p=0.005) 
+ 842   
(p=0.01) 
   Lactose, ML80 + 1 (p=0.000) + 0.63 
+ 13.2 
(p=0.002) 
+ 117.1 
(p=0.002) 
+ 597   
(p=0.03) 
   Glucose             + 1 (p=0.000) - 0.08 
+ 16.4 
(p=0.016) 
+ 191.1 
(p=0.005) 
+ 1236 
(p=0.000) 
   Calcium Phosphate + 1 (p=0.000) 
+ 1.47 
(p=0.012) 
+ 19.2 
(p=0.002) 
+ 316.9 
(p=0.000) 
+ 1599 
(p=0.000) 
      
Excipient Size Fraction Not Sign. 
Significant 
(p=0.015) 
Significant 
(p=0.000) 
Significant 
(p=0.001) 
Significant 
(p=0.006) 
         45-75 m  + 0.34 
+ 9.6   
(p=0.018) 
+ 96.4   
(p=0.013) + 216 
       75-106 m  0 0 0 0 
     106-150 m  
- 0.91 
(p=0.028) - 5.2 - 47.2 - 135 
      
Drug Concentration Not Sign. Significant (p=0.007) 
Significant 
(p=0.001) 
Significant 
(p=0.005) 
Significant 
(p=0.002) 
     1.00%  0 0 0 0 
     0.50%  - 0.61 + 13.8 (p=0.014) + 86.9 + 245 
     0.25%  - 0.87 (p=0.035) + 6.1 
+ 72.2  
(p=0.048) + 216 
      
Fluidization Conditions Not Sign. Significant (p=0.002) Not Sign. 
Significant 
(p=0.010) 
Significant 
(p=0.000) 
     Re = 18440  0  0 0 
     Re = 11070  - 0.79  - 3.7 + 267 
     Re = 7720     
 - 0.78 
(p=0.030)   
+ 110.5 
(p=0.003) + 65 
      
Dose (mg) Not Sign. Significant (p=0.004) Significant Not Sign. Not Sign. 
     40  0 0   
     20  - 0.50 + 2.59   
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The effects that the formulation variables have on the charging of albuterol are summarized in 
Table 4.8. With a larger number of trials conducted, the dataset around albuterol is richer (it includes 
an analysis of excipient size fractions as well), and as a result there is more confidence in the 
individual parameter estimates. The excipient clearly impacts the polarity of charge. Whereas 
budesonide always charged negatively, albuterol charged either positive or negative, depending on 
the excipient in the formulation. Formulated with SV94 lactose, albuterol particles were 
predominantly negatively charged. Formulated with the other sieved lactose batch, SV425, albuterol 
particles were either negatively or positively charged, whereas in combination with glucose and CP 
albuterol primarily charged positively. It can be deduced that albuterol has a pseudo work function 
that is somewhere in between that of sieved lactose and glucose. No other variables affected charge 
polarity significantly. However, all formulation variables, i.e. excipient, excipient size fraction, drug 
concentration, and fluidization conditions had effects on absolute and relative charge magnitudes. In 
the case of drug concentration, fluidization conditions, and dose, larger charges were associated 
with increased deposition of drug, that is higher concentration, more turbulent charging, and larger 
dose resulted in higher charge depositions. However, a look at the normalized responses shows that 
increased mass delivery does not fully account for the additional charge. As seen before with 
budesonide, smaller drug concentrations and less turbulent actuation conditions result in higher per 
particle charges. The positive effect of the smaller drug concentration on charge supports the active 
site hypothesis, i.e. that lower drug concentrations result in closer particle contact (possibly at active 
surface sites) and thus stronger contact charging. The lower Re actuation conditions also result in 
higher per particle charges, though the effects are variable and the individual parameter contributions 
lack statistical significance. Nevertheless, this result is in agreement with the results for budesonide. 
As stated previously, one explanation for this is the shift towards larger particle sizes which can 
accommodate larger charges. Another reason for this result is that fewer dispersed particles create 
fewer opportunities for charge neutralization or backflow. Excipient particle size also contributes to 
particle charging. The charge of the delivered drug decreases as the excipient particles increase in 
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size. While the overall contribution of the effect is modest, the effect is nonetheless consistent with a 
surface area effect; as the carrier particles become larger, their specific surface area decreases and the 
drug particles reach a higher degree of surface saturation on the carrier particle surface. The drug 
particles become less charged, because there is less surface area available with which to exchange 
electrons. This explanation may be seen as an extension of the active site hypothesis, provided the 
highly energetic surface sites are also more prone to electron exchange. 
Comparing the charging effect of the excipient reveals an apparent paradox: CP and glucose 
result in the least charged budesonide particles, but they give rise to the most highly charged albuterol 
particles. These observations seem at odds, but are actually consistent with each other when the 
polarities of the charges are considered: in both instances, CP and glucose result in the most positive 
drug charges. This allows CP and glucose to be placed at the very top of the triboelectric series. 
Construction of a triboelectric series for the materials and the ramifications thereof are discussed in 
the next section.  
 
4.4.7. Triboelectric series 
Based on the observed charging behavior we can construct triboelectric series for the excipients 
and drugs. As discussed in Chapter 1, a triboelectric series ranks materials in order of polarity of 
charge after contact charging and separation from another material, in this case contact charging 
between the drug and an excipient. Triboelectric series are constructed for insulators for which work 
functions cannot be measured reliably.  
Based on charges/area data (Sum Q / A), albuterol acquires charge in the following order after 
separation from the given excipients: 
Albuterol:   (most positive) CP > Glucose > ML58 ≈  ML80 > SV425 (±0) > SV94  (negative)  
Note that this order is slightly different from what might be expected based on individual 
contributions in Table 4.8 because the results of the statistical analysis were obtained by treating 
charge magnitude and polarity strictly separated to avoid cancellation of opposite charges recorded on 
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different stages in the summation process. Given these charges on albuterol, and assuming the 
charges resulted in equal but opposite countercharges on the excipient particles, the triboelectric 
series looks as follows: 
(+) SV94 > SV425 ≈ Albuterol > ML80 ≈  ML58 > Glucose > CP (-) 
Similarly, based on charges/area raw data (Sum Q / A), budesonide acquires charges in the following 
order in the given excipients: 
Budesonide:   (least negative) CP > Glucose > SV94 > SV425 > ML58 > ML80 (most negative) 
Based on this charging order, the triboelectric series would look like this: 
(+) ML80 > ML58 > SV425 > SV94 > Glucose > CP > Budesonide (-). 
It is difficult to reconcile these triboelectric series and consolidate them into one. Doing so would 
result in the following triboelectric series: 
(+) ML80 ≈ ML58 ≈ SV425 ≈ SV94 ≈ Albuterol > Glucose > CP > Budesonide (-). 
While CP and glucose consistently seem to result in the most positively (or least negatively) charged 
drug, the lactose excipients behave less predictably; the differences between them are less 
pronounced. This seems reasonable given the lactose batches are the same material and batch-to-
batch differences are expected to be relatively smaller. Another reason for the difficulty in creating a 
consolidated triboelectric series is the fact that the charges associated with budesonide particles are 
about an order of magnitude larger than those associated with albuterol. Differences in excipient size 
fraction were not considered since they are insignificant compared to inter-excipient differences. 
In an attempt to create a consolidated triboelectric series the data were also analyzed using SPSS. 
Using a reduced data set, containing actuations involving both drugs, but only the 45-75um sieve 
fractions of the excipients, and only two of the fluidization conditions, the program converged to a 
model and provided parameter contribution estimates. The results, indicated a high degree of co-
dependency between the factors, resulting in strong secondary effects involving drug-lactose batch 
combinations. Even when the two ML and two SV batches were combined into one ML and SV batch 
each, the codependency persisted. This shows that while different lactose batches can be 
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differentiated from one another using charge deposition studies in the ELPI, their behavior is hard to 
predict a priori when combined with a different drug. This may also indicate simply that the effective 
work function of albuterol is close to that of the lactose batches, resulting in more variable behavior. 
On the other hand, CP and glucose behave in a way consistent with their relative position in the 
triboelectric series. Moreover, the results are largely consistent with the results from Faraday well 
experiments and surface free energy measurements, which suggested budesonide, CP, and glucose 
charged most negatively (Faraday well experiments) and CP and glucose had most electron accepting 
surface characteristics. The agreement among the three measurements is a very important result.  
 
4.4.8. Per Particle Charge Levels  
One of the primary aims of this research project was to determine the role electrostatic charging 
plays in DPI particle interactions. Knowing that it arises from triboelectric charging and that it is 
highly dependent on formulation factors is important, but before this knowledge can be exploited to 
advance the formulation development of DPIs, it is necessary to understand the impact of charging. A 
number of simulation28 and in vivo29 studies have suggested that micron-size particles need to have 
charges in the 100s of elementary charges range to be affected in their trajectory and their deposition 
in the respiratory tract. Using Faraday cage data and some basic geometric assumptions, Byron et al.30 
estimated DPI particles could have charges in the 200e per particle range.  
The results of this study indicate triboelectric charging in the DPI can give rise to significant 
charging with charge levels that are much higher than previously estimated. Surveying the data range 
for budesonide formulations (Table 4.7) and albuterol formulations (Table 4.8), the data  indicate per 
particle charge levels of 542 ± 381 and 6112 ± 7930 elementary charges per particle (unbalanced, 
non-weighted means of entire dataset ± standard deviation) on albuterol and budesonide particles in 
the 0.655m (stage 7) to 4.09m (stage 10) range, respectively. Particles in this size range account 
for the bulk of the drug delivered to the lungs. Figure 4.15 shows the entire charge distribution 
(absolute magnitude) for two representative formulations, 0.5% budesonide in ML80 lactose (45-
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75m sieve fraction) and 0.5% albuterol in ML58 lactose, as well as the upper and lower charge 
limits. The lower limit is the Boltzmann equilibrium charge distribution, which is the charge level 
expected for naturally occurring aerosols; it was calculated using equation 1.7. The upper limit is the 
negative charge limit for solid particles, above which spontaneous emission of electrons from a 
surface is expected; the points in this graph were determined using equation 1.8. The graphs indicate 
very high charges, well into the 1,000s and even 10,000s of elementary charges per particle range. 
These charges, which are by no means the highest charge levels recorded in these experiments, far 
exceed the Boltzmann equilibrium charge distribution. They are clearly the result of an active 
charging process, specifically contact charging in the formulation. Yet, as indicated in Tables 4.7 and 
4.8, the formulation variables have significant effects on the charge distribution and can in fact 
produce much higher particle charge levels.  
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Figure 4.15. Charge distribution (average particle charge) for drug deposited in ELPI. Shown are 0.5% 
budesonide in ML80 lactose (45-75m) (blue diamonds), 0.5% albuterol in ML58 lactose (45-75m) (yellow 
diamonds), both actuated from SET A (high Re). For comparison, the graph shows the charge limit expected for 
the particles (green triangles) and the Boltzmann charge distribution (red squares). In both cases, over 80% of 
the deposited particles carry >100 charges per particle.  
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 An important question is how this charging compares to other processes. As cited by Johnston et 
al.31, Kosenko conducted studies of aerosol charging in industrial processes and found the most highly 
charged aerosol particles (resulting from sandblasting operations) to have mean charge levels in the 
order of 30 elementary charges per m2. This level is much lower than the mean charge of 142±80e 
observed for albuterol particles and 1333±2003e per m2 observed for budesonide particles. Johnston 
et al. conducted their own studies in the laboratory and found mean charges of 550e for 4m quartz 
particles dispersed in a fluid bed dryer.32 Again, these charges are much smaller than those that can be 
generated during DPI actuation. The reason for this is likely the close and prolonged contact of the 
drug and excipient particles in the formulation, followed by the vigorous separation.  
 
4.4.9. Study Design Critique 
Considerable thought went into developing an efficient experimental framework that effectively 
tested the hypotheses using a relatively small number of experiments in a comprehensive manner. The 
experimental scheme developed used only 33 formulations and 63 experiments (not counting 
replicates that were employed to challenge the intrinsic variance) to examine a large number of 
possible interactions. Including duplicates and auxiliary experiments designed to test specific 
conditions, over 100 ELPI experiments were conducted. The large dataset generated by these 
experiments elucidate the contributions of different formulation variables to charge of delivered drug. 
However, the experimental design has some weaknesses. Insufficient experiments were allocated 
to the low fluidization conditions (Re=7720) and the low drug concentration (0.25%) for the results to 
be useful in determining trends. Clearly, the inherent variability of the triboelectric charging process 
has been underestimated. Similarly, only one experiment each was assigned to the intermediate and 
boundary conditions of dosing 30mg and 10mg of formulation, respectively. The data set consisting 
of 10mg, 20mg, 30mg, and 40mg formulation 1% albuterol in 45-75um ML80 lactose does not show 
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a consistent trend with respect to any of the charge measures. More experiments should have been 
conducted for these conditions.  
An additional flaw was an underestimation of the potential of the strong storage effects which 
provide very interesting insight into the storage process but effectively reduce the number of 
replicates and, thus, reduce the statistical power that could be applied towards the analysis of 
formulation effects, which were the primary objective of the study. 
Last, while the study clearly shows differences in the dispersion and charging behavior of the 
different lactose batches, the differences are smaller and more variable than those seen between 
different materials. As a result the different lactose batches cannot be applied towards the creation of 
a triboelectric series. 
 
4.5. Summary and Conclusion 
The ELPI offers significant advantages for studying electrostatic interaction between the particles 
in DPI formulations. The most significant advantage, which sets the instrument apart from other 
scientific instruments or experimental apparatuses, is its ability to measure particle size and charge 
distributions simultaneously for particles in the single-micron range, the size range required for 
respiratory drug delivery. An experimental apparatus was developed that allowed different DPI 
formulations to be tested at the commonly used 60L/min flow rate and deposition to be measured 
within the ELPI. An experimental framework was devised to test which formulation factors 
contribute to triboelectric charging in DPI formulations. The framework included roughly 100 
experiments (including replicates and auxiliary experiments), of which a number of replicates had to 
be excluded due to storage effects.  
The remaining experiments offer an extensive data set of charge and mass deposition data that 
give insight into which formulation factors contribute to triboelectric charging in the DPI. The choice 
of excipient is clearly important and most profoundly affects the charge characteristics of the 
deposited drug. Batch to batch variability in the behavior of the four lactose batches was clearly 
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indicated. However, a consolidated triboelectric series for all materials could not be established; it is 
clear that some excipients behave differently when combined with albuterol or budesonide, which 
shows the difficulty in determining certain effects a priori. 
The particle size of the excipient also appears to have an effect on the charge profile of deposited 
drug, with smaller particles (with increased surface area) giving rise to stronger charging interactions. 
The concentration of drug in the DPI formulation was also shown to affect the particle charge; 
lowering the drug concentration results in lower fine particle fractions with more highly charged drug 
particles, a result that adds weight to the often cited "active site hypothesis": due to lower surface 
coverage drug particles are concentrated around more energetic carrier particle surface sites where 
forces are stronger and electron exchange may be more extensive; as a result fewer particles separate 
from the carrier. 
The actuation conditions also have a strong effect on the particle size and charge distribution of 
drug. Contrary to expectations, however, the more turbulent conditions result in somewhat lower per 
particle charge levels. This result is consistent with the idea that contact charging is the cause of the 
particle charge and that fluidization merely affects the particle separation process. A lower delivered 
dose also slightly raises the particle charge level. An explanation for these unexpected results is that a 
smaller amount of dispersed drug decreases the chance of opposite charges canceling each other 
during transit or deposition.  
While the study provided statistically strong evidence to show the profound effect of some 
formulation variables, the study design also had some drawbacks. The inherent variability of the 
charging phenomena was underestimated; as a result some of the marginal conditions that were 
written into the design to test response surface curvature lacked sufficient data and, thus, statistical 
power to give conclusive results: the very low drug concentration of 0.25% and the very low Re 
actuation conditions have too few response points and too much variability to provide trends. 
The results indicate that particle charging in DPI formulations is highly significant. Charging is at 
least one order of magnitude higher than had previously been estimated, and greater particle charges 
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are generated during DPI actuation than in other industrial or laboratory processes studied thus far. 
The particle charge levels are indicative of the active contact charging process, and provide a 
scientific basis for the problems with electrostatic charging which have been observed in the clinical 
use of respiratory delivery devices, MDIs and DPIs. 
The charge levels are high enough to have clinical consequences, either due to change in 
trajectory, adhesion to device, or modified in vivo deposition patterns. It is clear, electrostatic 
interactions should be studied as part of the DPI formulation development and characterization 
process.  Failure to consider the process presents a significant liability for product performance. At 
best it is a lost opportunity to moderate a phenomenon that can be affected through formulation 
considerations. Table 4.9 summarizes how charging can be affected. 
 
Table 4.9. Using formulation techniques to affect drug charging.  
 
To minimize drug particle charge To maximize drug particle charge 
-  Increase drug coverage (drug concentration) 
of excipient particle 
-  Increase excipient particle size 
-  Use excipients with similar effective work 
function (i.e. close position in triboelectric 
series) 
-  Reduce drug concentration 
-  Decrease excipient particle size 
-  Use excipients with different effective work 
function (i.e. further removed from drug in 
triboelectric series) 
 
Finally, it is particularly noteworthy that the charging behavior brought about by the different 
excipients is consistent with observations stemming from Faraday well experiments and IGC studies. 
The triboelectric series, developed based on drug charge levels measured in the deposition studies 
agrees with the triboelectic series constructed from raw material bulk electrostatic charging studies, 
and with a ranking of the materials based on measured surface acid/base properties. While the 
comparison is based on semi-quantitative rank-order correlations, it is nevertheless a strong indication 
that the three processes are correlated.  
The next chapter discusses these results in a wider framework and in combination with the results 
of the IGC studies and Faraday well data, which complete our understanding and help evaluate the 
hypotheses. The hypotheses are revisited and recommendations for future studies are made. 
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5. GENERAL CONCLUSIONS AND FUTURE WORK 
 
Dry powder inhalers (DPI) are an important drug delivery option, for the treatment of respiratory 
diseases, and, increasingly, for fast and noninvasive delivery of systemically acting drugs and 
vaccines.1, 2 Most DPI formulations consist of micronized drug blended with larger carrier particles. 
The interactions between drug and carrier particles are one of the major determinants of DPI 
performance and have therefore been one of the main pursuits in inhaled drug delivery research. 
Much of the research in this area has focused on particle design, both the design of drugs and the 
design of carriers3-6 with specific surface properties, that should enhance their dispersion. Studies 
have included the use of large porous particles,7, 8 particles coated with surface modifying agents,9-14 
"mechano-fused" particles,9, 15-17 needle-shaped particle agglomerates,18 particles crystallized from 
supercritical fluids,19-25 spray-freeze dried particles,26 and spray-dried27 particles with varying levels 
of corrugation26, 28-30 to list just a few recent examples. 
Far less research has been conducted aimed at understanding the interactions between particles 
independently of specific systems. The major physical interactions between particles include 
mechanical interlocking, capillary forces, intermolecular interactions, and electrostatic forces. 
Mechanical interlocking, due to surface asperities, may prevent particles from dislodging and may 
thus inhibit particle dispersion. Regular particle shapes with smooth surface morphology may reduce 
the propensity for particles to interlock. The presence of moisture, even in small quantities, may bring 
about capillary forces. Electrostatic interactions between particles are recognized as playing an 
important role. Simulations,31-34 in vitro35, 36 and in vivo37 studies suggest that electrostatic charge can 
affect the delivery and deposition of aerosol particles in the lung. Due to their design and material 
characteristics DPI devices and formulations lend themselves to triboelectric charging. Yet, the 
importance of electrostatic charge on the behavior of medicinal aerosols has not been extensively 
investigated and is poorly understood. This project is the first classification of these electrostatic 
interactions, to estimate their magnitude and prevalence, and finally understand how they arise and 
whether they can be predicted from physical measurements of the raw materials. 
 
5.1. Hypotheses 
It was postulated that electrostatic charge is a major factor in drug delivery from DPIs and that 
charging can be controlled through the selection of formulation variables. Furthermore, it was 
proposed that the charging characteristics of a pharmaceutical material are related to the specific 
material surface properties and could thus be determined a priori. In detail, the hypotheses porposed 
were as follows: 
5.1.1. Electrostatic charging is a consequence of triboelectrification during inhaler actuation. 
5.1.2. Magnitude and polarity of charge on drug particles can be controlled by formulation variables, 
independently of the chemical identity of the drug being delivered. 
5.1.3. The acid-base characteristics of a pharmaceutical material, as determined by inverse gas 
chromatography, are directly related to its triboelectric charging characteristics and its 
position in the triboelectric series.  
5.1.4. By selecting formulation properties and inhaler, micronized drug can be made to acquire 
charges well beyond the Boltzmann equilibrium charge distribution theory. 
 
5.2. Specific Aims 
A series of specific aims were adopted to address the hypotheses and the conclusions derived from 
the previous chapters were as follows. 
 
5.2.1. To elucidate the phenomenon of triboelectric charging during DPI actuation.  
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 The electrostatic properties of albuterol sulfate, budesonide and three excipients (lactose, glucose, 
and calcium phosphate), including different batches, size fractions, and blends were studied. 
Materials were characterized (Chapter 2) using a combination of techniques, including Faraday well 
experiments to determine their charging characteristics in the absence of frictional triboelectrification. 
The experiments indicated a low level of charge, in the order of ±0.5nC/g for excipients to ±1nC/g for 
the micronized drugs. From the results of the Faraday well experiments, the materials were organized 
in a triboelectric series, which arranged the materials from highest to lowest work function (most 
electron accepting to most electron donating material) as follows: 
 -   Budesonide >> Glucose  CP > ML80 > ML58 > SV425 > SV94 > Albuterol + 
 Formulations of different drug/excipient combinations were prepared and tested using the 
electrical low pressure impactor (ELPI) in conjunction with standard entrainment tubes (Chapter 4). 
The mass depositions were assayed, and the charges of the delivered drug particles were measured 
and analyzed with respect to their magnitude and charge polarity. The analysis showed charges in the 
1-300 C/g range depending of the formulation and actuation conditions, which are 3-5 orders of 
magnitude larger than the charges recorded in Faraday well experiments. This large difference in 
charge clearly indicates an active charging mechanism in connection with the aerosolized drug 
particles. A triboelectric series was constructed based on the ELPI recovered charges. From highest to 
lowest work function (most electron accepting to most electron donating material) the series is as 
follows: 
 -   Budesonide > CP > Glucose > ML80 ≈ ML58 ≈ SV425 ≈ SV94 ≈ Albuterol + 
In general, differences between the lactose batches were less pronounced, which is expected 
given that they are the same chemical substance. However, CP and glucose consistently resulted in 
the most positively (or least negatively) charged drug, which was in agreement with the results of the 
Faraday well experiments. This is strong evidence in support of the hypothesis that the charge of 
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aerosolized drug particles is the result of contact charging between particles of the formulation 
followed by separation of particles during the DPI actuation process. 
 
5.2.2. To determine the contribution of specific formulation factors.   
The effect of chemistry (drug and excipients), manufacturing process, blend concentration and 
pressure drop on electrostatic charge were determined in ELPI deposition experiments. Formulation 
factors had significant effects on both the magnitude and the polarity of the charge. The choice of 
excipient has the most profound effect on the charge characteristics of the deposited drug; lactose 
batch to batch variability was also indicated. In addition, the particle size of the excipient appears to 
have an effect on the charge profile of deposited drug, with smaller particles giving rise to stronger 
charging. Drug concentration in the formulation had an effect consistent with the active site 
hypothesis. The effect of the actuation conditions was strong but contrary to expectations, turbulent 
conditions result in somewhat lower individual particle charge levels. This result is further evidence 
that contact charging is the cause of the particle charge and that fluidization merely affects the 
particle separation process.  
The results of the ELPI deposition study show clearly that the drug charge can be affected 
through formulation factors. Per particle or per mass charge levels differed by as much as two orders 
of magnitude depending on how the drug was presented, i.e. what excipient was used in the 
formulation and what fluidization conditions were used in delivery. 
 
5.2.3. To determine the correlation between surface acid/base properties and triboelectric charging.  
 The dispersive surface free energy and specific acid/base surface characteristics of the excipients 
were studied by inverse gas chromatography (Chapter 3). The excipients were arranged in order of 
most electron accepting to most electron donating; the rank order is as follows: 
- CP > Glucose > ML58 ≈ ML80 > SV 425 > SV094 + 
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This order is in agreement with the triboelectric series derived from Faraday well experiments 
and mostly in agreement with ELPI deposition studies. This result strongly suggests bulk electrostatic 
charging (Faraday well experiments), electron exchange between surfaces (IGC experiments), and 
contact charging (ELPI studies) are all closely related, perhaps different manifestations of the same 
physical phenomenon. The variability of the data precludes establishment of a quantitative 
relationship but the rank-order relationship is highly preserved across the experiments and supports 
this conclusion. 
 
5.2.4 To determine if tribocharging can increase particle charge beyond Boltzmann distribution.  
The ELPI deposition studies allowed calculation of approximate per particle charge levels for 
drug deposited in the ELPI (Chapter 4). The results showed very high particle charge levels, often in 
the 1,000s and even 10,000s of elementary charges per particle range. These charges were several 
orders of magnitude higher than charge levels predicted by the Boltzmann charge distribution. The 
charge levels are considerably higher than had previously been estimated (ca. 200e per particle38), and 
substantially higher than what had been observed in other laboratory and industrial processes, in 
which aerosol charging is known to occur. 
 
5.3. Discussion 
The study relies heavily on two techniques not commonly used in pharmaceutical research, IGC 
and ELPI. As outlined in earlier chapters, both techniques have been used previously, but this is the 
first study in which the techniques have complemented each other.  IGC is increasingly being used to 
study the surface energy of powders, which is thought to play an important role in adhesive processes. 
The acid/base parameters have so far, however, not been related to electrostatic material properties 
and/or charging. The ELPI has only recently been applied to the study of DPI products,39 with two 
recent studies examining the effects of storage humidity on charging.40, 41 A search of the National 
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Center for Biotechnology Information database (PubMed ) still returns only 21 citations with "ELPI" 
as keyword, with a majority pertaining to environmental aerosols.  
The results of this work clearly show that triboelectric charging is an important consideration in 
DPI product development and clinical inhaler use. Charge levels observed in these studies were 
significantly higher than had previously been estimated and higher than what is needed to affect the 
trajectory and the deposition of drug particles in the respiratory tract. Ignoring this phenomenon will 
result in reduced design control and formulation variability, resulting in performance inconsistencies 
and potentially failure of product to meet specification. This is particularly true in light of the fact that 
the occurrence of tribocharging is neither a random nor an uncontrollable process. The results of this 
project show that drug charging is highly dependent upon formulation variables and that it can be 
affected by formulation variables such as the choice of excipient or the drug concentration in the 
formulation. Results from Faraday cage experiments show that relative charge magnitude can be 
predicted from material properties prior to combining them in the formulation, though more work is 
needed here to develop a mean of quantitative prediction. Finally, IGC experiments offer a physical 
explanation for the charging phenomena by linking the position of a given material in the triboelectric 
series to measurable surface characteristics, i.e. surface acid and base parameters, KA and KB, 
respectively. This is a first; while it has been suggested that triboelectric charging of insulators is 
related to the presence of electron donor and electron acceptor sites on their surface, this hypothesis 
had previously not been tested. The data set in support of this hypothesis is small and the connection 
drawn is semi-quantitative (rank-order relationship). Yet, the results from IGC experiments are 
consistent with those from Faraday well experiments and, for the most part, ELPI deposition studies. 
This suggests that these phenomena are linked, or perhaps different manifestations of the same 
physical process. Extending this work would increase understanding of insulator charging, and 
confounding data in the literature may be explained. The result would have implications not just to 
the field of pharmaceutical sciences, but could advance the field of particle electrostatics. 
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Finally, it is worth noting, that the results of this dissertation project have direct and immediate 
applicability to the DPI formulation development process. And unlike many of the techniques cited in 
the introduction to this chapter, exploiting the lessons of this project does not require the use of 
specialized or proprietary equipment or techniques, of complicated manufacturing process, or of 
materials not approved for respiratory drug delivery. The project has clearly shown that electrostatic 
charge can be affected by conventional formulation techniques such as the choice of excipient or the 
concentration of drug. All that is required is a thorough characterization of the raw materials and an 
understanding of contact charging, which is provided herein. 
 
5.4. Future Work 
The study indicates that electrostatic charging is an important interaction in DPI formulations. 
But the results have been limited to two drugs and six excipients, whereby four of these excipients 
were different batches of the same material (lactose monohydrate) from the same manufacturer. 
While the two drugs, albuterol and budesonide, are chemically distinct from each another, they do not 
cover the range of different compounds that are currently used or are being developed for use in DPIs. 
Moreover, while batch-to-batch variability was investigated in lactose, it may also play a role for 
drugs. Current research effort in the field of inhaled drug pharmaceutics focuses on drug particle 
design techniques, e.g. supercritical fluid crystallization. Testing the electrostatic properties of 
particles in Faraday well experiments and ELPI deposition studies may add to the understanding of 
how different particle properties (or manufacture methods) affect their propensity to charge. 
Similarly, a larger set of excipients should be tested, including lactose and glucose products of 
different origin, or different polymorphs or anhydrates. 
This project has shown that triboelectric charging plays a significant role in DPI formulations. 
Using well defined systems charge was shown to be highly dependent on the formulation factors. In 
order to elucidate the importance of these effects for all applications, it is important to acknowledge 
that the number of potential system variables is much larger than addressed here. Storage effects were 
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omitted from the analysis but some auxiliary data (presented in the appendix) indicate they have an 
important effect on the performance of DPIs. In an effort to decouple air flow from the other variables 
that make up an inhaler, standard entrainment tubes were used in the experiments in lieu of inhaler 
devices. This, too, is a simplification of the system. Thus, a natural extension of this work would be 
the measurement of charging in more complicated systems, with more variables, which more closely 
approximate real use situations for the inhaler. One important experiment might be to test several 
commercially available inhaled products. 
A principal aim in this project has been to elucidate the triboelectrification process between the 
constituent particles of a DPI formulation. Contact charging is well understood for conducting 
materials, such as metals, but not for insulators, such as the constituents of a pharmaceutical 
formulation. This has been the first such time surface acid/base parameters, which are readily 
measurable, have been linked with triboelectrification. However, the data have only allowed for a 
rank-order type correlation, not a fully quantitative approach. This has two reasons which could be 
addressed in follow-up work: (1) variability in the Faraday well experiments, (2) the IGC method. 
Contact charging between insulators is an inherently variable process that makes it difficult to obtain 
data that is statistically unequivocal. The approach and the methodology could likely be improved, 
but, importantly, the data set must be expanded. (2) The IGC equipment did not allow a complete 
characterization of all materials. KA and KB could not be determined for glucose monohydrate 
because the material is subject to dehydration and physical instability at elevated temperatures. If a 
cooling element were added to the equipment, experiments could be performed at lower temperatures, 
which would allow calculation of ΔHsp and thus determination of KA and KB. The IGC equipment 
also makes characterization of micronized drug difficult. Micronized particles are difficult to pack 
and would require carrier gas pressures that are higher than the glass column and the Swagelock 
fittings can sustain. However, some development work on equipment and method might overcome 
this limitation. Another problem associated with the IGC method is that it requires quantities of 
material that are often not available for developmental drugs. (Typical material requirement for IGC 
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is 2.0g while 1.5g of budesonide were available for the entire project, of which a portion was lost in 
the jet-milling process). One approach to solve both of the problems (high pressure and quantity 
required) would be to blend drug with inert beads (e.g. deactivated glass beads) and pack the column 
with the blend. 
The ultimate goal in this research as well as that of any pharmaceutical or biomedical sciences 
research project must be the improvement of clinical outcomes. Based on the measurements of per 
particle charge levels and the previous work of other scientists, it was suggested that the electrostatics 
arising from DPI formulation and actuation could affect deposition in the respiratory tract. It would 
be useful to determine, first by modeling, what the clinical signifcance of the charge levels is.  
This study has focused on particle interactions in the formulation. By showing that charges are 
present even at highly humid conditions, the study was shown to be relevant to physiological systems. 
However, that experiment does not replace actual in vivo studies. To determine the true effect of 
particle charging on drug deposition, there is no substitute for initial animal or ultimately clinical 
experiments. 
In conclusion, future work can be grouped into several major categories: (1) expanding the scope 
/ extending the conclusion to a larger number of systems, including a larger number of drugs and 
excipients; (2) testing the electrostatic properties of real systems, e.g. in a setting more approximating 
clinical conditions; (3) improving IGC technique to allow characterization of more materials; (4) 
improving Faraday well technique to decrease data variability and allow more quantitative results; (5) 
modeling to understand the clinical significance and, ultimately, (6) testing actual deposition effects 
in vivo. 
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APPENDIX A. 
FARADAY WELL DEVICE AND OPERATING CIRCUIT 
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Figure A.1. Non-integrating circuit for Faraday well. 
  
 
Figure A.2. Photo of Faraday well. The removable aluminum pan rests on top of a Teflon disc, 
the grounded enclosure (note the green cable which grounds the enclosure), can be slid on and off 
the disc. The outlet in the front feeds into a DI-154RS analog-to-digital converter (Dataq, Akron, 
OH) and which is connected to a computer were voltage over time is  recorded using the Windaq 
data aquisitition system. 
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ABSTRACT: Inverse gas chromatography (IGC) has been employed as a research tool
for decades. Despite this record of use and proven utility in a variety of applications, the
technique is not routinely used in pharmaceutical research. In other fields the technique
has flourished. IGC is experimentally relatively straightforward, but analysis requires
that certain theoretical assumptions are satisfied. The assumptions made to acquire
some of the recently reported data are somewhat modified compared to initial reports.
Most publications in the pharmaceutical literature have made use of a simplified
equation for the determination of acid/base surface properties resulting in parameter
values that are inconsistent with prior methods. In comparing the surface properties of
different batches of a-lactose monohydrate, new data has been generated and compared
with literature to allow critical analysis of the theoretical assumptions and their
importance to the interpretation of the data. The commonly used (simplified)
approach was compared with the more rigorous approach originally outlined in
the surface chemistry literature.  2007 Wiley-Liss, Inc. and the American Pharmacists
Association J Pharm Sci 96:2647–2654, 2007
Keywords: inverse gas chromatography; surface free energy; acid–base interactions;
lactose; batch-to-batch variability
INTRODUCTION
Inverse gas chromatography (IGC) applies gas
chromatography principles to the surface analysis
of powders, fibers, or coatings. Techniques for
determining surface energy and acid/base inter-
actions of surfaces by IGC were developed by
Schultz et al. who studied polymers and composite
materials.1 Subsequent workwas largely based on
this approach, though some experimenters have
deviated from the method. The first use of IGC for
surface energy measurements of pharmaceutical
powders appears to be by Ticehurst et al. where
chemically and structurally equivalent batches of
salbutamol sulfate were differentiated by IGC.2
Since this article, IGC has been used to char-
acterize a number of different pharmaceutical
systems, and surface energy and acid–base
parameters were correlated with various material
performance characteristics, including the dis-
persion of drugs from dry powder inhaler (DPI)
formulations.3–6
In determining the acid-base parameters of
salbutamol, Ticehurst et al. assumed that entropic
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contributions to Gibb’s free energy of adsorption
could be neglected.2 This assumption has been
adopted in many subsequent publications, and
some investigators appear to have lost sight of the
fact that this simplifying assumption results in an
approximation. Unlike Ticehurst, they frequently
have not acknowledged this deviation from
Schultz’ original method. Assuming negligible
entropy simplifies the IGC experiment and
analysis of data, but does not always hold true
and can lead to erroneous interpretation of data.
As IGC use continues to grow and surface forces
are linked to an increasing number of perfor-
mance criteria, the correct analysis of data may be
critically important.
Inverse Gas Chromatography
IGC has been extensively reviewed.7–9 In brief,
the technique is based on interactions of gaseous
probe molecules with stationary phase in a
packed column which give rise to a characteri-
stic net retention volume, VN, which can be
related to free energy of adsorption, and used
to calculate various other thermodynamic
parameters.
Surface Free Energy
Surface free energy is a critical determinant of
particle adhesion, which is an important factor
in the performance of several pharmaceutical
systems, including compressed tablet strength
and dry powder aerosol dispersion. Surface free
energy is due to Lifshitz–van der Waals (LW)
forces and acid-base interactions.10 The LW
component of surface energy is primarily the
result of dispersion forces and may be considered
an intrinsic material property. Acid-base interac-
tions are considered ‘‘specific’’ as they are only
evident when surfaces interact with other mole-
cules. Following Fowkes’ reasoning that different
phenomena contribute to intermolecular forces
independently,11,12 surface energy can be repre-
sented as the sum of dispersive and nondispersive
(specific) contributions as
gS ¼ gDS þ gspS (1)
where gS stands for the total surface free energy of
the solid, gDS designates the dispersive surface free
energy, and gspS the specific surface energy.
Dispersive and Specific Free Energy by
Inverse Gas Chromatography
Net retention volume, VN and free energy of
adsorption, �DGA, are related by the following
equations
� DGA ¼ RT lnVN þ C (2)
¼ 2NAA
ﬃﬃﬃﬃﬃﬃ
gDS
q ﬃﬃﬃﬃﬃﬃ
gDL
q
þ C (3)
where NA is the Avogadro’s number, A the
effective surface area of the probe molecule, gDS
and gDL the dispersive free energies of interacting
solid and probe, and C is a constant that
depends on the chosen reference state.1 Based
on Eqs. (2) and (3), surface free energy can be
found from a plot ofRT ln VN versus 2NAA
ﬃﬃﬃﬃﬃﬃ
gDL
q
for
a series of n-alkanes.
Specific free energy, gspS , is determined from
polar probe retention times. When RT ln VN is
plotted versus 2NAA
ﬃﬃﬃﬃﬃﬃ
gDl
q
the distance above the
alkane line is the specific free energy of adsorp-
tion, DGspA , between the surface of the stationary
phase and the respective probe.
Determination of dispersive and specific free
energies is well established and mostly straight-
forward. Since it is difficult to correlate the
specific free energies of different probes individu-
ally to the character of the interacting surface,
Schulz et al. developed a method for consolidating
specific free energies into two comprehensive and
descriptive parameters. The method is based on
the acid/base approach to molecular interac-
tions,13 based on which specific interactions are
classified as either electron donor or electron
acceptor type interactions. Donor and (corrected)
acceptor numbers, DN and AN�, have been
determined for different solvents; these values
represent the ability of a probe to donate or accept
electrons from reference acceptors and donors,
respectively. Gutmann defined the DN as the
molar enthalpy of a given substance with SbCl5, a
reference acid, in 1.0 mM dichloroethane solution
ðDN � �DHDSbCl5Þ.13 AN� was defined as the
molar enthalpy of adduct formation of a substance
with (CH3CH2)3PO, a reference base,
14 a correc-
tion over the initial AN definition.13
Using this approach, the surface can be
characterized by two constants related to the
acid/base interactions via the equation
DHspA ¼ KADNþ KBAN� (4)
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where DHspA is the specific enthalpy of adsorption,
and KA and KB are the acid (acceptor) and base
(donor) parameters of the studied surface, respec-
tively. Eq. (4) originated from work to predict
enthalpies of adduct formation15 that was
extended to solid adsorption phenomena.1,16 It
is a semi-empirical relationship, based on the
observation that acid-base interactions are linked
to changes in enthalpy. It has been shown that
heat of adsorption of a basic probe onto an acidic
surface can be accurately and quantitatively
predicted based on acid/base parameters.17 Since
KA and KB of the adsorbent are analogous to
the DN and AN� of the probes (which as shown are
defined by enthalpy), they are considered relative
to the same reference state.
Ticehurst2 and others5,8,18–24 have used an
alternative expression based on surface free
energy given by equation
DGspA ¼ KADNþ KBAN� (5)
Early literature clearly stated that Eq. (5) is
based on the assumption of negligible entropic
effects.2 Most subsequent papers no longer state
this assumption, and in some cases erroneously
cite the original Schultz et al. article as the source
of this equation. Tong et al. compared the two
approaches for polymorphs of salmeterol, and
concluded they were not equivalent.25 Despite
these results, many authors continue to use the
simplified approach.
Use of Eq. (5) instead of (4) has important
experimental consequences. Using Eq. (5) the
experimenter can quickly determine KA and KB
from data at a single temperature, by plotting
DGspA =AN
� versus DN/AN� of a number of acidic
and basic probes. By contrast, determination ofKA
and KB from eq. (4) requires IGC measurements
at several temperatures so that DHspA can first be
determined via Gibb’s equation.
Lactose monohydrate is examined because it is
the main component of most DPI formulations.26
Efforts to predict and/or improve dispersion of
drug from DPI have focused on the selection or
design of lactose batches.3,5,27–33 IGC measure-
ments of surface free energy of lactose have been
used extensively in this context, and results were
often based on the simplified specific free energy
approach.3,5 This paper compares the simplified
to the more rigorous approach using different
batches of a-lactose monohydrate, one milled and
two in sieved form.
MATERIALS
Lactose monohydrate, RespitoseTM, was provided
by DMV-Fonterra Excipients. One batch of milled
(ML001, batch 10136780), designated ML A and
two batches of sieved (SV003, batches 10190094
and 10135425) lactose, designated SV A and SV B
were evaluated. The alkane probes used for
dispersive free energy determination were hexane
(99þ%, Aldrich), heptane (99þ%, Aldrich), octane
(99.5þ%, Fluka), nonane (99þ%, Aldrich), and
decane (99þ%, Aldrich). Polar probes were
chosen to cover a wide DN/AN� range. The probes
used were tetrahydrofuran (THF) (EM Science,
99.99%), chloroform (100%, Mallinkrodt), acetone
(99.7%, Mallinkrodt), ethyl acetate (99.9%,
Mallinkrodt), diethyl ether (99%þ, Acros), and
ethanol (100%, Aaper).
METHOD
IGC experiments were conducted with a Hewlett-
Packard 5890 Series II GC with flame ionization
detector. The chromatograph was modified to
allow installation of 205 mm, 4 mm ID glass
columns. Carrier gas employed was dry N2 at a
flowrate of 30 mL/min. Oven temperatures used
were 608C, 458C, and 308C in that order. Lactose
was packed into deactivated34 glass columns and
plugged with silanated glass wool. Necessary
corrections for pressure drop across column and
temperature effects on flow rate were made. After
installation and temperature changes, packed
columns were allowed to equilibrate for 6 h before
subsequent injections were made. Injections
were made with a 1 mL-Hamilton syringe. Infinite
dilution was ensured by detector response,
detector signals below 10� limit of detection were
permitted; this corresponds to injection volumes
<0.01 mL. Each injection was made at least three
times; the relative standard deviations in the
retention times of these injections were <1% in
each case. Each batch was examined with four
different packed columns. Since even inert probes
can be somewhat retarded,35 dead-times were
calculated using the retention times of heptane,
octane, and nonane.36 Data were analyzed using
SigmaStat 2.03 (SPSS, Chicago, IL) and plotted
using Excel 2000 (Microsoft, Seattle, WA). Differ-
ences between batches were probed for statistical
significance using the two-sample t-test for
independent samples with unequal variances
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(Satterthwaite’s method). Probe surface areas
were taken from Schultz et al.1 Other properties,
including surface tension, are readily available
from chemistry handbooks.37
RESULTS AND DISCUSSION
In preliminary work, experiments were conducted
in a temperature range of 308C–808C. However,
differential scanning calorimetry showed struc-
tural changes occurred in lactose monohydrate
after prolonged exposure to 808C. Specifically,
dehydration and polymorphic changes were
observed.38 A temperature range of 308C–608C
did not modify the lactose.
Dispersive surface free energywas calculated at
each temperature as discussed above; RT ln VN
versus 2NAA
ﬃﬃﬃﬃﬃﬃ
gDL
q
was plotted and straight lines
were fitted to the data. The fit was excellent
in each case (R2> 0.999). Table 1 shows the
dispersive free energies determined at each
temperature; the dispersive free energies are
similar for the three batches and agree with
published data.23,30,32,39 When the dispersive free
energies are plotted against temperature, straight
lines with excellent correlation coefficients
(R2> 0.99) can be fitted to each data set.
Specific interactions were analyzed (a) assum-
ing negligible entropic effects, (b) using the
approach of Schultz et al. which requires prior
determination of enthalpy of adsorption. Figures 1
and 2 contrast the two methods; for clarity only
one batch (milled lactose) is shown in the figures.
Results for all batches are presented in Table 2
(negligible entropy) and Table 3 (including
entropic contribution).
Since Eq. (5) does not account for the tempera-
ture dependent contributions (�TDS) to DGspA ,
analysis at different temperatures yields separate
sets of results. As shown in Figure 1 and Table 2,
these results are quite distinct at different
temperatures; each best-fit (least squares) trend-
line results in a different intercept and slope,
which give different KA and KB values at every
temperature. Magnitude varies and not even
rank-order of KA and KB is preserved. The method
differentiates the two sieved batches (which are
intrinsically similar) from the milled batch; KA
and KB of the two sieved batches are more similar
to each other than to the milled batch. However,
the large standard error of KB (RSD� 50% for all
KB) precludes inferring the relative magnitudes of
the basic properties. The ratio of KA to KB, which
has sometimes been used to contrast materials,
also varies widely, from 0.80 at 308C to 1.12 at
608C for sieved lactose, and from 0.95 at 308C to
2.34 at 608C for the milled lactose. However, the
large standard error once again precludes a
comparison of this ratio between the batches.
The more rigorous (DHspA -based) analysis
produces different results, both in terms of
absolute parameter magnitudes and relative
rank-order. When entropic contributions (�TDS)
are included, we arrive at a single set of acid/base
parameters, independent of temperature. As
shown in Figure 2(B) and by the correlation
Table 1. Dispersive Free Energies (Standard
Deviation) of Sieved andMilled LactoseMonohydrate at
the Respective Temperature
Dispersive
Surface Free
Energy, gDS (mJ/m
2) 308C 458C 608C
SV A 42.0 (1.0) 38.5 (0.1) 35.3 (0.8)
SV B 42.0 (0.3) 39.1 (0.2) 35.7 (0.9)
ML A 41.7 (0.3) 39.2 (0.3) 36.2 (0.5)
Relative standard deviation was<2.5% in each case (n¼ 4).
Figure 1. Estimating KA and KB for milled lactose
monohydrate, ML A assuming negligible entropic
effects. DGspA /AN
� is plotted over DN/AN� for each polar
probe at four temperatures. Each point is average of
n¼ 4 columns� standard deviation. The fitted lines
miss several points (ethanol, ethyl acetate, ether), even
though the standard deviations on those points are very
small. Acid and base parameters based on this approach
are shown in Table 2.
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coefficients (R2) in Table 3, the data fit the linear
relationship represented by Eq. (4) very well. The
data allow a more meaningful interpretation than
was proposed previously. The acidic parameters
KA of the two sieved batches are essentially
identical but differ from the milled batch
(p< 0.05). This is consistent with the DG analysis,
though there is no ambiguity, since there is only
one value. The analysis suggests that KB varies
between SV A and the other two batches. This
result is not apparent from the simplified correla-
tion. The KA /KB ratio is also more meaningful
and shows differences among all three batches.
These differences are not detectable from the
DG-based analysis at any one temperature.
Note the correlation coefficients for the best fit
straight lines obtained for the rigorous analyses
(R2> 0.99). In the case of the analyses based on
DG, the correlation coefficients (R2) also suggest
strong correlations, with R2> 0.95 in each case.
However, upon closer examination, several probes
clearly do not fall onto the regression line. Ether,
which has a DN/AN� ratio of 13.7, does not fit
the line at all, at any temperature. This may
explain why ether has been used infrequently in
these analyses, although it has favorable probe
properties (volatility and single functional group)
and a useful DN/AN� in the intermediate range.
(Note that DHspA =AN for ether is predicted very
well.) A strong correlation is obtained nonetheless
because some of the points are so close together.
The best-fit line is determined almost entirely by
THF and chloroform, the most basic and the most
acidic probes used, respectively. In fact, determin-
ing the trendline based solely on chloroform and
THF results in an almost identical fit, giving
similar KA and KB.
The discrepancy between the rigorous and the
simplified approach was also observed by Tong
et al.25 However, they obtained more precise data
using the simplified correlation, whereas we show
much lower standard errors for the enthalpy
based correlation. In fact, estimation of KB
appears impossible with the reduced correlation.
As shown by Figure 1 the data suggest that the
assumption of negligible entropy does not hold for
all probes. Tong et al. do not plot their data and do
not provide measures of ‘‘goodness of fit’’. When
plots are constructed from their DG data, linearity
is poor. Within the limits of their experimental
observations their conclusions were correct. How-
ever, we appear to have improved technique that
supports a different conclusion.
It is worth noting that the assumption of
negligible entropic effects has found little use
outside the pharmaceutical literature, even
while there have been numerous publications in
the interfacial chemistry and chromatography
disciplines. It seems reasonable that as a
Figure 2. Determination of KA and KB for milled
lactose monohydrate, ML A following the approach of
Schultz et al. (A) DHspA for each polar probe is
first determined form a plot of DGspA vs. Temperature;
(B) KA and KB are determined from a plot of DH
sp
A /AN
�
vs. DN/AN�. The straight line fit is very good
(R2¼ 0.998), with points evenly distributed around it
(i.e. no bias). Each point is average of n¼ 4 columns�
standard deviation. Acid and base parameters with
correlation coefficient of each lactose batch are shown
in Table 3.
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technique is being established for a new appli-
cation, assumptions might be made. However,
given the present interest in IGC and numerous
attempts to correlate the data with performance
measures, the pharmaceutical literature should
strive for the same level of accuracy in experi-
mentation and data interpretation as others.
There are recent examples of meaningful
results obtained with the rigorous approach,40
though publications using the DG approach still
predominate.
Lastly, themost significant short-comings of the
acid–base approach to specific surface free energy
relate to the determination of KB, which is
determined from the intercept of the correlation,
whether the rigorous or the simplified approach
is used. One potential way to overcome this
problem is to concurrently plot DHspA =DN versus
AN�/DN, in addition to DHspA =AN� versus DN/AN�
and determine KB from the slope of the line.
The limitation of this approach is the lack of
probes which display a useful DN/AN� range.
However, the analysis is possible if in addition
to the commonly used probes, benzene (AN�/
DN¼ 1.7) and/or nitromethane (AN�/DN¼ 1.6)
are used.
CONCLUSION
Using the same set of data obtained for three
batches of lactose monohydrate, two sieved and
one milled, two approaches to characterizing
surface acid/base interactions using IGC were
compared. A simplified approach (where DG of
adhesion is assumed to be equal to DH) that has
been popular in the pharmaceutical literaturewas
compared with a more rigorous approach for the
determination of surface acid/base properties.
While assuming DGspA � DHspA results in immense
experimental simplification, it gives a reduced
correlation that strongly depends on method and
experimental conditions. The values obtained are
internally inconsistent, as displayed by tempera-
ture dependence, and do not agree with those
obtained in the rigorous analysis. While the
simplification may be useful for the comparison
of different materials, a rigorous analysis of
Table 2. Lactose Surface Acid–Base Constants (Standard Error) with Corresponding Correlation Parameters
Assuming Negligible Entropic Contributions, According to Eq. (5)
Lactose Batch Temperature (8C) KA KB R
2 KA/KB
SV A 30 0.0439 (0.0016) 0.0552 (0.0275) 0.970 0.80 (0.43)
45 0.0389 (0.0016) 0.0343 (0.0285) 0.958 1.13 (0.98)
60 0.0336 (0.0015) 0.0314 (0.0275) 0.958 1.07 (0.98)
SV B 30 0.0442 (0.0015) 0.0551 (0.0269) 0.968 0.80 (0.42)
45 0.0388 (0.0014) 0.0383 (0.0262) 0.959 1.01 (0.73)
60 0.0340 (0.0015) 0.0304 (0.0282) 0.951 1.12 (1.09)
ML A 30 0.0475 (0.0014) 0.0500 (0.0234) 0.980 0.95 (0.47)
45 0.0421 (0.0014) 0.0353 (0.0246) 0.972 1.19 (0.87)
60 0.0363 (0.0017) 0.0155 (0.0300) 0.944 2.34 (4.64)
The parameters in the table correspond to the slopes and intercepts of the lines in Figure 1, determined with four columns each,
with n �3 injections each. Note that the results are highly dependent on the temperature at which the IGC experiment has been
conducted. Despite high number of data points (with column RSD < 5%) the correlation parameter is only �0.96.
Table 3. Sieved and Milled Lactose Monohydrate Surface Acid–Base Constants (Standard Error) with
Corresponding Correlation Parameters Based on the Approach of Schultz et al., in Accordance with Eq. (4)
Lactose Batch KA KB R
2 KA/KB
SV A 0.146 (0.007) 0.463 (0.120) 0.991 0.315 (0.097)
SV B 0.146 (0.003) 0.354 (0.053) 0.996 0.412 (0.070)
ML A 0.158 (0.003) 0.331 (0.057) 0.998 0.477 (0.091)
The parameters in the last row of the table (ML A) correspond to the slope and intercept of the line in Figure 2(B). The
sieved batches appear to have a more basic surface, particularly batch SV A, which has a significantly larger KB than the other two
batches.
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similar materials (such as for the detection of
batch-to-batch variability of a single product,
where differences are presumed to be minute)
may require the more exact correlation.
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Abstract
Electrostatics and triboelectrification phenomena in dry powder inhalers (DPI) are not well understood, but as shown in this study they may
play an important role. Using model formulations of albuterol in lactose, the extent of triboelectrification in the operation of DPI was investigated
using an electrical low pressure impactor (ELPITM). An experimental apparatus was developed, the performance of the ELPITM was evaluated for
consistency and reproducibility, and compared to a conventional inertial impactor. Using a statistical experimental design the effects of lactose
type, drug load, capsule fill, capsule material, and inhaler were assessed. DPI formulations appear to be subject to strong triboelectric effects.
Charge separation can occur between different size fractions, i.e. different fractions can carry charges of different sign. In particular, lactose type,
inhaler, and capsule material have a strong effect on the magnitude and polarity of the charge developed during DPI operation. The study suggests
that the polarity of the aerosol can be controlled by choice of lactose type, capsule material, and inhaler, which could be exploited for targeting
different lung physiologies.
© 2006 Elsevier B.V. All rights reserved.
Keywords: Triboelectrification; Dry powder inhaler (DPI); Electrical low pressure impactor (ELPITM); Formulation
1. Introduction
Electrostatic attraction between particles is a well-known
event. It is of particular importance to small particles which
have comparatively large surface areas. For particles smaller
than 10m in size electrostatic forces can be many times larger
than gravitational, fluid-dynamic forces, and other forces acting
upon them. The property is exploited by various air-cleaning and
aerosol sampling equipment, such as the electrostatic precipita-
tor and the electrical mobility analyzer. While particle charging
has been studied in a manufacturing and environmental context,
its effects on the delivery of therapeutic aerosols have yet to be
fully elucidated.
Dry powder inhalers (DPI) are important delivery devices
for respirable medicines (Timsina et al., 1994). As the name
suggests, DPI formulations consist of dry blends, typically con-
sisting of micronized drug and larger carrier particles (Telko and
∗ Corresponding author. Tel.: +1 919 962 0223; fax: +1 919 966 0197.
E-mail address: ahickey@unc.edu (A.J. Hickey).
Hickey, 2005). Carriers, often lactose monohydrate, reduce drug
agglomeration and aid in metering and dispersion. For effective
delivery to the peripheral lungs, drug particles need to be≤5m
in aerodynamic diameter. Particles in this size range have spe-
cific surface areas in the order of several square meters per gram.
Since charging is a surface phenomenon, particles in the res-
pirable size range can accommodate large charges. In addition,
most drugs and pharmaceutical excipients are organic molecules
with high resistivity maintained at low humidities, which makes
them prone to electrostatic charging.
Deposition in the lungs occurs by inertial impaction, diffu-
sion, interception, and electrostatic deposition (Gonda, 2004).
Computer simulations have indicated that electrostatic deposi-
tion dominates in the lower lung regions, particularly the alveoli
(Balachandran et al., 1997). The alveolar region is the site of
most -adrenergic receptors (Labiris and Dolovich, 2003) as
well as the region from which systemic absorption is most
efficient, thus it is an important site for targeting therapeutic
aerosols.
Aerosol particles can acquire charge by flame charging, static
electrification, diffusion charging, and field charging (Hinds,
0378-5173/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.ijpharm.2006.12.018
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1999). Of these mechanisms, static electrification plays the pre-
dominant role during DPI actuation. Static electrification occurs
when particles are detached from surfaces or the bulk phase
resulting in a separation of charges. In DPIs, this takes the
form of surface charging, or triboelectrification. When drug
and carrier particles are separated from each other or the sur-
faces of the dosage form or inhaler, charge can be transferred
resulting in a net charge on the particles. Particles experience
significant friction during DPI discharge which tends to amplify
this effect. The extent to which triboelectrical charging in DPIs
occurs, however, has not been investigated from a formulation
perspective.
The studies described here evaluate the influence of tri-
boelectrical charging of simple two-component DPI model
formulations; magnitude and polarity of resulting currents are
measured over time and the effects of lactose type, drug load,
capsule fill weight, capsule material, and inhaler type are investi-
gated in the framework of a comprehensive experimental design
scheme. The experimental setup makes use of the electric low
pressure impactor (ELPITM), a particle sizing device that detects
particles by charge (Keskinen et al., 1992).
The ELPITM has been used primarily in the analysis of envi-
ronmental effects in the automotive industry (Holmen and Qu,
2004; Lehmann et al., 2004; Maricq et al., 2002; Sanders et al.,
2003) and in industrial hygiene applications (Brouwer et al.,
2004; Ferge et al., 2004). Only recently it has been applied to
the evaluation of metered dose inhaler electrostatics (Kwok et
al., 2005).
A detailed discussion and evaluation of the ELPITM is
available elsewhere (Marjamaki et al., 2000). The ELPITM
is composed of a unipolar corona aerosol charger and a low
pressure cascade impactor. Deposition inside the impactor is
dependent on particle aerodynamic diameter. Unlike conven-
tional cascade impactors which are disassembled and the stages
assayed chemically or gravimetrically after operation, ELPITMs
detect deposited particles by measuring the current resulting
from dissipation of the particles’ electrical charge. The collected
particle fractions can be measured simultaneously on all stages
using a multichannel electrometer. Thus, when the ELPITM is
operated with charger turned on, it functions as a near real-time
particle sizer. However, when operated with the charger off, par-
ticle charge is measured (main focus in this paper). The ELPITM
is a low pressure impactor; operation at reduced absolute pres-
sures (10 kPa on the final stage) allows collection of particles
down to a size of 30 nm (with filter stage to 7 nm). (By contrast,
the Anderson cascade impactor operates at ambient pressures
with a pressure drop of ∼5 kPa across the device at flowrates of
30 L/min.)
Studies of medicinal aerosol electrostatics have been
attempted before. Electrostatic charge carried by a DPI aerosol
cloud has been measured using a grid probe (Murtomaa et
al., 2003); however, the particles were rather large and the
system was of little pharmaceutical relevance. The effects of
particle morphology and crystallinity on triboelectrification
of dry powder inhalers have also been studied, but parti-
cle deposition was not considered (Murtomaa et al., 2004).
Moreover, a Faraday cage was used for the charge measure-
ment, which precluded analysis of different size fractions and
charge distribution. Use of the ELPITM for studying DPI elec-
trostatics allows a more comprehensive investigation of the
phenomenon, with accurate determination of magnitude and
polarity of charges on particles in the respirable size range
over time. Furthermore, since each impactor stage is electri-
cally isolated from the next, charges can be measured across
individual stages, allowing size specificity of charging to be
evaluated.
2. Materials and methods
2.1. Materials
Lactose monohydrate, RespitoseTM, was provided by DMV-
Fonterra Excipients. One batch of milled (ML001), and one
batch of sieved (SV003) lactose, were used. Milled albuterol
sulfate (median particle size 2m) was supplied by Chemaco
(Beetsterzwaag, NL) from drug manufactured by P.F.C. Italiana
S.r.1 (Caronno Pertusella, Italy). Hard gelatin capsules (Cap-
sugel Coni-snapTM, lot 70016321) and carrageenan capsules
(Capsugel NPcapsTM, lot 38611), both #3 and transparent, were
used in the study.
Two different inhalers were tested; both deliver their doses
from capsules, but have otherwise different operational prin-
ciples. The Rotahaler® (GlaxoSmithKline, RTP, NC) is a low
resistance device; the capsule is discharged after separation of
the cap from the capsule body. The Inhalator® single capsule
inhaler (Boerhinger Ingelheim, Germany) is a high resistance
device in which drug is removed from the capsule through
punctured holes (Dunbar et al., 1998). Specific device resis-
tance of Inhalator® and Rotahaler® are 0.180 and 0.040 cm H2O
1/2/(L/min), respectively (Clark and Hollingworth, 1993).
2.2. Blending
Four formulations were manufactured in 5.0 g batch sizes
using a method that had previously been validated in the lab-
oratory. Drug and lactose were sieved prior to blending using
a #125 mesh to promote deagglomeration. Albuterol was geo-
metrically diluted to concentrations of 0.5% or 1% with lactose,
then blended for 2 min in a 60 mL vial using a custom made
small-scale planetary mixer operating at 150 rpm.
2.3. Blend uniformity
Content uniformity of the blends was ascertained by with-
drawing 5 samples (∼10 mg each) from different locations in
the powder bed using a 1 mm inner diameter sample thief. Four
of the locations were at ∼90◦ to one another, close to the vial
wall; the fifth sample was withdrawn from the center. Use of
the narrow bore thief allowed lateral sampling of small material
quantities representing powder from varying bed heights. The
samples were weighed and dissolved in water. UV absorbance
of the solutions was assessed at a wavelength of 224.6 nm using
a Shimadzu 160U spectrophotometer. Lactose has negligible
absorbance at this wavelength.
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2.4. Capsule ﬁlling
Capsules were hand-filled with 15± 1 mg or 30± 1 mg of
formulation. Actual net fill weight averages were 15.2± 0.3 mg
and 30.2± 0.4 mg. Empty capsule and net-fill weights were
determined for each capsule. Each capsule was stored in an indi-
vidual, labeled container. Since capsules were filled immediately
prior to dosing, no capsule was stored for more than 2 h. After
dosing each empty capsule was removed from the inhaler and
placed back into its weigh boat; empty (post-dosing) capsules
were weighted and weight delivered was determined. Actual
material delivered averages were 14.6± 0.7 mg (15 mg nomi-
nal fill weight) and 29.2± 1.2 mg (30 mg nominal fill weight).
When more than 10% of the fill weight was retained in the cap-
sule (select cases), the recorded ELPITM data were excluded
from the analysis. No significant differences in emitted dose
were observed between the different inhalers, formulations, or
capsules.
2.5. ELPITM experimental apparatus
The experimental apparatus was developed to overcome two
major obstacles: (1) operation at 30 L/min and (2) pre-separation
of agglomerates. (1) The ELPITM (Dekati Ltd., Tampere, Fin-
land) operates at 30 L/min, but inhalers are typically tested at
60 L/min airflow rates; (2) unlike the Anderson cascade impactor
(ACI, ThermoAnderson, Smyrna, GA), the ELPITM does not
have a preseparator capable of removing large quantities of mate-
rial. However, initial work made clear that failure to remove
carrier particles and agglomerates from the aerosol prior to
introduction into the ELPITM could result in flooding of the
top stages after a single inhaler actuation. The setup that was
devised to address these issues is shown in Fig. 1. The DPI
is connected to the mouthpiece and standard USP induction
Fig. 1. Experimental set-up.
port, which is connected to the ACI pre-separator (loaded with
15 mL water) (cut-off size of 8.6m at 60 L/min). A custom-
manufactured aluminum part connected the pre-separator and
split the 60 L/min stream into two; 40 cm TygonTM tubing
(R3603) was used to connect the two outlets with ELPITM and
ACI, each connected to a vacuum pump operating at 30 L/min.
TygonTM tubing is commonly used in aerosol research; unlike
other materials, TygonTM has negligible electrostatic effects (Liu
et al., 1985). Deposition of drug in different parts of the exper-
imental setup was determined; deposition in the custom-made
part and tubing accounted for <5% of deposition in the ELPITM
and ACI. To prevent particle bounce ACI collection plates were
coated with silicon oil. Coated aluminum foils were used with
the ELPITM stages. The apparatus was leak tested prior to each
experiment.
Both ELPITM and ACI were used to classify the particles. In
accordance with manufacturer recommendations, the ELPITM
was switched on at least 1 h prior to measurement. Inlet air
was not filtered and baseline measurements of charge were
collected.
2.6. ELPITM versus ACI comparison
The ELPITM was operated with corona charger and trap volt-
ages turned off. Using the experimental arrangement described
particle size distributions were obtained from ELPITM and
ACI. Capsules (6× 30 mg) containing micronized albuterol,
and different formulations (10× 30 mg) were actuated with
ELPITM and ACI operating as described. The equipment was
then turned off and disassembled, and the stages assayed
gravimetrically (for total deposition) and chemically (for drug
deposition).
2.7. ELPITM output versus gravimetric determination
While it is used here for charge measurements, ELPITM is
primarily used for particle sizing. This function was assessed by
comparing the particle size distributions recorded by the device
with a gravimetric determination of deposited material. For this
purpose the ELPITM was run with charger, trap, and correction
(Virtanen et al., 2001) turned on. Capsules containing different
formulations (10× 30 mg) were actuated sequentially and sam-
pled by ELPITM and ACI. The ELPITM was then disassembled
and the total deposition on each stage was determined gravimet-
rically. The particle size distributions acquired by the ELPITM
were compared to the particle size distribution obtained from
gravimetric data.
2.8. Particle size analysis
After the ELPITM was validated with respect to the ACI and
gravimetric analysis of its stages, it was used to size the ELPITM
fractions (<8.6m) from each formulation. These experiments
were conducted with the corona charger and trap turned on.
Using the Inhalator®, each formulation was dosed in 30 mg-
filled capsules in randomized order three times (12 doses). The
data collected in each run were used to determine the quanti-
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ties and particle size distributions of ELPITM fractions of the
deposited formulations.
2.9. Experimental design
The objective of the experimental design was to quantify
the contributions of different formulation variables with respect
to magnitude and polarity of triboelectrification during DPI
actuation. The experimental design was used to investigate the
contribution of several common formulation variables:
(1) drug load: 0.5% (w/w) and 1.0% (w/w) albuterol;
(2) lactose grade: sieved lactose and milled lactose;
(3) capsule material: Carrageenan and Gelatin;
(4) capsule ﬁll: 15 mg and 30 mg;
(5) inhaler type: Rotahaler® (low resistance) and Inhalator®
(high resistance device).
The choice of full-factorial design for the above five vari-
ables each at two levels/categories yields 25 = 32 individual data
points. Each setting (combination of five factors) was tested
at least three times (n≥ 3). The experiments were divided into
blocks of 16 actuations and the order was randomized. Inhaler
and equipment were disassembled and cleaned between blocks.
2.10. Environmental conditions
The extent to which triboelectric charging occurs depends
in part on the environmental conditions; triboelectrification is
only observed at relative humidities of less than 65% (Hinds,
1999). Hence, conditions must be monitored closely. The data
for the experimental design were collected over the course of 2
weeks; the conditions during blending, storage, capsule filling,
and actuation were constant at a temperature of 23± 0.5 ◦C and
a relative humidity of 39± 1%.
2.11. Data analysis
Data were collected by the ELPITM data acquisition sys-
tem, ELPITMVI 4.0 (Dekati, Tampere, Finland). Raw data were
analyzed using Excel software (Microsoft, Seattle, WA). Each
actuation was isolated and charge was integrated over the time
the actuation had occurred. This data were fed into statistical
software Design-Expert 5 (Stat-Ease Corporation, Minneapolis,
MN). Total magnitude and polarity (summed across all stages)
were designated as response elements. The influence of each of
the five factors was determined.
3. Results and discussion
3.1. Blend uniformity
Blend uniformity was determined by withdrawing five sam-
ples (ca. 10 mg each) from each blend and determining the drug
content by chemical assay. All blends were within 5% of claim
and relative standard deviation of the five samples was <5% in
each case.
3.2. ELPITM versus ACI comparison
Since the ELPITM is not frequently used for pharmaceuti-
cal applications, initial experiments were conducted to assess
its ability to classify therapeutic aerosols consistently and in
accord with a conventional method, i.e. the ACI. The equip-
ment was validated using micronized albuterol alone and as
a component of a 1.0% formulation using two different DPIs.
These combinations were chosen to represent scenarios relevant
to subsequent studies. After actuations, the equipment was dis-
assembled and stages were weighed or deposition of drug was
determined chemically. The details and results of the valida-
tion experiments are shown in Table 1. Several capsules were
dosed sequentially in each case to ensure sufficient deposition
on each stage so discriminating particle size distributions could
be obtained. Particle size distributions shown reflect drug depo-
sition only.
The agreement between ELPITM and ACI was good with
almost superimposable particle size distributions for drug (rep-
resented by cumulative % fines, since the division of intervals
differs) and d50 values differing by no more than 0.1m. The
d50 values of approximately 2.0–2.2m are consistent with par-
ticle size given by the manufacturer. One representative particle
size distribution comparison for drug is shown in Fig. 2; 1.0%
albuterol in milled lactose produced identical drug particle size
distributions in both measurement devices.
3.3. ELPITM output versus gravimetric determination
The particle sizes acquired by the ELPITM compared well
to the particle size distribution obtained from gravimetric data.
This is shown in Fig. 3, where ELPITM output is compared to
the gravimetric determination of its stages. Discrepancy was
observed in the lower particle sizes; however, this may be
explained by the limited resolution of the gravimetric analy-
sis; deposition on the lower stages (≤0.39m) was in the single
microgram range, which is the resolution of the analytical bal-
ance used. The ELPITM is thought to be more reliable in this
Table 1
Formulations/device combinations tested for ELPITM ACI comparison and d50 of recovered drug
Formulation Device Number of capsules, target fill weight d50, cumulative undersize
Micronized albuterol Rotahaler® 5× 6.0 mg capsules ELPITM: d50 = 2.0; ACI: d50 = 2.1
1.0% albuterol in milled lactose Rotahaler® 10× 30 mg capsules ELPITM: d50 = 2.1; ACI: d50 = 2.2
Inhalator® 10× 30 mg capsules ELPITM: d50 = 2.0; ACI: d50 = 2.1
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Fig. 2. Particle size distribution of micronized albuterol dosed in 30 mg capsules of 1.0% albuterol in milled lactose via the Inhalator® at 60 L/min (determined
chemically): (a) fraction per stage normalized for interval width; (b) cumulative % undersize. White triangles represent data collected with ELPITM, solid diamonds
data collected with ACI.
region. Note that chemical analysis was not used, because total
deposition (of drug and lactose) was measured.
3.4. Particle size distributions
The ELPITM was in agreement with the ACI (Section 3.2)
and the particle size distributions it generates were consistent
with gravimetric analysis of the stages (Section 3.3). Having
confidence in its ability to size particles, the ELPITM was used
to determine the particle size distributions of the deposited fines
(<8.6m) of each of the four formulations. The resulting particle
size distributions accounting for both drug and lactose (each the
average of three measurements/actuations) are shown in Fig. 4.
The particle size distributions are similar, most points are within
the standard deviations of the actuations. Standard deviations
Fig. 3. Particle size distribution of 1.0% albuterol in milled lactose, dosed in
10× 30 mg capsules delivered by Rotahaler® at 60 L/min. Figure shows the size
distribution as recorded by ELPITM (white triangles) and by gravimetric analysis
(black diamond). Conformance is good except in lower region, where resolution
of gravimetric analysis is highly limited. Error bar gives resolution of analytical
balance, ±0.003 mg.
on the particle size distributions indicate that particle size dis-
tribution varies somewhat from one actuation to the next; the
largest variability is observed on the lowest stages, where depo-
sition was very low. The amount of material deposited varied
for the formulations; the more disperse milled lactose has a
larger portion of fine particles compared with sieved lactose
(11.8% versus 7.3% below 8.5m, internal data), and therefore
resulted in higher deposition on all stages. Total relative deposi-
tions are given in Table 2. This deposition pattern is considered
in subsequent analyses of electrostatics.
3.5. Charge versus particle size
Charge does not appear to be uniformly distributed with
respect to particle size or formulation. Fig. 5 shows five actu-
ations of 0.5% albuterol in milled lactose in 30 mg gelatin
Fig. 4. Particle size distributions of fine particles (<8.6m) of the four formu-
lations used as recorded by ELPITM (n= 3, mean± S.D.).
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Table 2
Relative deposition of particles <8.6m (entire formulation) in ELPITM
Formulation (drug load and
lactose)
Amount deposited average
of 3× 30 mg capsules
0.5% albuterol/SV lactose 100
1.0% albuterol/SV lactose 102
0.5% albuterol/ML lactose 198
1.0% albuterol/ML lactose 240
Deposits relative to 0.5% A/SV. Total deposit for this formulation was 0.5 mg.
Fig. 5. Five actuations (each performed in different block, i.e. different day, in a
different order) of 0.5% albuterol in ML lactose, 30 mg gelatin capsule, dosed via
Inhalator®. Double line indicates temporal discontinuity. Capsule emptying and
deposition on stages takes about 6 s in each case. The numbers on first actuation
indicate the stages on which the electric charge was recorded. While there is
some variability, particularly with regards to magnitude, the overall rank/order
and polarity is preserved in each trial as shown on the subsequent actuations.
capsules, dosed via Inhalator®. Each actuation was performed
in a different experimental block, i.e. on different days (graphs
have been merged to facilitate direct comparison). The figure
provides insight into formulation delivery by the inhaler. Clearly
there is some variability, however there are many common
features. The data provide temporal insight into how emis-
sion from the device and deposition in the ELPITM occurs.
Capsule emptying and deposition in the ELPITM takes about
6 s in each case but deposition on the stages does not occur
simultaneously. This temporal data might make ELPITM a
useful screening tool to evaluate formulation and device dif-
ferences in emission; a thorough discussion of this is beyond
the scope of this paper. The numbers (shown on first actua-
tion) indicate the stages on which the charge was recorded.
While there is variability with regards to magnitude, the overall
rank/order and polarity is preserved in each trial. For exam-
ple, stage 6 (cut-off size 0.39m) is highly positive in each
actuation, while stage 9 (cut-off size 1.6m) delivers a highly
negative charge in each actuation. Actuations of the same for-
mulation/capsule/inhaler combination give a consistent charge
distribution which differs for other formulation/capsule/inhaler
combinations.
Fig. 6 shows the particle size distribution and total charge
observed (integrated over the time course of the actuation) dur-
ing actuations for two formulations (a) 0.5% albuterol in milled
lactose, delivered from 15 mg carrageenan capsule and (b) 1.0%
albuterol in sieved lactose, delivered from 30 mg gelatin cap-
sules. Each of the charge profiles is the average of five actuations,
performed via the Inhalator® on different days. Particle size dis-
tributions were determined separately as described in Section
3.4. Note that the charge profiles of the two formulations are
very different. Formulation (a) has a large portion of positively
charged particles below stage 9 (cut-off size 1.6m), but is neg-
atively charged at and above stage 9. This formulation clearly
shows that different size particles can carry opposite charges,
as observed by Murtomaa et al. (2004). By contrast, the second
graph shows an entirely negative charge distribution. In both
graphs, and in most cases observed in these experiments, the
largest charge (whether positive or negative) was observed at
particle size fractions which accounted for the largest portion of
particles by surface area, i.e. stages 7 and 8 (cut-off sizes of 0.63
and 0.97m, respectively).
Fig. 6. Particle size distribution (n= 3, mean± S.D.) (solid) and deposited charge per stage (i.e. current flow) (n= 5± S.D.) (white) for (a) 1.0% albuterol in milled
lactose, delivered from 15 mg carrageenan capsule and (b) 1.0% albuterol in sieved lactose, delivered from 30 mg gelatin capsules, both delivered via Inhalator®.
The dashed line indicates charge neutrality.
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3.6. Experimental design analysis
Magnitude and polarity of electrical charge recorded varied
widely depending on the combination of formulation, capsule,
and inhaler used. To facilitate statistical analysis, the charges
were integrated over time and summed across the different
stages, and total charges were recorded as response variables.
Using the statistical software, the effects of the five factors
(inhaler type, drug load, lactose grade, capsule fill, and cap-
sule material) were evaluated with respect to net charge, as well
as to magnitude of charge and polarity (−1 was assigned to
each actuation that yielded a net negative charge, +1 where the
net charge was positive). The important distinction between net
charge and charge magnitude is that opposite charges cancel
each other when they are summed to obtain net charge, whereas
absolute values, i.e. magnitudes, are summed to obtain charge
magnitude.
The results of the experimental analysis, with contribution
and significance level for each factor are presented in Table 3.
The complete data set with net charge and charge magnitude for
the 32 different factor combinations is summarized in Table A1
in Appendix A. The average magnitude for all actuations was
0.473± 0.337 nC. Note that electrostatic charge had been mea-
sured previously using Faraday cage experiments (not shown);
the average recorded charges were in the±0.25 to 2.0 nC/g range
for several lactose batches and select drugs. Based on the amount
of material recovered on the ELPITM stages the expected charge
captured by the ELPITM would have been in the 100–1000 fC
range. However, the charges recorded were at least four orders
of magnitude larger in each case, which strongly suggests that
triboelectrification during DPI actuation is the main contributor
to overall charge.
As can be observed in Table 3, magnitude and polarity of
charge are highly correlated with most factors studied. Despite
the inherent variabilities in the data, net charge is highly corre-
lated with all factors except fill weight. There are a number of
relevant two-factor interactions. Separation of net charge into
absolute magnitude (where negative and positive charges do not
cancel each other) and polarity deconvolutes the analysis and
allows contributions to be considered separately. Thus, choice
of capsule has a large effect on the polarity of the charge but has
only a minor (though also statistically significant) effect on the
magnitude of the charge. Similarly, fill weight is shown to affect
the magnitude (as would be expected) but not the polarity. There
are no two-factor interactions that affect polarity, but choice of
Inhalator® and milled lactose and/or carrageenan capsules has
a synergistic effect on charge magnitude.
The effects of drug load and fill weight on magnitude of
charge are predictable since they are tied to the amount of mate-
rial deposited. The effects of lactose can only partly be explained
by mass considerations. Milled lactose has a larger fraction
of fine particles, so fraction depositing inside the ELPITM is
greater, but the contribution of lactose exceeds the effects of
drug load and fill weight. It is, therefore, likely that the mor-
phology (shape and surface characteristics) of the milled lactose
promotes triboelectric charging (compared to sieved lactose).
It has been suggested that different morphology could result
in change in polarity of charge (Murtomaa et al., 2004) as
observed in the present studies. However, the ELPITM experi-
ments provide additional insight with regards to bipolar charging
during single actuations. The effects of inhaler and capsule mate-
rial cannot be explained by mass considerations alone, since
differences in amount of material delivered between the two
inhalers were small and there were no differences between
the capsules. The increased charge of the Inhalator® is likely
tied to the increased friction, since the Inhalator® has a higher
pressure drop, which results in a higher rate of shearing and
thus more charge separation (Srichana et al., 1998). The effect
Table 3
Calculated effects and standard errors for 25 factorial ELPITM experimental design
Factors (reference level) Effect on net
chargea± standard error
Effect on absolute polarity
of charge± standard error
Effect on charge
magnitudeb± standard error
Main effects
Inhaler (Inhalator®) +0.074± 0.025 nC p= 0.0032 +0.28± 0.064* +0.246± 0.029 nC*
Drug load (1.0%) −0.049± 0.021 nC p= 0.022 No effect +0.124± 0.026 nC*
Lactose (milled) +0.234± 0.022 nC* +0.65± 0.055* +0.143± 0.026 nC*
Fill weight (30 mg) +0.0055± 0.021 (no effect) No effect +0.134± 0.026 nC*
Capsule (carrageenan) +0.143± 0.034 nC* +0.29± 0.055* +0.081± 0.025 nC p= 0.0017
Two-factor interactions
Inhaler× drug load (Inhalator®× 1.0%) No effect −0.15± 0.057 p= 0.0116 +0.098± 0.026 nC p= 0.0003
Inhaler× lactose (Inhalator®×milled lactose) +0.178± 0.022 nC* No effect +0.110± 0.026 nC*
Inhaler× fill weight (Inhalator® ×30 mg) No effect No effect +0.082± 0.026 nC p= 0.0021
Inhaler× capsule (Inhalator®× carrageenan) +0.094± 0.022 nC* No effect No effect
Drug Load× lactose (1.0%×milled lactose) +0.142± 0.021 nC* No effect No effect
Lactose× fill weight (milled lactose× 30 mg) +0.117± 0.021 nC* No effect No effect
Lactose× capsule (milled× carrageenan) +0.089± 0.021 nC* +0.10± 0.055 p= 0.0634 +0.149± 0.025 nC*
Three-factor and higher interactions Insignificant
a Net charge refers to the currents summed across stages and integrated over time.
b Charge magnitude refers to the absolute values of the currents summed across stages and integrated over time.
* p< 0.0001.
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of capsule material is perhaps more surprising. Use of cap-
sules made of carrageenan, a carbohydrate polymer, results
in higher triboelectric charging than use of gelatin (protein)
capsules.
The effects on magnitude of charge are difficult to inter-
pret unequivocally, since they are tied in part to mass deposited
inside the ELPITM, which is variable and was not determined
for each individual actuation. The effects on absolute polarity
are easier to interpret as they are consistent and independent
of mass. Use of the Inhalator®, milled lactose, and/or car-
rageenan increased the formulation’s propensity to acquire a
positive charge, while Rotahaler®, sieved lactose, and/or gelatin
led to negative charging. These effects are statistically highly
significant, and these properties could be exploited for deliv-
ery purposes. Several studies have implicated electrical charge
in lung deposition and have suggested exploiting charge for
enhanced delivery (Bailey, 1997; Bailey et al., 1998; Hashish
et al., 1994; Wilson, 1947). The results of this study suggest that
polarity can be exploited for delivery purposes as well, since it
can be controlled quite well and quite easily. Of course there are
limitations to the approach. The current study considers only two
devices that use single dose capsules to deliver drug, whereas
blister packs and reservoirs are more commonly used. Also, stor-
age effects are not considered, but would be expected to play a
role.
This paper considers electrical charges of particles in the
<8.6m range. Note that charged particles can remain in the
inhaler and thus result in poor delivery from the device. Only
particles that have been emitted from the device, have sepa-
rated successfully from the carrier particles, and have cleared the
preseparator, i.e. particles smaller than 8.6m in aerodynamic
size (cut-off size of ACI preseparator) are recorded. Despite the
fact that these particles account only for a small fraction of the
total, the results can help predict situations (e.g. formulation,
device) where electrostatics may either be a design advantage
or limitation.
4. Conclusions
Triboelectric charging during DPI actuation was quantita-
tively assessed using an ELPITM. DPI actuation gives rise to
significant triboelectric charging, which is orders of magnitude
larger than the charge predicted from Faraday cage experiments.
The charge magnitude and polarity of fine particles deposited
in the ELPITM was measured and correlated with various for-
mulation variables. Choice of lactose grade, inhaler device,
and capsule material have a strong effect on both magnitude
and polarity of triboelectrification. These properties could be
exploited for therapeutic purposes. The ELPITM is a device that
is not regularly used in pharmaceutical aerosol work. The study
has assessed the ELPITM and validated its measurements against
chemical and gravimetric analysis of its stages, and against the
more commonly used Anderson cascade impactor. A potentially
valuable attribute of the ELPITM is its ability to provide tempo-
ral deposition data across the stages; while not analyzed and
discussed thoroughly in the context of this study, this data could
help evaluate device and formulation emission and deposition
characteristics from a temporal perspective.
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Appendix A
See Table A1 .
Table A1
Results of experimental design studies: net charge and charge magnitude, average value (n≥ 3)± standard error
Lactose Drug load (%) Inhaler Capsule fill (mg) Capsule Net charge (nC) (rank
order)a
Charge magnitude (nC)
(rank order)b
Milled 0.50 Inhalator® 30 Gelatin 0.161 ± 0.195 (7) 0.726 ± 0.259 (6)
Milled 0.50 Inhalator® 30 Carrageenan 0.809 ± 0.248 (2) 1.227 ± 0.331 (3)
Milled 0.50 Inhalator® 15 Gelatin 0.079 ± 0.057 (9) 0.417 ± 0.183 (9)
Milled 0.50 Inhalator® 15 Carrageenan 0.351 ± 0.178 (4) 0.607 ± 0.233 (8)
Milled 0.50 Rotahaler® 30 Gelatin −0.076 ± 0.092 (19) 0.241 ± 0.139 (17)
Milled 0.50 Rotahaler® 30 Carrageenan 0.073 ± 0.075 (10) 0.325 ± 0.087 (13)
Milled 0.50 Rotahaler® 15 Gelatin −0.031 ± 0.016 (16) 0.117 ± 0.075 (26)
Milled 0.50 Rotahaler® 15 Carrageenan 0.021 ± 0.052 (12) 0.151 ± 0.117 (21)
Milled 1.00 Inhalator® 30 Gelatin 0.351 ± 0.348 (5) 0.737 ± 0.303 (5)
Milled 1.0 Inhalator® 30 Carrageenan 1.403 ± 0.305 (1) 2.002 ± 0.532 (1)
Milled 1.0 Inhalator® 15 Gelatin −0.092 ± 0.169 (21) 0.368 ± 0.059 (11)
Milled 1.0 Inhalator® 15 Carrageenan 0.797 ± 0.107 (3) 1.218 ± 0.192 (4)
Milled 1.0 Rotahaler® 30 Gelatin −0.121 ± 0.050 (24) 0.254 ± 0.035 (14)
Milled 1.0 Rotahaler® 30 Carrageenan 0.176 ± 0.047 (6) 0.250 ± 0.106 (15)
Milled 1.0 Rotahaler® 15 Gelatin −0.006 ± 0.058 (14) 0.122 ± 0.071 (25)
Milled 1.0 Rotahaler® 15 Carrageenan 0.129 ± 0.019 (8) 0.209 ± 0.111 (20)
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Table A1 (Continued )
Lactose Drug load (%) Inhaler Capsule fill (mg) Capsule Net charge (nC) (rank
order)a
Charge magnitude (nC)
(rank order)b
Sieved 0.50 Inhalator® 30 Gelatin −0.186 ± 0.156 (26) 0.236 ± 0.174 (18)
Sieved 0.50 Inhalator® 30 Carrageenan 0.025 ± 0.062 (11) 0.096 ± 0.042 (27)
Sieved 0.50 Inhalator® 15 Gelatin −0.113 ± 0.080 (23) 0.144 ± 0.065 (22)
Sieved 0.50 Inhalator® 15 Carrageenan 0.016 ± 0.060 (13) 0.062 ± 0.030 (30)
Sieved 0.50 Rotahaler® 30 Gelatin −0.106 ± 0.024 (22) 0.131 ± 0.007 (24)
Sieved 0.50 Rotahaler® 30 Carrageenan −0.067 ± 0.013 (18) 0.074 ± 0.010 (29)
Sieved 0.50 Rotahaler® 15 Gelatin −0.049 ± 0.025 (17) 0.051 ± 0.026 (31)
Sieved 0.50 Rotahaler® 15 Carrageenan −0.029 ± 0.013 (15) 0.042 ± 0.009 (32)
Sieved 1.0 Inhalator® 30 Gelatin −1.170 ± 0.228 (32) 1.265 ± 0.263 (2)
Sieved 1.0 Inhalator® 30 Carrageenan −0.653 ± 0.373 (31) 0.725 ± 0.359 (7)
Sieved 1.0 Inhalator® 15 Gelatin −0.356 ± 0.117 (30) 0.379 ± 0.110 (10)
Sieved 1.0 Inhalator® 15 Carrageenan −0.294 ± 0.139 (29) 0.363 ± 0.197 (12)
Sieved 1.0 Rotahaler® 30 Gelatin −0.220 ± 0.070 (28) 0.243 ± 0.060 (16)
Sieved 1.0 Rotahaler® 30 Carrageenan −0.211 ± 0.031 (27) 0.218 ± 0.035 (19)
Sieved 1.0 Rotahaler® 15 Gelatin −0.132 ± 0.021 (25) 0.141 ± 0.025 (23)
Sieved 1.0 Rotahaler® 15 Carrageenan −0.082 ± 0.056 (20) 0.090 ± 0.048 (28)
a Determined by addition of all charges across the stages; starts with most positive charge.
b Determined by addition of absolute value of all charges across the stages; starts with largest charge.
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APPENDIX D.  
EFFECT OF STORAGE ON DISPERSION AND CHARGE 
To assess storage effects, 20 randomly selected formulations were retested (roughly 1/3 of the 
experiments). These retests were performed on different days, after varying times of storage in closed 
glass vials at lab conditions (i.e. 23-24oC and 35±5% RH); varying from hours to 50 days of storage. 
The following figures show drug depositions (after 3 actuations, determined from chemical assay) 
and the distribution of charge (average of 3 actuations with standard deviation). Figure D.1 shows a 
formulation that was retested five days after the original sample was examined; this formulation 
(0.5% albuterol in 45-75μm ML80 lactose) showed very good reproducibility in both mass deposited 
(FPF) and charge distribution.  
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Figure D.1. Formulation (0.5% albuterol in 45-75μm ML80 lactose, 40mg) actuated from SET A (three times) on 
different days, separated by 5 days of storage. The differences in deposition (actual quantities shown) are minimal. 
Differences in charge distribution mirror the differences in deposition, and are within a standard deviation from 
one another. 
 
Figure D.2 also shows excellent reproducibility for a different formulation, with different drug 
concentration and utilizing a different lactose batch (1% albuterol in 45-75μm ML58 lactose). 
Retested nine days after the first experiment, the reproducibility of both mass and charge distribution 
was also excellent in this case.  
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Figure D.2. Formulation (1% albuterol in 45-75μm ML58 lactose, 20mg) actuated from SET A (three times) on 
different days, separated by 9 days of storage. Reproducibility is very good. 
 
Figure D.3 shows the reproducibility for a formulation containing 1% budesonide (in 45-75μm 
ML80 lactose); drug deposition and charge distribution are similar after 6 days of storage. However, 
the lower pressure drop fluidization conditions (SET C) result in larger variability in the charge 
deposition (or standard deviation) than seen in previous figures. 
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Figure D.3. Same formulation (1% budesonide in 45-75μm ML80 lactose) actuated from SET C (three times) on 
different days, separated by 6 days of storage. Differences in deposition (actual quantities shown) are minimal; 
differences in charge distribution are within standard deviation and follow deposition patterns. 
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In general, very good reproducibility of both drug deposition and charge was observed when the 
replicate was performed less than two weeks after the first run; in these cases, the FPF and d25, d50, 
and d75 values varied by no more than 10% and the total charge recovered varied by no more than 
20% from the first actuation. However, an analysis of all 20 replicates and comparison to original 
actuations revealed in part significant variation in deposition when storage time exceeds 
approximately two weeks. This suggests the prevalence of significant storage effects. Two such 
examples are given in Figures C.4 and C.5, which show the reproducibility of a budesonide and an 
albuterol based formulation after 33 and 49 days of storage, respectively. However, somewhat 
unexpectedly, both figures show a significant increase in the fine particle fraction after storage. The 
changes in the charge distributions on the other hand are inconsistent. Figure D.4 shows a virtually 
identical charge distribution after storage (despite the dramatically larger mass deposited on the 
stages), while Figure D.5 shows an altogether different charge distribution profile. Clearly, storage 
affects the triboelectric properties of different formulations differently. 
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Figure D.4. Same formulation (0.5% budesonide in 45-75μm ML80 lactose) actuated from SET A (three times) on 
different days, separated by 33 days of storage. The differences in deposition (actual quantities shown) are quite 
large with significantly more deposition after storage. Despite these differences the charge distributions are 
virtually the same. 
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Figure D.5. Same formulation (0.5% albuterol in 75-106μm ML80 lactose) actuated from SET A (three times) on 
different days, separated by 49 days of storage.  
 
The observation that drug delivery from the formulation improves after storage, highlighted in 
Figures C.4 and C.5, is counter-intuitive. Yet, it was also observed in many other replicates, though a 
small number of formulations showed deterioration in delivery. Figure D.6 shows the observed 
percentage changes in (a) FPF and (b) total charge (sum of actual recovered charges and sum of 
absolute magnitudes) plotted over storage time for all replicates. Because each point represents a 
different formulation, it is perhaps difficult to speak of trends; individual formulations respond 
differently to storage. However, two general observations can be made: (1) The longer the storage 
time, the more pronounced the changes in FPF. Up to the first two weeks of storage changes in 
delivery are minor, but increase afterwards. (2) While the data is quite variable, most formulations 
seem to have better delivery after storage; a line that is fitted to the data has a positive slope, only two 
formulations show significant deterioration in delivery. The observation seems to hold for both 
albuterol and budesonide formulations, but the most dramatic improvements are seen with the lactose 
batches. Note that the changes in the FPF are not accompanied by changes in the normalized particle 
size distributions ; d25, d50, and d75 remain unchanged.  
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Figure D.6. Changes in (a) FPF and (b) charge as a result of storage. Each point in the graph represents a 
different formulation that was retested after a variable number of days in storage (x-axis). For most 
formulations, storage seems to increase the FPF, i.e. it results in an improvement of drug/carrier separation. The 
charge becomes more positive after storage, even though the magnitude remains unchanged. 
 
Figure D.6(b) shows changes in the charge deposition over storage time. Total charge (sum of 
actual recovered charges) is shown in blue and absolute charge magnitude (sum of absolute value of 
charges summed across the size fractions) is plotted in red. It appears that after storage, most 
actuations result in slightly more positive charge deposition, while the magnitude of the charge itself 
(on average) does not change. The absolute charge magnitude varies little, with most points within 
20% of the initial measurements (despite the fact that the magnitude itself varies widely between 
different actuations); the best-fit line for the change in absolute magnitude is almost horizontal 
(+0.04%/day), indicating no change on average. This is a surprising result; based on the larger 
deposition of mass, more charge would be expected. Instead the charges become more positive; yet 
on a per mass basis they may actually decrease. This is highlighted in Figure D.7, where the changes 
in charge are plotted against the changes in mass deposition (FPF). The total captured charge 
becomes more positive as the mass deposition is increased, yet the absolute magnitude of the charge 
changes little, which actually implies a per particle decrease in charge. One plausible explanation for 
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this observation is that the charge relaxes upon storage, i.e. the formulation components lose their 
charge to each other or to their environment (e.g. storage container), and that the reduction in charge 
results in lower attractive forces and thus better particle separation. This effect requires further 
investigation with respect to defined formulations. 
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Figure D.7. The change in charge plotted against the change in deposited mass. Essentially, 
the ordinate data in Figures 5.10 (a) and (b) give the abscissa and ordinate in Figure 5.11. 
The figure indicates more clearly that the total charge becomes more positive but the sum of 
charges changes little in absolute magnitude.  
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